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Abstract 
Introduction 
Data on the burden of influenza-associated hospitalisation and mortality in relation to other aetiologies 
of pneumonia as well as risk groups for severe and complicated disease are important to guide influenza 
prevention policy. 
 
Materials and methods 
We estimated influenza-related deaths as excess mortality above a model baseline during influenza 
epidemic periods from monthly age-specific mortality data using Serfling regression models. For 
individuals aged ≥65 years from South Africa and the United States of America (US) we evaluated 
influenza-related deaths due to all causes, pneumonia and influenza (P&I) and other influenza-
associated diagnoses for 1998-2005. For adults with acquired immune deficiency syndrome (AIDS) aged 
25-54 years in South Africa (1998-2005) and the US (pre-highly active antiretroviral therapy (HAART) era: 
1987-1994; HAART era: 1997-2005) we estimated deaths due to all-causes and P&I. 
 
We prospectively enrolled individuals with severe acute respiratory illness (SARI) at six hospitals in four 
provinces of South Africa from 2009-2012. Using polymerase chain reaction, respiratory samples were 
tested for ten respiratory viruses and blood for pneumococcal DNA. Cumulative annual SARI incidence 
was estimated at one site with available population denominators. 
 
Results 
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Age-standardised excess mortality rates amongst seniors were higher in South Africa than in the US (545 
vs. 133 per 100,000 for all-causes, p<0.001; 63 vs. 21 for P&I, p=0.03). The mean percent of winter 
deaths attributable to influenza was 16% in South Africa and 6% in the US, p<0.001. For all respiratory 
causes, cerebrovascular disease and diabetes age-standardised excess death rates were 4- to 8-fold 
greater in South Africa than in the US, and the percent increase in winter deaths attributable to 
influenza was 2- to 4-fold higher. 
 
In the US pre-HAART, influenza-related mortality rates in adults with AIDS were 150- (95% confidence 
interval (CI) 49-460) and 208- (95% CI 74-583) times greater than in the general population for all-cause 
and P&I respectively and 2.5- (95% CI 0.9-7.2) and 4.1- (95% CI 1.4-13) times higher than in seniors. 
Following HAART introduction, influenza-related mortality in adults with AIDS dropped 3-6 fold but 
remained elevated compared to the general population (all cause relative risk (RR) 44, 95% CI 16-12); 
P&I RR 73, 95% CI 47-113). Influenza-related mortality in South African adults with AIDS was similar to 
that in the US in the pre-HAART era. 
 
From 2009-2012 we enrolled 8723 children age <5 years with SARI. The human immunodeficiency virus 
(HIV) prevalence among tested children was 12% (705/5964). The overall prevalence of respiratory 
viruses identified was 78% (6517/8393), which included 26% (n=2216) respiratory syncytial virus (RSV) 
and 7% (n=613) influenza. The annual incidence of SARI hospitalisation in children age <5 years ranged 
from 2530-3173 per 100,000 and was 1.1-3-fold greater in HIV-infected than HIV-uninfected children. In 
multivariable analysis, compared to HIV-uninfected children, HIV-infected children were more likely to 
be hospitalised >7 days (odds ratio (OR) 3.6, 95% CI 2.8-5.0) and had a 4.2-fold (95% CI 2.6-6.8) higher 
case-fatality ratio.  
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From 2009-2012, we enrolled 7193 individuals aged ≥5 years with SARI. HIV-prevalence was 74% 
(4663/6334) and 9% (621/7067) tested influenza positive. The annual incidence of SARI hospitalisation in 
individuals age ≥5 years ranged from 325-617 per 100,000 population and was 13 to 19-fold greater in 
HIV-infected individuals (p<0.001). On multivariable analysis, compared to HIV-uninfected individuals, 
HIV-infected individuals were more likely to be receiving tuberculosis treatment (OR 2.1, 95% CI 1.3-3.2), 
have pneumococcal infection (OR 2.2, 95% CI  1.6-2.9), be hospitalised for longer (>7 days rather than <2 
days OR 2.4, 95% CI  1.8-3.2) and had a higher case-fatality ratio (8% vs. 5%; OR 1.6, 95% CI 1.2-2.2), but 
were less likely to be infected with influenza (OR 0.6, 95% CI 0.5-0.8).  
 
Influenza was identified in 9% (1056/11925) of patients of all ages enrolled in SARI surveillance from 
2009-2011. Among influenza case-patients, 44% (358/819) were HIV-infected. Age-adjusted influenza-
associated SARI incidence was 4-8 times greater in HIV-infected (186-228 per 100,000 population) than 
HIV-uninfected (26-54 per 100,000 population). On multivariable analysis, compared to HIV-uninfected 
individuals, HIV-infected individuals with influenza-associated SARI were more likely to have 
pneumococcal co-infection (OR 2.3, 95% CI 1.0-5.0), influenza type B than type A (OR 1.6, 95% CI 1.0-
2.4), be hospitalised for 2-7 days (OR 2.8 95% CI 1.5-5.5) or >7 days (OR 4.5, 95% CI 2.1-9.5) and more 
likely to die (OR 3.9, 95% CI 1.1-14.1). 
 
Discussion and conclusions 
The mortality impact of seasonal influenza in the South African elderly may be substantially higher in an 
African setting compared to the US. Adults with AIDS in South Africa and the US experience substantially 
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elevated influenza-associated mortality rates, which although lessened by widespread HAART treatment 
does not completely abrogate the heightened risk for influenza illness.  HIV-infected children and adults 
also experience substantially elevated incidence of hospitalisation for influenza-associated SARI and 
have higher case-fatality ratios. Influenza is commonly detected amongst children (7%) and adults (9%) 
with SARI. Less frequent identification of influenza amongst HIV-infected than -uninfected individuals 
aged ≥5 years likely reflects increased relative burden and role of other opportunistic pathogens such as 
pnuemococcus and Pneumocystis jirovecii. Improved access to HAART for HIV-infected individuals and 
vaccination against influenza virus amongst HIV-infected individuals, young children and the elderly, 
where the influenza burden is great may reduce the high burden of hospitalisations and mortality 
associated with influenza. 
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Chapter 1  Introduction 
Pneumonia is the commonest cause of death amongst children aged less than five years globally, and 
the majority of this disease burden occurs in sub-Saharan Africa and South East Asia.1-3 In South Africa, 
pneumonia and influenza (P&I) was the second leading underlying natural cause of death amongst 
persons aged 0-14 and 15-49 years from 2009-20104 and pneumonia is an important cause of morbidity 
and mortality in human immunodeficiency virus (HIV)-infected adults and children.5;6 Influenza is an 
important cause of pneumonia and approximately 8-10% of all cases of pneumonia test positive for 
influenza.7  
 
1.1 Influenza virology, clinical manifestations and seasonality  
The influenza virus is a negative stranded RNA virus with a segmented genome. There are 3 types of 
influenza virus: A, B and C, but only influenza A and B cause widespread outbreaks.8 Influenza A viruses 
are divided into subtypes based on antigenic differences of the haemaglutinin and neuraminidase 
surface glycoproteins. There have been more than 14 haemaglutinin and more than 8 neuraminidase 
subtypes recovered from birds but only 3 haemaglutinin subtypes (H1, H2 and H3) and two 
neuraminidase subtypes (N1 and N2) have circulated stably in the human population. Influenza B has 
only one subtype but two antigenically distinct lineages (Victoria and Yamagata) which co-circulate 
globally. Circulating influenza viruses evolve constantly by accumulating point mutations in the surface 
glycoproteins. This evolution is known as “antigenic drift” and may allow the virus to evade immune 
recognition and contributes to annual influenza epidemics. This antigenic drift is the reason why 
seasonal influenza vaccines need to be updated each year. Influenza virus A subtypes may also be 
generated by a major genetic reassortment (known as “antigenic shift”) which gives rise to a virus that is 
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substantially antigenically different from viruses that have caused infection in humans over the previous 
years and have the potential to cause a pandemic.9;10  
 
The most recent influenza pandemic virus was influenza A(H1N1)pdm09 which emerged globally in April 
2009. The virus was first identified in Mexico and the US but rapidly spread to the rest of the world with 
the first case detected in South Africa on 14 June 2009.11-13 Initial reports suggested that the novel virus 
was associated with high case-fatality ratios. Later studies estimated the mortality burden of the virus to 
be similar to that of seasonal influenza but characterised by a substantially younger age distribution of 
cases, leading to greater years of life lost than a typical influenza season.14  
 
Influenza causes a wide range of clinical illness ranging from asymptomatic infection to severe 
hospitalised disease and death.8 Influenza typically presents with sudden onset of fever accompanied by 
headache, sore throat, myalgia, malaise anorexia and dry cough.9 Symptoms may be atypical in young 
children and the elderly. The commonest complication of influenza is pneumonia which may be a 
primary viral pneumonia or secondary bacterial pneumonia, most commonly causes by Streptococcus 
pneumoniae, Staphylococcus aureus, Haemophilus influenzae and Streptococcus pyogenes. A wide range 
of other complications may occur less commonly, including neurologic, cardiac and musculoskeletal 
disease. 
 
Disease due to influenza is highly seasonal in temperate countries where epidemics generally occur each 
year with minimal virus circulation between epidemics.8  In tropical countries influenza may circulate 
throughout the year with one or two annual peaks which may be related to the rainy season or other 
climatic events.15  
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1.2 Risk groups for severe influenza  
There are a number of established risk groups for severe influenza.16;17;17;18 Risk groups include 
individuals at the extremes of extremes of age (≥65 years and <2 years), pregnant women and 
individuals with underlying chronic illness such as cardiac, respiratory and renal disease, diabetes and 
metabolic disorders and immunosuppression. An additional risk group which came to prominence 
during the 2009 influenza pandemic was persons with obesity. In addition, pregnancy which had been 
an established risk group prior to the 2009 pandemic was identified as a major risk factor for severe 
pandemic influenza.19;20 
 
In 2012, the World Health Organization (WHO) Strategic Advisory Group of Experts on Immunisation 
(SAGE) published an updated position paper on influenza vaccines.17 In this paper, 5 main groups were 
recommended to be targeted for influenza vaccination: pregnant women (highest priority), children 
aged 6-59 months, the elderly, individuals with specific chronic medical conditions and healthcare 
workers. The paper also emphasised the need for country-specific information about risk groups, 
disease burden and cost-effectiveness to aid local decision making about target groups and timing of 
vaccination. 
 
In sub-Saharan Africa and South Africa, HIV-infected individuals are a group of particular importance due 
to the extremely high burden of underlying HIV in the region. It is estimated that there are more than 5 
million HIV-infected individuals living in South Africa.21;22 In South Africa in 2009, the HIV prevalence 
amongst antenatal attendees was 29%.23;24 The interaction between HIV and influenza is discussed in 
Chapter 4 and 7. Children aged <5 years and particularly those aged <1 year as well as the elderly aged 
≥65 years are another important risk group for severe influenza outcomes.17;25  
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It has been suggested that the mortality burden associated with the 1918 and 2009 influenza pandemics 
was greatest in low-income countries.14;26;27 Possible contributing factors include high baseline mortality 
rate, poor nutritional status, high prevalence of comorbid conditions, young age distribution of 
population, poverty and poor access to health care.27 While there are numerous published studies 
evaluating seasonal influenza-related mortality in more affluent northern hemisphere and tropical 
countries,28-30 only 2 studies provide information on mortality associated with influenza in Africa and 
they are geographically and temporally limited.31;32  
 
1.3 Influenza in Africa 
A systematic review of research published from 1980 to 2009 on seasonal influenza epidemiology in 
sub-Saharan Africa identified only 49 articles.33 While a fair amount of data was available on the 
proportion of patients with acute respiratory illness testing positive for influenza from different settings, 
data were lacking in many other areas. Particular gaps identified included representative data on 
influenza seasonality, data on influenza incidence and burden, data on case-fatality ratios amongst 
patients with influenza, data on the contribution of influenza to acute respiratory illness amongst 
hospitalised adults, economic burden data and data on the interaction between influenza and prevalent 
disorders in Africa such as HIV, tuberculosis and malaria. The authors concluded that data from sub-
Saharan Africa were insufficient to allow most countries to prioritise strategies for influenza prevention 
and control.  
 
Concern about the poor capacity for surveillance and detection of influenza in Africa, coupled with 
outbreaks of influenza A(H5N1) on the African continent from 2006 have led to an increasing 
international interest in strengthening the capacity for influenza surveillance in the African region.34-37 
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Technical and financial support has been provided to various African countries by a number of partners 
including the WHO, the United States of America (US) Centers for Disease Control and Prevention (CDC), 
other US government agencies, the international network of the Institute Pasteur and the National 
Institute for Communicable Diseases in South Africa.35 In addition, a number of African networks and 
initiatives focusing on influenza surveillance and research have been established, these include the 
Africa Flu Alliance, the African Network for Influenza Surveillance and Epidemiology (ANISE) and the 
Strengthening Influenza Sentinel Surveillance in Africa (SISA) project.34;35;38-40 These initiatives have led to 
an unprecedented expansion of influenza surveillance activities in the African region. More than 25 
countries now contribute influenza specimens to WHO and more than 6000 specimens are contributed 
each year.40;41 As many of these programmes are largely supported by external funds, critical challenges 
now exist regarding the sustainability of these networks. In 2012, a supplement to the Journal of 
Infectious Diseases entitled “Influenza in Africa” was published including 25 articles from 16 African 
countries. These articles begin to address some of the data gaps within the region and include 
descriptions of the 2009 influenza pandemic in the region.35 While the supplement addresses some of 
the data gaps, data still remain limited on influenza burden, mortality, interaction with underlying 
conditions prevalent in Africa and economic impact.  
 
1.4 Influenza surveillance and control in South Africa  
South Africa has operated a sentinel surveillance network for influenza-like illness (ILI), the “Viral 
Watch” programme, since 1984.42 This programme has provided valuable data on the timing of the 
influenza season and circulating influenza virus strains each year. The system does, however, have a 
number of limitations, including lack of data from patients with more severe respiratory illness, lack of 
data on burden and severity of influenza and inability to provide data on risk groups for severe 
influenza. In order to address these gaps, the severe acute respiratory illness (SARI) surveillance 
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programme was established in 2009.43 Details of this programme are described in Chapter 2 Methods 
Section 2.2. 
 
Influenza virus circulation in South Africa in highly seasonal and occurs mainly during the Southern 
Hemisphere winter.42 South Africa has published annual recommendations for influenza vaccination 
since 2005.44 In addition, since 2009, a more comprehensive guideline for the prevention and 
management of influenza has been published online and updated annually.45 Groups recommended to 
receive influenza vaccine in South Africa include pregnant women, persons (adults or children) at 
increased risk of complications of influenza due to the presence of underlying medical conditions 
(including HIV infection), residents of chronic care facilities, medical and nursing staff and persons aged 
>65 years. Trivalent inactivated influenza vaccine (TIV) distribution in the private sector in South Africa 
varies each year but has averaged approximately 1 million doses each year from 2006 through 2012 (B. 
Greenblatt, personal communication). TIVs have been available to a limited extent (<40 000 doses each 
year) through the public health system since 1996, from 2005-2009 annual doses distributed in the 
public sector ranged from 128,000 to 205,000 each year (B. Greenblatt and W. Ramkrishna, personal 
communication). In 2010, 1,022,000 TIV doses were distributed and these were supplemented with 
approximately 3,5 million doses of monovalent influenza A(H1N1)pdm09 vaccine donated by the WHO. 
Since 2010, TIV distribution in the public sector has dropped somewhat, and was estimated at 850,000 
doses in 2012 (W. Ramkrishna, personal communication). The population of South Africa was estimated 
to be 51,770,560 in 201146 with an estimated 70% accessing initial care in the public sector in 2010.47 
Using these data, in 2007 <3% of the South African population received influenza vaccination. In 
contrast,  ~33% of the US general population had received the annual influenza vaccine in the 2008-09 
season, while coverage in US seniors have remained at ~65% since the mid 1990s.48 Oseltamivir 
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treatment is made available free of charge through the public health sector in South Africa, although 
challenges in procurement and distribution may limit practical availability. 
 
1.5 Justification for the research and statement of the problem  
 
There are few published estimates of influenza-associated severe morbidity and mortality in Africa. A 
contributing factor is the fact that such studies are difficult to conduct in a low- or middle-income 
country setting. Direct estimates of hospitalisation and mortality rates require resource-intensive 
surveillance programmes, while indirect estimates require high quality vital statistics or other routine 
surveillance data sources. The perception that influenza does not cause substantial mortality in Africa 
may contribute to the underutilisation of influenza vaccines, antivirals and other control measures in 
this setting.49 
Estimates of seasonal influenza hospitalisation and mortality burden are useful to identify groups at 
elevated risk of mortality and to identify geographical high risk areas. Data on risk groups for severe 
hospitalised influenza and mortality, as well as data on the relative contribution of influenza to the 
syndrome of pneumonia in relation to other pathogens are important to guide decision-making around 
seasonal and pandemic influenza prevention and control measures including vaccination in South Africa 
and other countries in Africa. In addition, it is important to obtain baseline seasonal estimates of 
morbidity and mortality burden, to allow comparison against the impact of the influenza A(H1N1)pdm09 
2009 pandemic.  
 
1.6 Aims and Objectives  
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Aims: To evaluate the burden of hospitalisations and mortality associated with influenza in South Africa, 
the relative contribution of influenza to the syndrome of SARI in relation to other respiratory viruses and 
the epidemiologic characteristics of patients with influenza-associated SARI. These data will inform 
policy on preventive strategies such as influenza vaccination as well as facilitate planning for future 
influenza pandemics in South Africa. 
 
Objectives: 
1. To estimate the excess mortality associated with influenza in South African adults ≥65 years of 
age from 1998 through 2005 and compare these estimates to those from the US for the same 
period 
2. To estimate the excess mortality associated with influenza in South African young adults with 
acquired immune deficiency syndrome (AIDS) aged 25-54 years of age from 1998 through 2005 
and compare these estimates to those from the US from 1987 through 2005 
3. To describe the epidemiologic characteristics of HIV-infected and -uninfected children aged <5 
years with SARI in South Africa from 2009 through 2012 
4. To describe the epidemiologic characteristics of HIV-infected and -uninfected individuals aged 
≥5 years with SARI in South Africa from 2009 through 2012  
5. To estimate the incidence of hospitalisation for influenza-associated SARI and describe the 
epidemiologic characteristics and clinical course of illness in HIV-infected and -uninfected 
individuals of all ages in South Africa from 2009 through 2011 
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Chapter 2  Materials and Methods 
This thesis consists of two separate components; a primary analysis of existing vital statistics data which 
addresses objectives 1 and 2 and a prospective surveillance study to address objectives 3, 4 and 5. A 
summary of the project is outlined in figure 2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Overview of thesis objectives and public health relevance 
SARI – Severe acute respiratory illness, HIV – Human immunodeficiency virus 
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2.1 Primary mortality data analysis (Objectives 1 and 2, Chapters 3 
and 4) 
 
2.1.1 Overview 
The mortality burden of influenza cannot be measured directly, as influenza diagnoses are generally not 
confirmed in the laboratory and many influenza-related deaths are not coded as such in death 
certificates but are attributed to other co-morbid conditions or secondary complications of infection.50 
Instead, indirect statistical regression methods are used to quantify the seasonal increase in mortality 
above a baseline of expected mortality for broad disease categories occurring during influenza activity 
periods, termed “excess mortality”.30;51-54 We applied statistical regression models to monthly US and 
South African mortality statistics by age and cause of death, combined with country-specific estimates of 
population sizes and deaths, as detailed below and in Chapter 3 and Chapter 4.  
 
2.1.2 Sources of data 
2.1.2.1 Mortality data 
Data on underlying causes of death were obtained from Statistics South Africa55-57 from 1998-2005 and 
from the US National Centre for Health Statistics from 1987-2005 (http://www.cdc.gov/nchs/nvss.htm). 
Data included age group, month and year of death, and underlying causes of death. For South Africa it is 
estimated that from 1998 to 2005 the completeness of reporting of deaths increased from 73% to 90% 
for males and 63% to 88% for females.56 Causes of death were manually coded and verified by trained 
coders and coding practices were consistent over the study period.55-57 Data were not adjusted to 
account for under-reporting and thus represent a minimum estimate of mortality. 
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We used the International Classification of Diseases (ICD) versions 9 and 10 to compile monthly 
mortality time series for all causes and underlying causes of death as specified in Chapter 3 and 4. For 
the US, we adjusted for the conversion from ICD-9 to ICD-10 in 1999, by multiplying the reported 
number of P&I deaths in 1998 by published comparability ratios.58 Estimation of deaths in persons with 
AIDS is described in Chapter 4. 
 
2.1.2.2 Population denominators 
We obtained annual population estimates for South Africa from Statistics South Africa 
(http://www.statssa.gov.za/publications/populationstats.asp) or the Actuarial Society of South Africa 
(ASSA) model as described in Chapter 3 and 4. We obtained annual population estimates for the US from 
the US Census Bureau (http://www.census.gov/popest/national/national.html). For South Africa from 
1998-1999, age-specific denominators were unavailable and were estimated by linear interpolation 
from data available from 2000 onwards. Determination of denominators by HIV status is described in 
Chapter 4. 
 
2.1.3 Estimation of influenza-related excess mortality 
To determine influenza-related excess mortality we compared the mortality observed during influenza 
epidemic periods to a seasonal model baseline of “expected” mortality, separately for each population 
group and mortality outcome. First, we identified influenza epidemic periods separately for each winter 
and country by applying a linear seasonal regression model to influenza-specific deaths for all ages (ICD-
9 code 487-488, ICD-10 code J9-J10), excluding winter months (December-March in the US, May-August 
in South Africa) and estimating the expected mortality in the absence of influenza circulation. We 
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defined “epidemic months” as the months for which reported influenza-specific deaths exceeded the 
upper 95% confidence limit of that predicted by the model (the “epidemic threshold”), separately for 
each winter. This has been shown to accurately estimate the timing of influenza virus circulation in the 
US.51;59;60 To estimate influenza-related excess mortality we used a Serfling-type linear regression 
approach in the elderly as described in Chapter 3 and a spline model in adults with AIDS, young adults 
and the elderly as described in Chapter 4. 
 
Non-demographic differences between countries, such as access to health care, socioeconomic factors, 
and coding practices (for cause-specific deaths), may also affect baseline and influenza-related mortality 
rates and bias geographical comparisons. To adjust for differences in baseline mortality, we estimated 
the proportion of deaths attributable to influenza, estimated as the excess deaths divided by the model 
predicted baseline of deaths in summer and/or winter respectively, as used in past research and as 
described in Chapter 3 and 4.59;60  
 
2.2 Prospective SARI surveillance (Objectives 3, 4 and 5, Chapters 5, 6 
and 7) 
2.2.1 Description of the surveillance programme 
From February 2009, active, prospective, hospital-based surveillance (the SARI programme) was 
implemented in three of the nine provinces of South Africa (Chris Hani-Baragwanath Academic Hospital 
(CHBAH) in Gauteng Province, Edendale Hospital in KwaZulu-Natal Province and Matikwana and 
Mapulaneng Hospitals in Mpumalanga Province). In June 2010, an additional surveillance site was 
introduced at Klerksdorp and Tshepong Hospitals in the Northwest Province (Figure 2.2).  CHBAH is 
situated in an urban area close to the economic hub of Johannesburg, serves a population of 
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approximately 1,3 million people and has a temperate climate. Edendale hospital is situated in a peri-
urban area, serves a population of approximately 600,000 and has a sub-tropical climate. Matikwana 
and Mapulaneng Hospitals are situated in a rural area, serve a population of approximately 500,000 and 
have a sub-tropical climate. Klerksdorp and Tshepong Hospitals are situated in a peri-urban area, serve a 
population of approximately 550,000 people and have a temperate climate. 
 
Figure 2.2 Map showing the nine provinces of South Africa and the geographic locations of the four 
sentinel surveillance sites 
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2.2.2 Case definition 
A case of SARI was defined as a hospitalised individual with illness onset within seven days of admission 
meeting age-specific clinical inclusion criteria. We included children aged two days through <3 months 
with physician-diagnosed sepsis or lower respiratory tract infection, children aged 3-59 months with 
physician-diagnosed lower respiratory tract infection (including, for example bronchitis, bronchiolitis, 
pneumonia and pleural effusion) and patients aged ≥5 years meeting the WHO case definition for 
SARI:(1) sudden onset of fever (>38°C) or reported fever, (2) cough or sore throat, and (3) shortness of 
breath, or difficulty breathing.61 
2.2.3 Study procedures 
All patients admitted during Monday through Friday were eligible, except for adult patients at CHBAH 
where enrolment occurred for two of every five working days (selected days varied systematically) per 
week due to large patient numbers and limited resources. Numbers of patients admitted, numbers 
meeting study case definitions and numbers enrolled were collected. Study staff completed case report 
forms until discharge and collected respiratory (nasopharyngeal and throat swabs from patients aged ≥5 
years or nasopharyngeal aspirates from patients aged <5 years) and blood specimens from consenting 
patients within 48 hours following admission. All decisions on medical-care, including whether patients 
should be admitted to hospital, mechanical ventilation, intensive care unit (ICU) admission and other 
investigations such as blood, cerebrospinal fluid or pleural fluid bacterial culture, testing for 
Mycobacterium tuberculosis and CD4+ T-lymphocyte counts was undertaken at the discretion of the 
attending-physician.  At CHBAH, occasionally children with SARI, but without WHO signs of severe SARI 
and who did not require supplemental- oxygen treatment were admitted to a short stay observational 
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ward for one to two days, following which they were either discharged or admitted to the general 
paediatric wards. Children in the short stay wards were included in this study. 
  
2.2.4 Laboratory methods 
Respiratory specimens were immersed in viral transport medium and transported at 4-8°C to the 
National Institute for Communicable Diseases within 72 hours of collection. Respiratory specimens were 
tested by multiplex real-time reverse-transcription polymerase chain reaction (PCR) assay for 10 
respiratory viruses (influenza A and B viruses, parainfluenza virus 1, 2 and 3; respiratory syncytial virus 
(RSV); enterovirus; human metapneumovirus; adenovirus and human rhinovirus).43 All influenza A 
viruses were further subtyped as either H1 or H3 using primers and probe sets that target the HA genes 
of each virus as recommended by the WHO and CDC using the standard CDC subtyping kit [Influenza 
Virus Real-time RT-PCR Influenza A (H1/H3/H1pdm09) Subtyping panel, Cat# FluRUO-04 (CDC, Centres 
for Disease control and Prevention, Atlanta, USA available from 62)]. Due to challenges with availability 
of reagents, we did not test for adenovirus from August-October 2009. S. pneumoniae was identified by 
quantitative real-time PCR detecting the lytA gene from whole blood specimens.63 Blood culture 
specimens were undertaken at the discretion of the attending physician and processed at study 
hospitals using automated blood culture systems and standard microbiologic procedures for organism 
identification. Specimens for M. tuberculosis identification  were also submitted at the discretion of the 
attending-physician and examined by light microscopy for the presence of acid fast bacilli and culture 
performed using the BACTEC MGIT automated culture system (Becton Dickinson, Franklin Lakes, New 
Jersey). 
 
2.2.5 Definitions 
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Underlying medical conditions were defined as asthma, other chronic lung disease, chronic heart 
disease, liver disease, renal disease, diabetes mellitis, immunocompromising conditions (excluding HIV 
infection) or neurological disease and were considered absent if indicated in medical records or when 
there was no direct reference to that condition. For analyses of risk factors for influenza, pregnancy was 
included as an underlying condition, but pregnancy was not considered an underlying condition in the 
analysis of risk factors for SARI. Pneumococcal conjugate vaccine (PCV) vaccination was defined as 
receipt of all age-appropriate doses of PCV (scheduled doses at 6 weeks, 14 weeks and 9 months of age). 
Invasive bacterial isolates were defined as a bacterial pathogen isolated from blood or pleural fluid from 
a specimen taken within 48 hours of hospitalisation in Chapter 5 and 6; organisms viewed as likely 
contaminants were excluded. In Chapter 7 bacterial pathogens isolated from cerebrospinal fluid were 
also included as we wanted to identify any severe co-infections with influenza. In Chapter 7, current 
tuberculosis was defined as patients with either a laboratory-confirmed diagnosis of tuberculosis or 
receiving or initiated on anti-tuberculosis treatment during the current admission based on clinical 
assessment. 
 
2.2.6 Evaluation of HIV sero-status 
HIV-infection status data was obtained based on testing undertaken as part of standard-of-care,64  or 
through anonymised linked dried blood spot specimen testing by HIV PCR for children aged <18 months 
and by enzyme-linked immunosorbent assay (ELISA) for individuals aged ≥18 months.65 CD4+ T-cell 
counts were determined by flow cytometry using the PanLeucogating method.66 Patients were 
categorised into two immunosuppression categories: (1) mild immunosupression (CD4+ T-lymphocytes 
≥200/mm3 or equivalent age-appropriate CD4+ percentage for children aged <5 years), or (2) severe 
immunosuppression (CD4+ T-lymphocytes <200/mm3 or equivalent age-appropriate CD4+ percentage 
for children aged <5 years).67 We included any patient with a known HIV-status result whether it was 
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obtained through clinician testing or anonymised HIV-testing as described above. Age-specific HIV 
prevalence findings were not significantly different when only patients tested through anonymised 
linked testing were included for all SARI and for patients with influenza-associated SARI (results not 
shown).  
 
2.2.7 Calculation of incidence 
Calculation of incidence was conducted at one surveillance site (CHBAH) where population 
denominator data were available. This hospital is the only public hospital serving a community of about 
1,3 million black African persons in 2012 (about 120,000 children age <5 years) amongst whom <10% 
have private medical insurance.68 The vast majority (>80%) of uninsured individuals and approximately 
10% of insured individuals seek care at public hospitals, consequently the majority of individuals 
requiring hospitalisation from this community are admitted to CHBAH. We estimated the incidence of 
hospitalisations per 100,000 individuals, using the number of SARI hospitalisations, adjusting for non-
enrollment (refusal to participate and non-enrollment during weekends and in three of five adult wards) 
by age groups and HIV status divided by the mid-year total population estimates for each year, 
multiplied by 100,000.69 To estimate the incidence of influenza hospitalisations per 100,000 individuals 
we utilised the number of SARI hospitalisations testing positive for influenza virus. HIV prevalence in the 
study population was estimated from the projections of the Actuarial Society of South Africa AIDS and 
Demographic model.23 We assumed that the HIV prevalence by age group and influenza sub-type 
amongst patients not tested for HIV was the same as that amongst those tested. For 14 patients from 
whom influenza A virus subtyping was not performed, we imputed the influenza subtype based on the 
date of specimen collection and circulating influenza subtypes for estimation of incidence by influenza 
subtype.  
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Confidence intervals for incidence estimates were calculated using the Poisson distribution. Age-
specific and overall age-adjusted risk of SARI and influenza hospitalisation in HIV-infected and -
uninfected persons was determined using log-binomial regression. To explore the possible effect of 
missing data on estimates of HIV-specific incidence, a sensitivity analysis was conducted in which all 
cases not tested for HIV were assumed to be HIV uninfected. This scenario was chosen because our 
main question of interest was to estimate the excess hospitalisation risk in HIV-infected as compared to 
HIV-uninfected individuals. Exploring a scenario in which all untested individuals were assumed to be 
HIV-uninfected would bias towards a lower excess risk in HIV-infected individuals. 
 
2.2.8 Analysis of factors associated with HIV-positive serostatus and 
death  
To identify factors associated with HIV infection and death, we included both potential determinants 
for, as well as outcomes or characteristics of, the primary endpoints of the analysis. Univariate and 
multivariable analyses were performed with Stata version 9 (StataCorp Limited). Multivariable logistic 
regression models were evaluated, starting with all variables that were significant at p<0.1 on univariate 
analysis, and dropping non-significant factors with stepwise backward selection. All pairwise interactions 
of factors significant in the final multivariable additive model were evaluated. Two-sided p values <0.05 
were considered significant throughout. For each univariate analysis, we used all available case 
information. In the multivariable model, patients with missing data for included variables were dropped 
from the model. Age group, hospital, duration of hospitalisation and year were defined as categorical 
variables in multiple levels. All other variables were defined as the presence or absence of the attribute 
excluding missing data. To explore possible bias, patients tested for HIV were compared to those not 
tested. 
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2.3 Ethics 
Ethical approval for the mortality analyses was obtained from the University of the Witwatersrand 
Human Research Ethics Committee (Medical), South Africa. The US census and national HIV surveillance 
system data do not contain personal identifiers and their use in this report does not require human 
subjects oversight. The SARI surveillance protocol was approved by the Research Ethics Committees of 
the Universities of the Witwatersrand and KwaZulu-Natal. SARI surveillance was deemed non-research 
by the US CDC and human subjects review by that institution was deferred to the South African Ethics 
Committees. 
 
2.4 Funding  
Funding for travel to Bethesda for Dr Cohen to learn influenza mortality modelling statistical techniques 
was provided by the Fogarty International Centre.  
The SARI surveillance programme received funding from the National Institute for Communicable 
Diseases a Division of the National Health Laboratory Service and was supported in part by funds from 
the US CDC, Atlanta, Georgia Preparedness and Response to Avian and Pandemic Influenza in South 
Africa (Cooperative Agreement Number: U51/IP000155-04). The contents are solely the responsibility of 
the authors and do not necessarily represent the official views of the CDC.  
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Chapter 3 Elevated influenza-related excess mortality in South African 
seniors, 1998-2005 
 
3.1 Introduction 
Influenza infection is associated with substantial global mortality each winter season, with the greatest 
burden experienced in seniors ≥65 years of age.70 The incidence of influenza-related mortality in seniors 
ranges from 80-150 deaths/100,000 for all causes and 16-22/100,000 for P&I in the US and Europe.29;30;51 
Studies from high-income tropical locations such as Hong Kong and Singapore have found similar rates 
of excess deaths in the elderly to temperate northern hemisphere countries.71;72 To our knowledge there 
are no published studies estimating seasonal influenza-associated mortality amongst the elderly from 
Africa.  
Mortality is greatest in seasons where the more severe A(H3N2) influenza virus subtype predominates 
as compared to the milder A(H1N1) or B viruses.51 Seasonal increases associated with influenza virus 
circulation have been demonstrated for a number of mortality outcomes in the elderly including all-
cause mortality, P&I, diabetes, cerebrovascular disease (CVD) and ischaemic heart disease (IHD).30;53;71;72 
By contrast, cancer deaths show no clear seasonality.53 
Here, we aimed to compare the influenza mortality burden between South Africa and the US, using 
multiple years of data, 1998-2005, and focusing on seniors ≥65 years of age.  
3.2 Materials and Methods 
3.2.1 Sources of data 
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3.2.1.1 Mortality data 
Data on underlying causes of death for individuals aged ≥65 years were obtained from Statistics South 
Africa55-57 from 1998-2005 and from the US National Centre for Health Statistics from 1997-2005 
(http://www.cdc.gov/nchs/nvss.htm) as described in Methods section 2.1.2.1. Data included age group 
by 5-year age bands (65-69 years, 70-74 years, 75-79 years and ≥ 80 years), month and year of death, 
and underlying causes of death.  We used the ICD versions 9 and 10 to compile monthly mortality time 
series for P&I, all respiratory diseases, diabetes, ischaemic heart disease (IHD), cardiovascular disease 
(CVD), cancer, and all causes (Table 3.1).  
 
3.2.1.2 Population denominators 
 
We obtained annual population estimates in individuals aged ≥65 years for South Africa and the US from 
Statistics South Africa (http://www.statssa.gov.za/publications/populationstats.asp) and the US Census 
Bureau (http://www.census.gov/popest/national/national.html) respectively as described in Methods 
section 2.1.2.2.  
 
3.2.1.3 Influenza viral isolation data 
 
The climate in South Africa ranges from temperate to sub-tropical, and influenza virus circulation is 
seasonal.73 Data on number, timing and subtype of influenza virus isolates in South Africa was obtained 
from laboratory-based sentinel surveillance for influenza-like illness.73 Total annual numbers of influenza 
virus isolates varied markedly between study years due to changes in the surveillance methodology over 
the study period, and do not represent the true influenza burden. To confirm the validity of the 
mortality data as an indicator of influenza timing in South Africa, we compared the timing of peak viral 
isolation data with the timing of peak influenza mortality, as in past research.74 We considered an 
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influenza subtype (A(H3N2), A(H1N1) or B) to be dominant during the influenza season when it 
accounted for at least 50% of circulating viruses.  
 
3.2.2 Estimation of influenza-related excess mortality 
Influenza-related excess mortality was estimated for each of the 8 influenza seasons and 4 age groups 
for South Africa (winters 1998-2005) and the US (winters 1997/1998 through 2004/2005). To model the 
expected level of mortality in the absence of influenza virus activity, we used a Serfling-type linear 
regression approach, which includes harmonic terms to model seasonality and terms for time trends.51;59 
First, we identified influenza epidemic periods separately for each winter and country as described in 
Methods section 2.1.3. We then applied the seasonal regression model to monthly mortality rates for 
broader death categories and specific age groups, after standardising for month length and excluding 
data from winter months. Rates of monthly excess mortality were calculated as the observed minus 
predicted mortality rate for all “epidemic months”. Seasonal excess mortality was estimated as the sum 
of the monthly excess mortality after adjusting for true month length. All model terms included were 
statistically significant (p<0.001), but additional terms were not (p>0.05). Overall, excess mortality 
regression models fitted the South African data for persons aged ≥65 years well, especially for P&I 
(R2=0.82). For other influenza-associated causes of death (all causes, all respiratory causes, diabetes, IHD 
and CVD) R2 ranged from 0.68-0.77.  
 
To control for differences in the population age structure between the US and South Africa, we adjusted 
estimates for each 5-year age band to the US population in 2000. To adjust for differences in baseline 
mortality as described in Methods section 2.1.3, we calculated two measures of the proportion of 
deaths attributable to influenza, estimated as the excess deaths divided by the model predicted baseline 
of deaths in summer and winter respectively, as used in past research.59;60 We used negative binomial 
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regression models to compare annual excess mortality rates between countries and logistic regression 
to compare percentage excess deaths.
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3.3 Results 
3.3.1 Description of mortality data in South Africa and the US 
In South Africa, there were 3,831,176 deaths reported over the study period and age data was available 
for 3,808,121 (99%). Twenty-six percent of deaths (992,020) were in individuals aged ≥65 years; the 
annual number of reported deaths in the elderly increased by 18% over the study period (Tables 3.1 and 
3.2). The proportion of deaths coded as P&I, all respiratory causes, CVD and diabetes was similar 
between South Africa and the US, but a larger proportion of elderly deaths in the US were due to IHD 
and cancer (Table 3.1).  
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Table 3.1: Comparison of causes of death in persons aged ≥65 years, South Africa (SA) vs. United States 
of America (US), 1998-2005 
Cause of death ICD 9 code ICD 10 code 
US 
n (%) 
SA 
n (%) 
All causes Any Any 14,321,704 (100) 992,020 (100) 
All respiratory causes 460-519 J00.0-J99.0 1,627,057 (11) 126,729 (13) 
Pneumonia and influenza  480-487 J10.0-J18.9 479,390 (3) 50,461 (5) 
Cerebrovascular disease  430 – 438 I60.0-I69.8 1,117,140 (8) 104,296 (11) 
Diabetes mellitus 250 E10.0-E14.9 426,094 (3) 69,338 (7) 
Ischaemic heart disease  410 – 414 I20.0-I25.9 3,247,033 (23) 55,503 (6) 
Cancer 140 – 209 C00.0-C97 3,118,900 (22) 109,391 (11) 
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Table 3.2: Annual excess pneumonia and influenza (P&I) and all-cause deaths in individuals aged ≥65 
years, South Africa, 1998-2005 
Year 
Predominant 
influenza 
subtype 
Population 
≥65 years 
Annual all 
cause 
deaths 
Excess P&I deaths Excess all cause deaths 
Number  
per 100,000 
population Number  
per 100,000 
population 
1998 H3N2 1,750,648 113,248 1583 90 10,987 628 
1999 B 1,825,544 111,694 603 33 4680 256 
2000 H1N1 1,900,440 116,926 418 22 6075 320 
2001 H3N2 1,975,337 124,163 1239 63 7441 377 
2002 B 2,050,997 127,629 559 27 4175 204 
2003 H3N2 2,130,051 135,644 1040 49 9700 455 
2004 H3N2 2,211,678 129,031 465 21 5462 247 
2005 H1N1 2,295,512 133,685 705 31 5381 234 
Mean 2,017,526 124,003 827 42 6738 340 
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3.3.2 Timing of viral activity and mortality, South Africa 
In South Africa, laboratory-based sentinel surveillance demonstrates that influenza causes seasonal 
outbreaks during May-August (Figure 3.1).73 During the study period, timing of peak viral activity 
coincided with peak P&I and all-cause mortality in 6 of 8 years (0 month difference), and there was a 1-
month delay in peak mortality in 2 years (1998 and 2000 for P&I, 2000 and 2004 for all causes). For 
comparison, influenza A/H3N2 was the predominant subtype in 4 of 8 seasons in South Africa 
(Figure 1) and 6 of 8 seasons in the United States (1997/1998,1998/1999, 1999/2000, 2001/2002, 
2003/2004, and 2004/2005)(www.cdc.gov/flu). 
 
The mean rate of excess P&I and all cause deaths in seasons where influenza A H3N2 predominated was 
elevated compared to seasons when influenza A H1N1 or B predominated for all diagnoses evaluated, 
however this difference was not statistically significant (data not shown) due to the small number of 
observations available for comparison (Table 3.2). 
 
3.3.3 Comparison of influenza-related excess death rates, South Africa 
and US  
 
Rates of excess P&I and all-cause mortality in seniors were higher in South Africa than in the US (42 and 
387 per 100 000 respectively in South Africa as compared to 22 and 112 in the US, p=0.08 for P&I and 
p<0.001 for all-cause) (Table 3.3). For all diagnoses evaluated, except cancer, the estimated influenza-
associated excess mortality increased with age and the age-specific influenza-related excess mortality 
rates were higher in South Africa as compared to US (Table3. 4).  
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Figure 3.1 Observed and predicted* deaths in persons aged ≥65 years by month, 1998-2005, South Africa  
Figure 3.1A: Reported influenza deaths, predicted* deaths and epidemic threshold; and number of influenza viral isolations (all ages)  
Jan – January. *Number of deaths predicted assuming that influenza viruses were not circulating
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Figure 3.1B: Pneumonia and influenza (P&I) deaths 
Jan – January. *Number of deaths predicted assuming that influenza viruses were not circulating 
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Figure 3.1C:  All cause deaths  
Jan – January. *Number of deaths predicted assuming that influenza viruses were not circulating
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Table 3.3: Comparison of mean seasonal estimates of influenza-related excess mortality in individuals aged ≥65 years in South Africa for 1998-
2005 (SA) and the United States of America (US) for 1997/1998 to 2004/2005 seasons 
 Crude deaths per 100,000 (SD) 
Age standardised deaths per 
100,000 (SD)* 
Percent excess deaths over 
summer baseline (SD) ** 
Percent  excess deaths over 
expected winter deaths 
(SD) *** 
Cause of death SA US P+ SA US P+ SA US P++ SA US P++ 
All-cause 387 (203) 112 (62) <0.001 545 (190) 133 (79) 0.01 19 (9) 8 (4) <0.001 16 (6) 6 (3) <0.001 
All respiratory 
causes 
87 (45) 35 (21) 0.008 124 (62) 35 (21) 0.02 38 (23) 26 (13) <0.001 25 (11) 14 (8) <0.001 
Pneumonia & 
Influenza 
42 (21) 22 (13) 0.08 63 (35) 21 (13) 0.03 50 (36) 44 (25) <0.001 29 (14) 20 (11) <0.001 
Cerebrovascular 
disease 
40 (14) 7 (5) <0.001 54 (20) 7 (5) <0.001 18 (5) 6 (4) <0.001 16 (4) 4 (3) <0.001 
Diabetes 20 (5) 3 (2) <0.001 25 (6) 3 (2) <0.001 14 (3) 8 (3) <0.001 13 (3) 5 (3) <0.001 
Ischaemic heart 
disease 
12 (4) 25 (20) 0.036 15 (6) 24 (20) 0.40 10 (4) 8 (6) <0.001 9 (3) 6 (4) <0.001 
Cancer 3 (4) 7 (4) 0.221 6 (5) 7 (4) 0.83 1 (2) 2 (1) <0.001 1 (2) 2 (1) <0.001 
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Data are rate per 100,000 population or percent and standard deviation of annual estimates (SD) 
* Standardised to the US population in 2000 
**Percentage excess deaths over the baseline summer mortality rate for the relevant year (January, February, November, December - South 
Africa and May to August – US) 
*** Excess mortality expressed as percentage increase over the winter baseline (ratio of excess deaths during epidemic months divided by the 
baseline expected deaths from the seasonal model). 
+ Negative binomial regression 
++Logistic regression 
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Table 3.4: Age-specific estimates of influenza-related excess mortality rates per 100,000 population aged 
≥65 years, South Africa (SA) and United States (US)  
Diagnosis Country Age group (years) 
  65 to 69 70 to 74 75 to 79 ≥ 80 
All cause 
SA 156 (49) 243 (99) 429 (193) 1326 (438) 
US 22 (14) 40 (24) 85 (49) 377 (225) 
All respiratory 
SA 30 (17) 54 (32) 104 (68) 305 (136) 
US 9 (5) 15 (9) 27 (16) 86 (54) 
Pneumonia and influenza 
SA 10 (8) 30 (15) 32 (32) 175 (87) 
US 3 (2) 5 (3) 11 (7) 64 (39) 
Cardiovascular disease 
SA 18 (4) 31 (14) 40 (22) 126 (49) 
US 1 (1) 2 (1) 4 (1) 19 (15) 
Diabetes 
SA 17 (9) 8 (5) 31 (12) 44 (13) 
US 1 (1) 2 (1) 3 (2) 5 (3) 
Ischaemic heart disease 
SA 7 (4) 6 (4) 24 (9) 27 (15) 
US 5 (6) 9 (9) 14 (13) 68 (54) 
Malignant disease 
SA 1 (2) 9 (6) 8 (9) 5 (11) 
US 2 (1) 4 (3) 7 (4) 14 (8) 
Data are rate per 100,000 population and standard deviation of annual estimates 
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After standardising for population age structure, the differences in the rates of excess P&I and all-cause 
mortality per 100,000 population increased between the two countries (p=0.03 for P&I and p=0.01 for 
all cause mortality; Table 3.3). When standardising for coding practices and baseline mortality, the 
differences in influenza-related excess mortality were reduced but South African mortality estimates 
remained significantly higher. In addition, the proportion of all winter deaths attributable to influenza 
was higher in South Africa than in the US on average (16% vs. 6%, p<0.001, Table 3.3). Similarly, the 
percent of all deaths attributable to influenza standardised by the summer baseline was higher in South 
Africa (19% vs. 8%, p<0.001, Table 3.3).  
 
Rates of excess deaths due to all respiratory causes, CVD and diabetes were generally greater in South 
Africa than in the US and differences remained when standardised for demographics, death-coding 
practices and baseline mortality differences. Excess mortality rates for IHD were not significantly 
different between the US and South Africa. In both countries, deaths due to cancer had little seasonal 
variation that could be attributed to influenza.
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3.4 Discussion 
This was the first nationally representative study from Africa to estimate seasonal influenza-associated 
excess mortality. Overall, rates of seasonal influenza-related excess mortality in South African adults ≥65 
years of age were substantially greater than those observed in the US. These patterns were consistent 
for a variety of death outcomes which have been used in the past as indicators of influenza disease 
burden including all-cause, P&I, all respiratory diseases, CVD and diabetes.30;53;71 Standardisation for 
demographics, as well as proxies of death-coding practices and baseline health accounted for some, but 
not all of these differences. These data support increased efforts for control of seasonal influenza in 
seniors in South Africa and other low- and middle-income countries, where the excess seasonal 
mortality burden could be greater than previously thought. 
 
Studies from several northern hemisphere temperate countries, as well as urbanised tropical areas such 
as Hong Kong and Singapore, have yielded remarkably similar estimates of influenza-related excess 
mortality in the elderly to those from the US.29;30;51;71;72;75;76 By contrast, severe outbreaks of A(H3N2) 
influenza occurred in Madagascar and the Democratic Republic of Congo in 2002, suggesting that 
populations in African countries may experience increased risk of severe outcomes following influenza 
infection.32;77 Case-fatality ratios in these outbreaks were high, possibly due to limited access to medical 
care, high prevalence of underlying illness and malnutrition and crowded living conditions. Remote 
areas with less frequent influenza virus activity could experience higher influenza-related mortality,32;77 
although serological studies suggest that rural African populations may be exposed to influenza each 
season.78;79 While there are several published reports describing influenza circulation from various 
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locales in Africa, surveillance remains limited especially in rural areas, thus the epidemiology and 
seasonality of inter-pandemic influenza virus activity remains unclear in this region.80;81 
 
A previous study  evaluated influenza-associated excess mortality in the elderly occurring at a single 
South African hospital between 1997-1999 and found lower excess mortality rates than ours (82-
221/100,000 population ≥65 years).31 Given that only 50% of deaths occur in the hospital, this study may 
have substantially underestimated the influenza mortality burden.31;57 In addition, the hospital study 
only covered a short period and was conducted in an urban community with relatively good access to 
health care, limiting the generalisability of the findings.31 
 
Our study had several potential limitations. Some deaths in South Africa were not registered,57 however 
this improved over the study period and under-reporting is unlikely to vary with season. About 14% of 
deaths in South Africa were non-specifically coded, which is higher than in the US (0.8%-1.2%). If 
anything, this should lead to underestimation of the excess mortality in South Africa, especially for 
disease-specific mortality indicators. Standardisation for baseline should account for difference in coding 
practices or baseline mortality between settings, and did not eliminate differences in excess death rate 
between countries. There was a slight increase in the proportion of deaths not specifically coded in 
winter in South Africa (≤1%). However given that the seasonal component only explained 9% of the 
variance in the data (P=0.01), we did not further adjust for this factor. We also note that our analyses of 
all-cause mortality are not prone to biases in the proportion of non-specific codes.  
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All-cause excess mortality is less likely to be subject to differences in coding practices and the most 
pronounced and consistent differences between South Africa and the US were for this mortality 
outcome. We also found similar between-country differences for other diagnoses, such as P&I, all 
respiratory deaths, CVD and diabetes. Although not significant due to small sample size, we found 
elevated excess mortality in seasons when H3N2 viruses predominated in South Africa, as has been seen 
in previous studies.51 These patterns support the hypothesis that excess deaths were due to influenza, 
and not other causes such as temperature variation. Moreover, the observation of elevated mortality in 
South Africa is robust because our study period saw fewer A(H3N2)-dominated seasons in South Africa 
(4 of 8 seasons) compared with the US (6 of 8 seasons).51 Overall, this suggests that our estimates of 
excess mortality for South African seniors are valid and that South African populations experience 
similar risk factors to other countries, including older age and that impact is worse in seasons dominated 
by the A(H3N2) subtype. 
 
This study highlights that seasonal influenza-related excess mortality in Africa is likely greater than that 
observed in wealthier countries. Possible contributing factors may include socioeconomic differences as 
well as variability in the contributing role of co-circulating viral and bacterial respiratory pathogens. 
Studies have suggested that much of the morbidity and mortality associated with influenza infection 
may be due to secondary bacterial infection, particularly S. pneumoniae.82;83 In addition, the relative 
contribution of other respiratory viruses such as RSV to excess mortality in the elderly has been debated 
in the literature. The type of modelling we have used in this study is thought to account for the relatively 
constant year-to-year mortality from RSV in the baseline.30;84 Our approach cannot however evaluate 
the relative contribution of secondary bacterial infections or other viruses to influenza mortality in the 
US and South Africa, and this should be explored in further studies.  
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The observed differences in excess mortality are not explained by differences in influenza vaccination 
coverage between the US (approximately 65%) and South African elderly (15% of insured population in 
one study), because influenza associated mortality in the US elderly has remained constant since the 
1980s despite increased vaccination coverage.51;85 HIV/AIDS co-morbidity is also probably not a 
contributing factor in persons over 65 years, unless high HIV prevalence in younger populations is 
associated with increased intensity of influenza transmission in the community. It has been suggested 
that pandemic influenza-related mortality may be greater in lower socioeconomic settings.27 In 2001, it 
was estimated that >40% of South Africans resided in a rural setting and >50% were living in poverty.86;87 
Although it is difficult to predict how representative estimates from South Africa are of the situation 
elsewhere in Africa; it is likely that non-specific factors related to poverty may have contributed at least 
in part to the observed increased excess mortality. 
 
The mortality burden in the 2009 A(H1N1) pandemic differed from that of seasonal influenza, with 
highest apparent mortality risk in younger adults with underlying health conditions.11;88 We have 
demonstrated elevated influenza-associated mortality in the South African elderly. Our study is 
consistent with the concept that African populations in general may be at higher risk for severe 
mortality from pandemic influenza,27 which may be confirmed as more robust data become available 
from the African continent. Future studies are needed to estimate influenza disease burden in younger 
African populations and evaluate the impact of underlying host susceptibility, socioeconomic factors and 
co-circulating bacterial and viral pathogens. Such data are key to predict the potential impact of 
influenza pandemics and provide support for influenza vaccination programs and other control 
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measures in developing countries. The model presented here could be applied to any near-real time 
data available from South Africa, to estimate the burden in each wave as the pandemic progresses. 
Influenza mortality in adults with AIDS 
40 
 
Chapter 4  Influenza-related mortality among adults age 25-54 
years with AIDS in South Africa and the US  
 
4.1 Introduction 
There are approximately 30 million persons infected with HIV worldwide, including 5 million in South 
Africa and 1.2 million in the US.21;22 The burden of influenza in HIV-infected persons remains poorly 
studied, particularly in sub-Saharan Africa where HIV burden is greatest.89 Further, data are limited on 
the impact of widespread use of highly active anti-retroviral therapy (HAART) on mitigating severe 
influenza outcomes.90 There have been no population-based studies evaluating influenza-associated 
mortality in adults with AIDS from sub-Saharan Africa and none following the introduction of HAART in 
the US.   
 
During the US pre-HAART era, adults with AIDS were reported to experience higher influenza-related 
mortality rates compared to the general population and similar to those aged ≥65 years.91 Following the 
introduction of HAART in the mid-1990s,22 rates of influenza-related cardiopulmonary hospitalisations 
declined among US adults with AIDS but remained similar to those in other high-risk groups.90 In South 
Africa, hospital-based studies have shown an elevated risk of influenza hospitalisation and a potentially 
increased case-fatality ratio in HIV-infected children.89;92  
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In this study, we compared influenza-related mortality rates in young adults (defined as age 25-54 years) 
with AIDS in South Africa and the US during the pre-HAART era. Further, we evaluated trends in 
influenza-related mortality rates in young adults with AIDS following the widespread introduction of 
HAART in the US and compared estimates with those from reference population groups.  
 
4.2 Materials and Methods 
4.2.1 Mortality data  
Data on underlying and contributing causes of death were obtained from Statistics South Africa from 
1998-200555-57 and from the US National Center for Health Statistics from 1987-2005 
(http://www.cdc.gov/nchs/nvss.htm) as described in Methods section 2.1.2.1. We used the ICD versions 
9 and 10 to compile monthly numbers of P&I and all cause deaths, outcomes which have been used 
traditionally to measure influenza mortality burden in the US, South Africa and elsewhere.51;93 We 
focused on the age-group 25-54 years because this was the age group most affected by AIDS (Table 4.2). 
For comparison purposes, we also considered a similar age group in the general population, as well as 
seniors age 65 and older.55-57;94  
  
4.2.2 Population denominators  
For South Africa, we obtained annual age-specific population size estimates for the general population 
and individuals living with AIDS for 1998-2005 from the ASSA AIDS and Demographic model.21;23 For the 
US we obtained age-specific population denominators from for the general population from the US 
Census Bureau (http://www.census.gov/popest/national/national.html). We obtained annual population 
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size estimates for persons age 25-54 years living with AIDS in the US based on HIV surveillance data 
reported to the CDC, Atlanta, Georgia through June 30, 2010 (22 and CDC unpublished data). 
 
4.2.3 Estimation of deaths in persons with AIDS  
South Africa Estimates: In South Africa, it is estimated that 80%-90% of adult deaths were registered in 
2000.95 A diagnosis of AIDS is rarely coded on the death certificate (less than 2% of deaths in 2002),96 
although the estimated percentage of deaths due to AIDS in persons age 25-54 years increased from 
28% to 72% during 1998-2005, reflecting the increasing burden of the AIDS epidemic.21 To get around 
this coding issue, we compiled monthly deaths due to P&I (as the underlying or contributing cause) and 
total deaths in persons age 25-54 years. To estimate the monthly number of deaths in young adults with 
AIDS we multiplied the total monthly numbers of all-cause and P&I deaths in young adults by the 
proportion of all deaths associated with AIDS in this age group and year, as estimated by the ASSA AIDS 
and Demographic model (http://aids.actuarialsociety.org.za/ASSA2003-Model-3165.htm). This is a 
validated model which compares favorably with other sources of HIV data in South Africa.21;97  
 
US estimates: To estimate deaths in young adults with AIDS in the US we included all deaths in persons 
aged 25-54 years with AIDS listed either as an underlying or contributing cause (an estimated ~90% of 
US patients deceased with AIDS).98 To estimate P&I deaths in young adults with AIDS we included all 
deaths that had both AIDS and P&I listed anywhere on the death certificate.  
 
4.2.4 Estimation of influenza-related excess mortality  
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To determine influenza-related excess mortality we compared the mortality observed during influenza 
epidemic periods to a seasonal model baseline of “expected” mortality. First, we identified influenza 
epidemic periods separately for each winter and country as described in Methods section 2.1.3.  Next, to 
obtain seasonal baselines for all-cause and P&I mortality, we fitted spline models to monthly mortality 
data for each outcome and population subgroup, after exclusion of influenza epidemic months). In this 
approach, the seasonal baseline represents the expected number of deaths in the absence of influenza 
virus circulation and therefore observed data during winter months are set to missing (May-October in 
South Africa and November-April in the US). The model followed y(t)=α +β*t + χ*sin(2Pi*t/12) 
+δ*cos(2Pi*t/12), where y(t) is the monthly observed influenza deaths at month t, α and β are 
coefficients for linear time trends to be estimated from the data, and χ and δ are estimated coefficients 
representing annual seasonal cycles. Influenza periods were identified as the months where observed 
influenza-specific deaths exceeded the upper limit of 95% confidence interval of the seasonal 
baseline.51;59;93 
 
Next, a seasonal baseline for monthly all-cause and P&I deaths was established by fitting a spline model 
including linear terms for time trends and annual sine and cosine terms for seasonality, after exclusion 
of observed deaths during influenza periods. We chose to use spline models instead of linear regression 
to accommodate the steep increase in HIV/AIDS deaths seen in the pre-HAART era. Separate models 
were fitted to different population age subgroups, time periods (pre-HAART, HAART era in the US), 
cause of death (P&I and all-cause), and country. 
 
Monthly influenza-related excess deaths were estimated as the difference between observed and 
baseline P&I or all-cause deaths during influenza periods. Seasonal excess deaths were estimated as the 
sum of the monthly excess deaths for each winter. Influenza-related excess mortality deaths were 
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calculated by dividing the total excess deaths in the influenza season by the population size of the 
relevant country, year, age and HIV-status group. We derived 95% confidence intervals (CI) on seasonal 
excess mortality rate estimates based on the 95% CI of the monthly seasonal baseline model. 
  
We estimated influenza-related excess mortality for 8 winter seasons (1998-2005) in South Africa, and 
for 7 winter seasons in the pre-HAART era (1987/1988-1993/1994) and 8 seasons in the HAART era 
(1997/1998-2004/2005) in the US. We excluded US seasons from 1994/1995-1996/1997 as both HAART 
coverage and baseline mortality were changing rapidly. 
 
To adjust for differences in baseline mortality between countries, we calculated the proportion of winter 
deaths attributable to influenza as the winter-season excess deaths divided by baseline expected deaths 
during influenza epidemic months.59;60 These proportions were compared between different population 
subgroups using logistic regression. To obtain an estimate of the relative risk (RR) of influenza-related 
mortality associated with AIDS, we compared seasonal excess mortality rates in young adults with AIDS 
in the US and South Africa with rates in reference population groups (seniors, age-peers), using negative 
binomial regression. 
 
4.2.5 Sensitivity analysis 
We conducted a sensitivity analysis using a simple additive method for the estimation of influenza-
associated excess mortality relative to a peri-influenza baseline, as described previously.91 We defined 
the peri-influenza season baseline period as the 2 month period preceding and following the influenza 
season (rather than the period preceding the season only, as has been done previously).91 Using months 
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in the pre and post-influenza activity period allows fitting a stable baseline in periods of rapidly 
increasing mortality, such as in the pre-HAART era. 
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4.3 Results 
 
4.3.1 Overall trends and seasonality of deaths among persons with AIDS  
In South Africa between 1998 and 2005, there was a greater than 8-fold increase in the estimated 
number of young adults aged 25-54 yrs living with AIDS and a greater than 4-fold increase in annual 
deaths in young adults with AIDS (Table 4.1, Figure 4.1). In the US, the annual number of deaths in 
young adults with AIDS increased 2-fold during the pre-HAART era, 1987-1994, and decreased more 
than 2-fold in the HAART era (Table 4.1, Figure 4.2). Over 80% of all adult deaths due to AIDS in South 
Africa and the US throughout the study period were in persons age 25-54 years (young adults). The 
mean age at which people died increased over this period (Table 4.2). 
 
Influenza seasons occurred between May and September in South Africa and November and March in 
the US, averaging 4 months duration. All-cause and P&I deaths among young adults with AIDS were 
particularly winter seasonal in South Africa, and seasonality increased over time (Figure 4.1).  Mortality 
in US young adults with AIDS was less seasonal, especially in the pre-HAART era (Figure 4.2).
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Table 4.1 Estimated population size and number of annual deaths among adults age 25-54 years with 
AIDS - South Africa and United States of America (US) 
 Year 
Estimated adults 
age 25-54 living 
with AIDS 
Estimated all-
cause deaths in 
adults age 25-54 
with AIDS  
Estimated 
pneumonia & 
influenza deaths 
in adults age 25-
54 with AIDS  
South Africa 1998 63,923 37,912  3,979  
South Africa 2005 583,371 205,042  32,485 
US pre-HAART 1987 26,249 12,996  1,894 
US pre-HAART 1994 167,462  41,925 6,050 
US post-HAART 1997 224,437 17,600 2,573 
US post-HAART 2005 350,316 11,365 1,591 
 
AIDS – Acquired immunodeficiency syndrome, HAART – Highly active antiretroviral therapy 
Source of data: US: US National Center for Health Statistics from 1987-2005 
(http://www.cdc.gov/nchs/nvss.htm); South Africa: Actuarial Society of South Africa (ASSA) AIDS and 
Demographic model http://www.actuarialsociety.org.za/Models-274.aspx and Statistics South Africa 55-
57 
Influenza mortality in adults with AIDS 
48 
 
Table 4.2 Age distribution of deaths amongst persons with AIDS—United States of America (US) and 
South Africa 
AIDS deaths 
by age 
group in 
years 
South Africa 
pre-HAART 
South Africa 
pre-HAART 
US pre-
HAART 
US pre-
HAART 
US HAART 
era 
US HAART 
era 
1998 2005 1987 1994 1997 2005 
13-14 0% 0% 0% 0% 0% 0% 
15-24 9% 5% 4% 2% 2% 1% 
25-44 79% 76% 74% 72% 66% 43% 
45-54 10% 16% 14% 19% 23% 36% 
55-64 2% 3% 6% 6% 7% 14% 
>=65 0% 0% 3% 2% 3% 5% 
Total 
number 
51,417 300,821 14,808 46,051 19,901 14,244 
 
AIDS – Acquired immunodeficiency syndrome, HAART – Highly active antiretroviral therapy 
Source of data: US: US National Center for Health Statistics from 1987-2005 
(http://www.cdc.gov/nchs/nvss.htm); South Africa: Actuarial Society of South Africa (ASSA) AIDS and 
Demographic model http://www.actuarialsociety.org.za/Models-274.aspx and Statistics South Africa 55-
57 
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Figure 4.1 Monthly number of reported and predicted baseline all-cause and pneumonia and influenza (P&I) deaths in adults age 25-54 years 
with AIDS and influenza epidemic periods, South Africa, 1998-2005. Influenza epidemic periods were identified based on influenza-specific 
monthly mortality patterns. 
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Figure 4.2 Monthly number of reported and predicted baseline all-cause and pneumonia and influenza (P&I) deaths in adults age 25-54 years 
with AIDS and influenza epidemic periods, United States of America, 1987-2005. Influenza epidemic periods were identified based on influenza-
specific monthly mortality patterns.
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4.3.2 Estimates of influenza-related excess mortality in adults with 
AIDS, South Africa 
Influenza-related seasonal excess mortality rates in young adults with AIDS were estimated at 574 and 
127 per 100,000 for all-cause and P&I (Table 4.3). These excess mortality rates were 2.2-fold (95% CI 1.0-
5.1) and 3.8-fold (95% CI 2.2-6.6) greater than those in seniors over 65 years for the same time period 
(Table 4.4). In contrast, the proportion of winter deaths attributable to influenza was lower in young 
adults with AIDS as compared to seniors (all-cause 5% vs. 17%; P&I 7% vs. 43%, p<0.001) (Table 4.3). 
 
4.3.3 Trends in influenza-related excess mortality in young adults with 
AIDS and HAART, US 
In the US, in the pre-HAART era, young adults with AIDS experienced an average of 431 and 103 
influenza-related excess all-cause and P&I deaths per 100,000 population respectively (Table 4.3). Excess 
mortality rates declined by 3-6 fold with the widespread use of HAART (Table 4.4). In the pre-HAART era, 
influenza-related excess mortality rates in young adults with AIDS were similar to or greater than those 
in seniors, and 150-200 times greater than the experience in the general population aged 25-54 years. In 
the HAART era, influenza-related excess mortality rates in young adults with AIDS became similar to 
those experienced in seniors (RR not different from 1) but still remained substantially elevated when 
compared to their age peers (RR~40-70). 
 
Similar to South Africa, the influenza contribution to winter deaths in the pre-HAART era was lower in 
young adults with AIDS than in seniors (all-cause 2% vs. 5%; P&I 5% vs. 18%, p<0.001, Table 4.3). 
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Interestingly, while the absolute rate of influenza-related excess mortality declined from the pre- to the 
post-HAART era in young adults with AIDS, the percentage of winter deaths attributable to influenza 
increased over this period (from 2% to 5% of all-cause deaths, and from 5% to 17% of P&I deaths, 
p<0.001). 
 
Influenza-related mortality rates in South African young adults with AIDS in recent years were similar to 
those in the US in the pre-HAART era (RR not different from 1.0, Table 4.4) 
 
4.3.4 Results of sensitivity analysis using a different approach to 
estimate excess mortality 
Results using a simple additive model to estimate excess mortality91 are presented in table 4.5. 
Comparisons of influenza-related excess mortality rates between different age and HIV-status groups 
yielded similar results to those obtained using the more conservative spline model. 
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Table 4.3 Estimated influenza-related seasonal excess mortality rates in different population groups and time periods in South Africa and United 
States of America (US). Rates are based on excess all-cause and pneumonia and influenza (P&I) mortality derived from a seasonal regression 
modeling approach. 
 South Africa US 
 Persons with 
AIDS age 25-
54 years 
General 
population age 
≥65 years 
Persons with AIDS 
age 25-54 years 
General population 
age 25-54 years 
General population 
age ≥65 years 
 Pre-HAART Pre-HAART Pre-HAART HAART  Pre-HAART  HAART  Pre-HAART HAART  
         
Mean seasonal excess all 
cause deaths per 100 000 
population (95% CI) 574 (321-827) 264 (252-276) 431 (271-591) 77 (66-88) 3 (2.8-3.2) 2 (1.7-2.3) 104 (92-116) 96 (87-105) 
Mean percent winter all 
cause deaths attributable 
to influenza* (95% CI) 5 (3-7) 17 (12-22) 2 (0-4) 5 (2-8) 3 (2-4) 2 (1-3) 5 (3-7) 5 (3-7) 
Mean seasonal excess P&I 
deaths per 100 000 
population (95% CI) 127 (65-189) 34 (33-35) 103 (73-133) 40 (39-41) 0.5 (0-1) 0.5 (0-1) 40 (38-42) 43 (41-45) 
Mean percent winter P&I 
deaths attributable to 
influenza* (95% CI) 7 (5-9) 43 (22-64) 5 (2-8) 17 (13-21) 9 (6-12) 13 (10-16) 18 (11-25) 22 (14-30) 
 
Influenza mortality in adults with AIDS 
54 
 
CI-confidence interval, HAART - Highly active anti-retroviral therapy, AIDS – Acquired immunodeficiency syndrome 
Pre-HAART period US 1987-1994, HAART era US 1997-2005, pre-HAART period South Africa 1998-2005 
*Excess mortality expressed as percentage increase over the baseline (ratio of excess deaths during influenza epidemic months divided by 
baseline expected deaths during influenza epidemic months) 
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Table 4.4 Relative risk (RR) of influenza-related excess death rates in adults age 25-54 years with AIDS, as compared with reference population 
groups and periods, South Africa and the United States of America (US) 
 
South African adults age 25-54 
years with AIDS 
US adults age 25-54 years with AIDS 
Mortality 
outcome 
vs. South 
African 
general 
population 
age ≥65 years  
vs. US adults 
age 25-54 
years with 
AIDS in the 
pre-HAART 
Pre-HAART vs 
HAART era 
vs. general 
population age 
25-54 years in 
the pre-HAART 
era 
vs. general 
population age 
≥65 years in the 
pre-HAART era 
vs. general 
population age 
25-54 years in 
the HAART era 
vs. general 
population age 
≥65 years in the 
HAART era 
RR* of influenza-
related excess all 
cause death rate 
(95% CI) 
2.2 (1.0-5.1)  1.3 (0.3-5.3) 5.6 (1.3-24) 150 (49-460) 4.1 (1.4-13) 44 (16-121) 0.8 (0.2-3.3) 
RR* of influenza-
related excess P&I 
death rate (95% 
CI) 
3.8 (2.2-6.6)  1.2 (0.4-3.5) 2.6 (0.9-7.1) 208 (74-583) 2.5 (0.9-7.2) 73 (47-113) 0.9 (0.5-1.7) 
 
HAART - Highly active anti-retroviral therapy, P&I – pneumonia and influenza, AIDS – Acquired immunodeficiency syndrome 
*Negative binomial regression, data are relative risks (RR) and 95% confidence intervals 
All estimates given for South Africa are considered to predate the HAART era in this country.
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Table 4.5 Relative risk (RR) of influenza-related excess death rates in adults with AIDS, as compared with reference population groups, South 
Africa and United States of America (US) – use of an additive model with peri-influenza season baseline to estimate influenza related excess 
mortality 
 
South African adults age 25-54 
years with AIDS 
US adults age 25-54 years with AIDS 
Mortality outcome 
vs. US adults 
age 25-54 
years with 
AIDS in the 
pre-HAART 
vs. South 
African 
general 
population age 
≥65 years 
Pre-HAART vs 
HAART era 
vs. general 
population 
age 25-54 
years in the 
pre-HAART 
era 
vs. general 
population age 
≥65 years in the 
pre-HAART era 
vs. general 
population age 
25-54 years in 
the HAART era 
vs. general 
population age 
≥65 years in the 
HAART era 
RR* of influenza-
related excess all 
cause death rate 
(95% CI) 
5.9 (1.3-26.0) 2.7 (1.8-3.9) 4.0 (0.8-20.1) 
183.6 (22.1-
1522.7) 
1.3 (0.3-5.5) 30.4 (13.3-69.6) 0.3 (0.2-0.7) 
RR* of influenza-
related excess P&I 
death rate (95% 
CI) 
4.9 (2.5-9.3) 4.0 (2.8-5.6) 2.9 (1.3-6.7) 
101.6 (52.2-
197.6) 
1.4 (0.7-2.7) 34.0 (17.4-66.6) 0.5 (0.3-1.01) 
HAART - Highly active anti-retroviral therapy, P&I – pneumonia and influenza, AIDS – Acquired immunodeficiency syndrome 
*Negative binomial regression, data are relative risks (RR) and 95% confidence intervals 
All estimates given for South Africa are considered to predate the HAART era in this country. 
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4.4 Discussion 
This study evaluated influenza-related excess mortality both among adults with AIDS in South Africa and 
the US in the pre-HAART era and in the US during the HAART era. Our data suggest that in the absence 
of HAART, adults age 25-54 years with AIDS experienced a substantially elevated risk of influenza-
associated death, 150 to 200-fold higher than the general population of the same age, and 2-4-fold 
higher than seniors age 65 and over. This is consistent with the overall dramatic increase in total risk of 
death in patients with AIDS. In the US, influenza-related mortality rates in young adults with AIDS 
declined following the widespread introduction of HAART around 1995 but still remained approximately 
40-70 fold higher than those of their age peers and similar to those of seniors.22 The risk of influenza-
related mortality in untreated young adults with AIDS was similar in South Africa and the US. These 
findings suggest that AIDS remains a substantial risk factor for severe influenza-related disease in 
developed and developing world settings and support the ongoing importance of influenza prevention 
measures in persons with AIDS. 
 
Studies from South Africa have reported an approximately 8-fold elevation of influenza-associated 
hospitalisation rates and possible elevated case-fatality ratios in HIV-infected children.89;92 A US study 
set in the pre-HAART era91 reported an average excess P&I mortality rate of 122 per 100,000 and a 100-
fold mortality risk elevation in adults with AIDS aged ≥ 13 years relative to their age peers, which is the 
same order of magnitude as our estimates. Limitations of the previous study include the lack of 
adjustment for rapidly increasing background mortality in individuals with AIDS before HAART, which 
may have resulted in overestimation of excess mortality, and the inclusion of only 3 influenza seasons. 
Another US study in the pre-HAART era has shown that HIV-infected women experienced excess rates of 
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cardiopulmonary hospitalisation 50-75 times greater than their age peers.99 Our study suggests even 
higher influenza-related excess mortality risks in persons with AIDS. 
 
Our results suggest that the introduction of HAART in the mid 1990s in the US substantially decreased 
influenza-related excess mortality in young adults with AIDS, coinciding with an overall mortality rate 
decline in this group. Similarly, a population-based study demonstrated that influenza-associated 
hospitalisations in adults with AIDS age 15-50 years decreased after the introduction of HAART, although 
only one year of pre-HAART data was available for comparison.90 Overall, our study is more robust than 
earlier population-based studies in the US, as we compare 8 pre-HAART seasons to 7 post-HAART 
seasons, and confirm that the introduction of HAART has decreased the mortality burden of influenza 
among young adults with AIDS. Unfortunately, we were unable to evaluate the effect of HAART on 
influenza-related mortality in South Africa. Although a national treatment programmefor HIV-infected 
individuals was initiated in 2004 in this country, only an estimated 25% of those requiring treatment had 
been initiated on HAART by the end of our study period in 2005.100 
 
On average 11.6% (range 10.8%-12.1%) of deaths in South African adults age 25-54 were non-specifically 
coded (ICD 10 R0-99) compared to 2.0% (range 1.6%-2.7%) in the US. This may have led to 
underestimation of excess mortality risk for P&I in South Africa. In the US, clinicians may be more or less 
likely to report P&I as an underlying cause of death in persons with AIDS as compared to the general 
population. Similarly they may be more likely to seek an AIDS diagnosis or record AIDS as a cause of 
death in persons with pneumonia. The proportion of non-coded deaths in South Africa does not show 
substantial seasonal variation and should not affect between-group comparisons.93 In addition, our 
analyses of all-cause mortality are not prone to such biases in coding. 
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Our study is subject to several limitations. We used different methodologies for estimating mortality 
rates among persons with AIDS in South Africa and the US given differences in coding of deaths. While in 
the US, the majority of deaths in persons with AIDS receive an AIDS diagnosis on the death certificate,98 
this is not the case in South Africa.96 For this reason we estimated deaths in young South African adults 
with AIDS by multiplying total deaths in young adults by an estimated proportion of deaths due to AIDS 
in this age group, derived from a validated model.21;23 This method relies on the assumption that the 
proportion of deaths due to AIDS does not vary seasonally or by cause of death. Our methodological 
approach to estimate AIDS-related mortality in South Africa produced annual numbers of deaths 
approximately 20% lower than those presented by the ASSA model.21 This is expected because the ASSA 
model adjusts for unregistered deaths, which we did not do. Similarly, our estimates of excess mortality 
in persons with AIDS in the US likely represent a minimum estimate as we only included persons with 
AIDS-specific ICD codes if it was indicated anywhere on the death certificate.  Compared to the annual 
estimates of deaths among persons with AIDS from the CDC AIDS surveillance reports (which includes 
deaths from all causes), the numbers of deaths in our series were approximately 8% lower, possibly due 
to failure to record an AIDS diagnosis on the death certificate and the fact that CDC estimates are 
adjusted for delays in case and death reporting.98;101 Overall the underestimation of the number of 
deaths among persons with AIDS would tend to underestimate influenza-related excess death rates in 
this population. This, in addition to findings from sensitivity analyses comparing our mortality estimates 
with those published by other sources and evaluating the impact of deaths with no specific code of 
death, suggests that our estimates of the relative risk associated with AIDS are conservative. 
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Several internal and external consistency checks suggest the validity of our findings. Most 
importantly perhaps, we found similar levels of influenza-related excess mortality rates in untreated 
young adults with AIDS in South Africa and the US. Further, influenza-related mortality rate estimates 
were consistently 2-4 times greater in young adults with AIDS as compared with seniors in both 
countries. Further, our excess mortality approach to measure influenza burden produced estimates 
within 10% of those previously published for US seniors.30;93 The numbers of US AIDS deaths in our series 
was also within 10% of annual estimates of deaths among persons with AIDS from the CDC AIDS 
surveillance reports.98;101 Additionally, the increasingly strong winter seasonality of P&I and all-cause 
mortality in all South African young adults, at a time of rapidly increasing AIDS mortality burden, 
suggests a robust association between winter respiratory mortality and AIDS. Finally, we conducted a 
sensitivity analysis using a simple and less conservative method for the estimation of influenza-
associated excess mortality 91 While there was some variation in the absolute estimates of excess 
mortality between the two methodologies and in relation to previously published estimates,30;51;93 our 
main results remain valid. In particular, influenza-related excess mortality risk was elevated in untreated 
young adults with AIDS, as compared with seniors, and influenza-related excess mortality declined with 
HAART. Taken together, these comparisons and sensitivity analyses suggest that our modeling approach 
is robust and specific of influenza.  
 
An important caveat of our study is related to the unknown contribution of winter respiratory 
pathogens co-circulating with influenza. Our excess mortality approach assumes that all winter deaths 
occurring above a seasonal baseline during influenza activity periods are attributable to influenza. 
However, influenza-related mortality may be in part associated with secondary bacterial infection, 
particularly S. pneumoniae,82;102 and this may be even more marked in persons living with AIDS. In 
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addition, the relative contribution of other respiratory viruses such as RSV and the interaction between 
influenza and common AIDS-associated pathogens such as Pneumocystis jirovecii is unknown and may 
have caused us to over- or under-estimate influenza-associated mortality. We did not have access to 
data on these other pathogens, but this is an important area for future research.  
 
Surprisingly, although the absolute rate of influenza-related deaths in young US adults with AIDS 
declined with the introduction of HAART, the percent of winter deaths attributable to influenza 
increased 2-3 fold over this period. This suggests that as the background rate of mortality decreases in 
treated AIDS patients, together with the absolute influenza burden, the etiological fraction of influenza 
among total mortality may increase. Our study suggests that HAART may be less effective in reducing 
mortality risk from influenza than from other causes, leading to an increase in the relative contribution 
of influenza to winter mortality in the HAART era. In addition, our study is ecological, therefore changes 
in the uptake of interventions other than HAART (such as influenza or pneumococcal vaccination) could 
have impacted mortality trends although this effect would likely have been small. Indeed, observational 
cohorts show a very steep uptake in HAART coverage from 0% before 1995, when protease inhibitors 
were not available, to approximately 80% in 1997,103 coinciding with a 200-300% decline in influenza-
related mortality. In contrast, influenza vaccination coverage increased by about 10-15% from about 
29% to 42% during 1990-2002 in HIV-infected individuals,104 inconsistent with the level of decline seen in 
influenza-related mortality. Further, the major mortality reductions reported in our study predate by 
several years the introduction of the PCV in the US.105  
 
Recent US vaccination guidelines recommend influenza vaccination for all persons aged ≥ 6 months and 
identify persons with HIV and AIDS as a high risk group for influenza complications.10 This is in line with 
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our results showing that AIDS remains a risk factor for influenza-related death in the US. TIV is 
protective against laboratory-confirmed symptomatic influenza in persons with moderate or 
asymptomatic HIV infection.106-108 Effectiveness amongst persons with advanced HIV disease and low 
CD4+ T cell counts is however unclear. Very few sub-Saharan African countries have routine influenza 
vaccination programmes and high HIV-burden countries have to balance conflicting health priorities 
with limited available resources.37 A recommendation for state-sponsored influenza vaccination of HIV-
infected persons would have substantial economic and logistic cost,109 while our data suggest that 
HAART has a great impact in reducing influenza-related mortality risk.  
 
The 2009 influenza A(H1N1)pdm pandemic has highlighted the dearth of influenza-related mortality risk 
estimates in persons with underlying conditions, which are key to guide international guidelines for 
influenza vaccination and treatment. Our findings support the recommendation for vaccination of HIV-
infected individuals in the US in the HAART era. HIV-infected persons hospitalised with suspected or 
confirmed influenza infection should receive early influenza antiviral therapy. In addition, the US 
experience suggests that more widespread access to HAART in sub-Saharan Africa may substantially 
reduce influenza-related mortality in this region.
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Chapter 5 Epidemiology of viral-associated acute lower respiratory 
tract infection amongst children aged <5 years in a high HIV 
prevalence setting, South Africa, 2009-2012 
 
5.1 Introduction 
In 2010, an estimated 1.4 million children died due to pneumonia and an estimated 11.9 million were 
hospitalised.1;3 HIV infection is associated with increased severity of pneumonia and higher case-fatality 
ratios in children.110-112 The relative contribution of viral and bacterial aetiologies to the syndrome of 
childhood pneumonia also varies by HIV status.6;89 Data from Europe and North America suggest that 
even in the presence of widespread availability of HAART the incidence of pneumonia remains elevated 
in HIV-infected children.113;114  
 
There are limited data on the burden, aetiology and epidemiology of SARI in HIV-infected and -
uninfected children in sub-Saharan Africa in the era of HAART availability.  In South Africa among 
children age <5 years in 2011, the estimated HIV prevalence was 4% and coverage with HAART 
approximately 26%.23 H. influenzae type b conjugate vaccine was introduced into the South African  
immunisation programme in 1999 and PCV in 2009.115 As bacterial aetiologies decline due to 
vaccination, respiratory viral causes of SARI may gain greater prominence. We aimed to describe the 
incidence, aetiology and factors associated with death amongst HIV-infected and -uninfected children 
aged <5 years hospitalised with SARI in South Africa from 2009 through 2012. 
SARI epidemiology children <5 years 
64 
 
5.2 Materials and Methods 
 
Case definitions, study procedures, laboratory methods, definitions, evaluation of HIV serostatus and 
calculation of incidence are described in Chapter 2 Methods section 2.2.  
 
5.3 Results 
5.3.1 Demographic and clinical characteristics 
From February 2009 through December 2012, 13,815 children <5 years age fulfilling the SARI case 
definition were screened for study enrolment, of whom 8723 (63%) were enrolled (Figure 5.1). The most 
common reasons for non-enrolment were study refusal (n=1209, 24%) or unavailability of a legal 
guardian (n=1452, 29%). Of the children enrolled, 64% (5603) were <12 months age, and 69% (6024) 
were enrolled at CHBAH (Table 5.1).  
 
HIV infection status was determined in 5964 (68%) enrolled children (Figure 5.1). The proportion of 
children with available HIV results increased from 48% in 2009 to 77% in 2012 (p<0.001; Table 5.2). The 
proportion of children with available HIV results also differed by study site and duration of 
hospitalisation. The overall HIV prevalence was 12% (705/5964) and varied by age group: 10% 
(249/2565) in those <6 months, 13% (163/1290) in 6-11 months, 10% (125/1201) in 12-23 months and 
19% (168/908) in 24-59 months (p<0.001). HIV prevalence varied by hospital: 8% (322/3893) at CHBAH, 
23% (206/906) at Matikwana and Mapulaneng, 14% (118/850) at Edendale and 19% (59/315) at 
Klerksdorp (p<0.001). At CHBAH the HIV prevalence amongst children admitted to the short stay ward 
was 5% (97/1965) compared to 12% (225/1928) amongst those admitted to the general paediatric 
wards (p<0.001). 
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Figure 5.1 Flow chart of patients aged <5 years included in the study  
SARI – Severe acute respiratory illness, HIV – Human immunodeficiency virus
SARI patients aged  <5 years meeting 
case definition
N=13,815
SARI patients enrolled 
n=8723 (63%)
Tested for HIV 
n=5964 (68%)
HIV infected 
n=705 (12%)
Died 
n=47 (7%)
Survived
n=648 (92%)
Unknown outcome
n=10 (1%)
HIV uninfected
n=5259 (88%) 
Died 
N=46 (1%)
Survived
n=5194 (99%)
Unknown outcome 
n=19 (<1)
Not tested for HIV    
n=2759 (32%)
Died
n=57 (2%)
Survived 
n=2670 (97%)
Unknown outcome
n=32 (1%)
SARI patients not enrolled
n=5092 (37%)
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Table 5.1 Clinical and epidemiologic characteristics of HIV-infected and -uninfected children <5 years hospitalised with severe acute respiratory 
illness (SARI) at four sentinel surveillance sites, South Africa, 2009-2011  
 
Characteristics 
All patients 
n/N (%) 
HIV-infected 
n/N (%) 
HIV-uninfected 
n/N (%) 
Univariate analysis∼ Multivariable analysis*** 
OR(95% CI) p OR (95% CI) p 
Demographic characteristics        
Age group 
(months) 
<12 
12-23 
24-59 
5603/8723 (64) 
1747/8723 (20) 
1373/8723 (16) 
412/705 (58) 
125/705 (18) 
168/705 (24) 
3443/5259 (65) 
1076/5259 (20) 
740/5259 (14) 
Reference 
1.0 (0.8-1.2) 
1.9 (1.6-2.3) 
<0.001 Reference 
1.1 (0.9-1.4) 
2.1 (1.7-2.7) 
<0.001 
Female  3708/8723 (43) 334/705 (47) 2189/5259 (42) 1.3 (1.1-1.5) 0.004 1.3 (1.1-1.5) 0.010 
Black African race  8551/8709 (98) 693/704 (98) 5167/5253 (98) 1.0 (0.6-2.0) 0.883   
Year 2009 
2010 
2011 
2012 
2191/8723 (25) 
2004/8723 (23) 
2350/8723 (27) 
2178/8723 (25) 
180/705 (26) 
204/705 (29) 
153/705 (22) 
168/705 (24) 
869/5259 (17) 
1190/5259 (23) 
1697/5259 (32) 
1503/5259 (29) 
Reference 
0.8 (0.7-1.0) 
0.4 (0.3-0.5) 
0.5 (0.4-0.7) 
<0.001 Reference 
0.8 (0.6-1.0) 
0.4 (0.3-0.6) 
0.5 (0.4-0.6) 
<0.001 
Site CHBAH 
Matikwana and 
6024/8723 (69) 
1190/8723 (14) 
322/705 (46) 
206/705 (29) 
3571/5259 (68) 
700/5259 (13) 
Reference 
3.2 (2.7-4.0) 
<0.001 Reference 
2.8 (2.2-3.6) 
<0.001 
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Mapulaneng 
Edendale 
Klerksdorp 
 
1071/8723 (12) 
438/8723 (5) 
 
118/705 (17) 
59/705 (8) 
 
732/5259 (14) 
256/5259 (5) 
 
1.8 (1.4-2.2) 
2.6 (1.9-3.5) 
 
1.7 (1.3-2.2) 
2.4 (1.7-3.4) 
Underlying medical conditions        
Underlying medical condition 
excluding HIV*  
198/8713 (2) 15/704 (2) 133/5259 (3) 0.8 (0.5-1.4) 0.524   
2 or more doses of PCV (eligible 
children <5 years) (vs. <2 doses) 
1745/3765 (46) 131/321 (41) 1269/2643 (48) 0.7 (0.6-0.9) 0.015   
Infectious agents identified        
Invasive bacterial infection on 
culture† 
75/3196 (2) 12/311 (4) 51/2092 (2) 1.6 (0.8-3.0) 0.164   
Pneumococcal infection** 238/5094 (5) 42/524 (8) 168/3982 (4) 2.0 (1.4-2.8) <0.001   
Any virus identified 6517/8393 (78) 466/688 (68) 4098/5160 (79) 0.5 (0.4-0.6) <0.001   
>1 virus identified 2760/8393 (33) 190/688 (28) 1733/5160 (34) 0.8 (0.6-0.9) 0.002   
Influenza (any type) 613/8394 (7) 49/688 (7) 362/5161 (7) 1.0 (0.7-1.4) 0.917   
Influenza A 434/8394 (5) 32/688 (5) 243/5161 (5) 1.0 (0.7-1.4) 0.947   
Influenza B 171/8394 (2) 17/688 (2) 112/5161 (2) 1.1 (0.7-1.9) 0.614   
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Adenovirus  2061/7799 (26) 198/628 (32) 1298/4837 (27) 1.3 (1.0-1.5) 0.013   
Enterovirus 877/8393 (10) 56/688 (8) 513/5160 (10) 0.8 (0.6-1.1) 0.135   
Human rhinovirus 3115/8393 (37) 245/688 (36) 1952/5160 (39) 0.9 (0.8-1.1) 0.259   
Human metapneumovirus 504/8393 (5) 26/688 (4) 357/5160 (7) 0.5 (0.4-0.8) 0.002 0.5 (0.3-0.7) <0.001 
Parainfluenzavirus 1 161/8392 (2) 12/688 (2) 93/5160 (2) 1.0 (0.5-1.8) 0.914   
Parainfluenzavirus 2 116/8392 (1) 11/688 (2) 64/5159 (1) 1.3 (0.7-2.5) 0.434   
Parainfluenzavirus 3 535/8392 (6) 39/688 (6) 344/5159 (7) 0.8 (0.6-1.2) 0.320   
Parainfluenzavirus 1,2 or 3 789/8393 (9) 62/688 (9) 486/5160 (9) 1.0 (0.7-1.3) 0.731   
Respiratory syncytial virus 2216/8393 (26) 88/688 (13) 1412 /5160 (27) 0.4 (0.3-0.5) <0.001 0.5 (0.4-0.6) <0.001 
Any aetiology identified 6635/8723 (76%) 486/705 (69) 4164/5259 (79) 0.6 (05-0.7) <0.001   
Clinical presentation and course       
Symptoms ≥ 2 days prior to 
admission  
4754/8620 (55) 425/693 (61) 2841/5196 (55) 1.3 (1.1-1.5) 0.001 1.4 (1.2-1.7) <0.001 
Admission to intensive care††  109/8634 (1) 14/697 (2) 67/5228 (1) 1.6 (0.9-2.8) 0.120   
Mechanical ventilation ††  95/8635 (1) 14/698 (2) 49/5228 (1) 2.2 (1.2-3.9) 0.010   
Supplementary oxygen required   3042/8637 (35) 328/698 (47) 1796/5229 (34) 1.7 (1.4-2.0) <0.001 1.3 (1.1-1.7) 0.006 
Antibiotics prescribed on 7893/8471 (93) 675/690 (98) 4758/5120 (93) 3.4 (2.0-5.8) <0.001   
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admission   
Duration of 
hospitalisation (days) 
<2 
2-7 
>7 
3239/8616 (38) 
4011/8616 (47) 
1366/8616 (16) 
116/692 (17) 
245/692 (50) 
231/692 (33) 
1983 (5213 (38) 
2525/5213 (48) 
705/5213 (14) 
Reference 
2.3 (1.9-2.9) 
5.6 (4.4-7.1) 
<0.001 Reference 
1.4 (1.1-1.8) 
3.8 (2.8-5.0) 
<0.001 
Duration of hospitalisation (days) 
(median, interquartile range) 
3 (1-15) 6 (1-23) 3 (1-13)  <0.001   
Case-fatality ratio 150/8512 (2) 47/695 (7) 46/5240 (1) 8.2 (5.4-12.4) <0.001 4.2 (2.6-6.8) <0.001 
OR – Odds ratio, CI – confidence interval, HIV – human immunodeficiency virus, PCV-pneumococcal conjugate vaccine 
* Asthma, other chronic lung disease, chronic heart disease (valvular heart disease, coronary artery disease, or heart failure excluding 
hypertension), liver disease (cirrhosis or liver failure), renal disease (nephrotic syndrome, chronic renal failure), diabetes mellitis, 
immunocompromising conditions excluding HIV infection (organ transplant, immunosuppressive therapy, immunoglobulin deficiency, 
malignancy) or neurological disease (cerebrovascular accident, spinal cord injury, seizures, neuromuscular conditions). Comorbidities were 
considered absent in cases for which the medical records stated that the patient had no underlying medical condition or when there was no 
direct reference to that condition.  
**Detected on lytA PCR  
∼Comparing HIV-infected vs. HIV-uninfected 
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***Odds ratios and p values shown for all variables included in the multivariable model. Hosmer-Lemeshow goodness of fit test for the final 
multivariable model p=0.611. 
† Invasive isolates were defined as a bacterial pathogen isolated from blood or pleural fluid from a specimen taken within 48 hours of 
hospitalisation; organisms viewed as likely contaminants were excluded. Four percent (12/311) of HIV-infected patients had a positive blood 
culture (six Staphylococcus aureus, four Streptococcus pneumoniae, one Klebsiella pneumoniae and one Haemophilus influenzae). Two percent 
(51/2092) of HIV-uninfected patients had a positive blood culture (25 S. aureus, 13 S. pneumoniae, five K. pneumoniae, three Neisseria 
meningitidis, one H. influenzae, two Streptococcus agalactiae and two Escherischia coli). Two percent (12/793) of HIV-unknown patients had a 
positive blood culture (seven S. aureus, two Salmonella species, one S. pneumoniae, one K. pneumoniae and one H. influenzae). This variable was 
not evaluated on multivariable analysis due to a large proportion of missing data 
††62 of 109 patients admitted to ICU received mechanical ventilation, an additional 33 patients were ventilated outside of the ICU 
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Table 5.2 Percent of children tested for HIV by characteristic among children <5 years hospitalised with 
severe acute respiratory illness (SARI) at four sentinel surveillance sites, South Africa, 2009-2011 
 
Characteristics  Tested for HIV 
n/N (%) 
p 
Age group (months) <12 
12-23 
24-59 
3855/5603 (69) 
1201/1752 (69) 
908/1368 (66) 
0.220 
Sex 
 
Male  
Female 
3441/5015 (69) 
2523/3708 (68) 
0.570 
Race 
 
Other race 
Black African 
97/158 (61) 
5860/8551 (69) 
0.056 
Year 2009 
2010 
2011 
2012 
1049/2191 (48) 
1394/2004 (70) 
1850/2350 (79) 
1671/2178 (77) 
<0.001 
Site CHBAH 
Matikwana and Mapulaneng 
Edendale 
Klerksdorp 
3893/6024 (65) 
906/1190 (76) 
850/1071 (79) 
315/438 (72) 
<0.001 
Underlying medical condition 
excluding HIV* 
No 
Yes 
5815/8515 (68) 
148/198 (75) 
0.053 
Duration of symptoms prior to 
admission 
< 2 days  
≥ 2 days 
2623/3866 (68) 
3266/4754 (69) 
0.398 
ICU admission 
 
No 
Yes 
5844/8525 (69) 
81/109 (74) 
0.198 
Mechanical ventilation 
 
No  
Yes 
5863/8540 (69) 
63/95 (66) 
0.625 
Supplementary oxygen therapy No  
Yes 
3803/5595 (68) 
2124/3042 (70) 
0.077 
Duration of hospitalisation (days) <2 
2-7 
2099/3239 (65) 
2870/4011 (72) 
<0.001 
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>7 936/1366 (69) 
Died No 
Yes 
5842/8512 (69) 
93/150 (62) 
0.083 
ICU – intensive care unit 
*Asthma, other chronic lung disease, chronic heart disease (valvular heart disease, coronary artery 
disease, or heart failure excluding hypertension), liver disease (cirrhosis or liver failure), renal disease 
(nephrotic syndrome, chronic renal failure), diabetes mellitis, immunocompromising conditions 
excluding HIV infection (organ transplant, immunosuppressive therapy, immunoglobulin deficiency, 
malignancy) or neurological disease (cerebrovascular accident, spinal cord injury, seizures, 
neuromuscular conditions). Comorbidities were considered absent in cases for which the medical 
records stated that the patient had no underlying medical condition or when there was no direct 
reference to that condition. 
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Only 2% of children reported an underlying medical condition other than HIV-infection (Table 5.1). The 
case-fatality ratio was 2% (150/8512) and 1% (109/8634) were admitted to the ICU. Supplemental 
oxygen was administered to 35% (3042/8637) of children (63%, 277/437 at Klerksdorp; 62%, 661/1062 
at Edendale; 21%, 246/1181 at Matikwana and Mapulaneng; 59%, 1746/2932 in the CHBAH general 
paediatric wards and 4%, 115/3025 at the CHBAH short stay ward). Data on presence or absence of 
WHO criteria for clinical severity of pneumonia116 were only available for 44% (3841/8723) of children,  
of whom 23% (900/3841) would be classified as having pneumonia, 23% (894/3841) as severe 
pneumonia and 53% (2047/3841) very severe pneumonia. Patients with very severe pneumonia (8%; 
156/1969) were more likely to test positive for influenza than those with non-severe pneumonia (6%; 
48/859) or only severe pneumonia (6%; 51/862; p=0.03). All children were eligible to receive H. 
influenzae type b conjugate vaccine and 5292 to receive PCV. Coverage of H. influenzae type b conjugate 
vaccine was 78% (4477/5719) and PCV coverage was 46% (1745/3765) amongst eligible children with 
available data. Only 6 patients reported having received the influenza vaccine. 
 
5.3.2 Incidence of hospitalisation in HIV-infected and -uninfected 
patients 
The annual incidence of SARI hospitalisation amongst children <5 years at CHBAH ranged from 2530-
3173/100,000 population, being highest in infants (annual range: 8446-10532 per 100,000 population; 
Table 5.3). Additionally, the incidence was higher in children <4 months age (15573-21752 per 100,000 
population) than those age 4-11 months (5424-6792 per 100,000 population) (Table 5.4).  
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HIV-infected children had up to 3-fold greater incidence of SARI, although the risk of hospitalisation 
among HIV-infected individuals decreased in later years (Table 5.3). On sensitivity analysis, assuming 
that all patients not tested for HIV were HIV-uninfected, the trend toward a higher incidence of SARI 
hospitalisations in HIV-infected children remained in most age groups and most years, but relative risks 
were lower in more recent years. The overall incidence of SARI hospitalisation decreased from 2009 to 
2012 amongst children <5 years (3173/100,000 to 2530/100,000; p<0.001) and children <1 year 
(9965/100,000 to 8446/100,000; p<0.001) although elevated incidences were noted in all age groups in 
2011. 
SARI epidemiology children <5 years 
 
75 
 
Table 5.3 Incidence of severe acute respiratory illness (SARI) hospitalisations per 100,000 population by year and HIV status among children <5 
years at Chris Hani-Baragwanath Academic Hospital, South Africa 
 
Year 
Age 
group 
(month
s) 
% with  HIV 
result (n/N) 
HIV 
prev
alenc
e % 
IR 
(95% CI) 
All patients 
IR 
(95% CI) 
HIV infected 
IR 
(95% CI) 
HIV uninfected 
RR 
(95% CI) 
HIV infected vs. 
HIV uninfected 
RR 
(95% CI) 
HIV infected vs. 
HIV uninfected 
sensitivity 
analysis∫ 
2009 
<12 53 (573/1090) 15 
9965 (9572-
10373) 
36745 (32970-
40747) 
8857 (8480-
9251) 
4.1 (3.7-4.6) 2 (1.7-2.3) 
12-23 43 (155/357) 9 
3189 (2971-
3420) 
5753 (4486-7246) 
3054 (2835-
3287) 
1.9 (1.5-2.4) 0.8 (0.5-1.1) 
24-59 40 (133/332) 17 978 (909-1052) 3522 (2947-4206) 850 (783-920) 4.2 (3.4-5.0) 1.5 (1.1-2.0) 
All 48 (861/1779) 14 
3173 (3075-
3275) 
9502 (8725-9251) 
2862 (2767-
2961) 
3.7 (3.4-4.0) 1.6 (1.5-1.8) 
2010 
<12 66 (611/930) 9 
8861 (8478-
9258) 
23038 (19723-
26701) 
8372 (7994-
8765) 
2.7 (2.3-3.2) 1.7 (1.4-2.1) 
12-23 66 (189/286) 10 
2645 (2443-
2865) 
5508 (4218-7052) 
2500 (2295-
2715) 
2.2 (1.7-2.9) 1.4 (1.0-1.9) 
24-59 55 (103/189) 13 563 (510-621) 1508 (1137-1997) 516 (465-574) 2.9 (2.2-3.9) 1.5 (1.0-2.2) 
All 64 (903/1405) 9 
2561 (2471-
2655) 
5431 (4826-6101) 
2427 (2337-
2520) 
2.7 (2.4-3.0) 1.6 (1.4-1.9) 
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2011 
<12 75 (804/1071) 4 
10532 (10123-
10952) 
13309 (10890-
16181) 
10438 (10024-
10863) 
1.3 (1.0-1.5) 0.9 (0.7-1.2) 
12-23 84 (260/309) 5 
3009 (2796-
3239) 
3375 (2299-4691) 
2993 (2774-
3225) 
1.1 (0.8-1.6) 0.9 (0.6-1.4) 
24-59 74 (114/154) 11 494 (444-548) 1146 (813-1577) 463 (414-516) 2.5 (1.7-3.5) 1.8 (1.2-2.6) 
All 
77 
(1178/1534) 
5 
2972 (2876-
3072) 
3434 (2943-3984) 
2952 (2853-
3052) 
1.4 (1.2-1.6) 1.0 (0.9-1.2) 
2012 
<12 72 (625/870) 6 
8446 (8083-
8821) 
16893 (14088-
20021) 
8167 (7805-
8543) 
2.1 (1.7-2.5) 1.5 (1.2-1.8) 
12-23 77 (188/245) 4 
2375 (2186-
2579) 
2512 (1585-3681) 
2370 (2174-
2575) 
1.1 (0.7-1.6) 0.8 (0.5-1.3) 
24-59 72 (139/193) 8 618 (563-679) 1150 (817-1614) 595 (538-655) 2 (1.4-2.8) 1.4 (0.9-2.1) 
All 73 (952/1307) 6 
2530 (2442-
2622) 
3936 (3395-4536) 
2472 (2382-
2564) 
1.8 (1.6-2.1) 1.3 (1.1-1.6) 
IR – Incidence rate, RR – relative risk, CI – confidence interval, HIV – Human immunodeficiency virus 
*Significant value at p<0.05 are in bold ∫Assuming that all patients not tested for HIV are HIV-negative 
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Table 5.4 Incidence of severe acute respiratory illness (SARI) hospitalisations per 100,000 population by 
year and HIV status among children <1 years at Chris Hani-Baragwanath Academic Hospital, South Africa 
 
Year 
Age group 
(months) 
IR (95% CI) 
All patients 
IR (95% CI) 
HIV infected 
IR (95% CI) 
HIV uninfected 
2009 <4 20,955 (19,813-22,140) 49,966 (41,455-59,787) 19,754 (18,619-20,927) 
 4-11 6302 (5944-6681) 34,152 (30,0719-38,758) 5149 (4817-5497) 
2010 <4 19,171 (18,047-20,345) 47,724 (38,291-58,532) 18,185 (17,076-19,354) 
 4-11 5424 (5081-5787) 14,685 (11,659-18,147) 5105 (4767-5465) 
2011 <4 21,752 (20,583-22,972) 27,336 (20,570-35,920) 21,565 (20,378-22,796) 
 4-11 6792 (6414-7184) 8628 (6409-11384) 6730 (6347-7127) 
2012 <4 15,573 (14,598-16,609) 31,576 (24,176-40,599) 15,044 (14,068-16,078) 
 4-11 6071 (5719-6444) 12021 (9288-15108) 5874 (5520-6244) 
IR – Incidence rate, CI – confidence interval, HIV – Human immunodeficiency virus 
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5.3.3 Aetiologic agents identified 
Overall, 78% (6517/8393) of SARI episodes were associated with a viral infection, including 37%  
(3115/8393) for human rhinovirus, 26% (2216/8393) for RSV, 26% (2061/7799) for adenovirus, 10% 
(877/8393) for enterovirus and other individual viruses in <10% of children (Table 5.1). Thirty-three 
percent (2893/8723) of patients (311 HIV-infected, 2092 HIV-uninfected, 793 HIV-unknown) had sterile 
site specimens (2890 blood culture, two pleural fluid culture and one blood and pleural fluid culture) 
submitted for bacterial culture. Two percent (75/3196) of patients had a positive bacterial culture (Table 
5.1). Only 37 patients had laboratory-confirmed tuberculosis. Five percent (238/5094) of children had 
pneumococcal infection. Amongst patients testing positive for pneumococcus on lytA PCR, 78% 
(179/230) also tested positive for at least one respiratory virus, similar to the percent testing positive for 
respiratory viruses among pneumococcus-negative patients (78%, 3721/4764). The only virus with a 
significantly different prevalence amongst pneumococcal-positive compared to -negative children was 
influenza (13%, 29/230 detection amongst pneumococcus-positive vs. 7%, 344/4764 amongst 
pneumococcus-negative children, p=0.002). Patients with very severe pneumonia were more likely to 
test positive for influenza (6% [48/859] vs. 6% [51/862] vs. 8% [156/1969] in pneumonia, severe and 
very severe pneumonia respectively, p=0.03). There was no association between pneumonia severity 
and any other pathogen tested. 
 
When the proportion of patients testing positive for different pathogens was analysed by age group, the 
prevalence of infection increased with increasing age for influenza, adenovirus, enterovirus and human 
rhinovirus, while RSV was most common in the 0-3 month age- group (Table 5.5). The proportion of 
patients testing positive for individual or any respiratory viruses did not differ by pneumococcal 
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vaccination status (results not shown). SARI cases were enrolled throughout the year with peaks in late 
summer and autumn concomitant with RSV circulation and winter and spring associated with influenza 
circulation (Figure 5.2). 
 
5.3.4 Characteristics of HIV-infected children and factors associated 
with HIV infection 
Compared to children without HIV infection, using multivariable analysis controlling for year and 
hospital, HIV-infected children were more likely to be in the older 24-59 month age-group (odds ratio 
(OR) 2.1, 95% CI 1.7-2.7 vs. <12 months), have symptoms ≥2 days prior to admission (OR 1.4, 95% CI  1.2-
1.7), require supplementary-oxygen (OR 1.3, 95% CI  1.1-1.7), be hospitalised for longer duration (>7 
days OR 3.8, 95% CI  2.8-5.0, 2-7 days OR 1.4, 95% CI  1.1-1.8 vs. <2 days) and to die (OR 4.2, 95% CI  2.6-
6.8) (Table 5.1). In contrast, they were less likely to be infected with RSV (OR 0.5, 95% CI  0.4-0.6) or 
human metapneumovirus (OR 0.5, 95% CI  0.3-0.7). 
 
Only 25% (174/705) of HIV-infected patients had available CD4+ T-lymphocyte  data, of whom 64% had 
severe immunosuppression.67 Forty-four percent (96/217) of those with available data reported 
currently receiving HAART and 30% (207/690) reported receiving prophylaxis with trimethoprim-
sulfamethoxazole.  
 
5.3.1 Factors associated with in-hospital mortality among children 
hospitalised with SARI 
The unadjusted case-fatality ratio was seven-fold greater amongst HIV-infected (47/695, 7%) compared 
to HIV-uninfected (46/5240, 1%) children. On multivariable analysis, controlling for year and site, HIV-
positivity (OR 3.8, 95% CI  2.1-6.8), pneumococcal co-infection (OR 3.1, 95% CI  1.3-7.4), receipt of 
mechanical ventilation (OR 9.1, 95% CI  3.1-27.0) and receipt of supplementary-oxygen (OR 32.8, 95% CI  
14.7-72.1) were independent risk factors associated with death, while case-fatality ratio was lower in 
children who tested RSV-positive (OR 0.5, 95% CI  0.3-0.9) (Table 5.6). The case-fatality ratio was not 
significantly different between patients with (8%, 9/112) and without (3%, 2/61) severe 
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immunosuppression, (p=0.221) or patients receiving (3%, 3/95) and not receiving (8%, 9/118) HAART 
(p=0.160) although numbers were small. 
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Table 5.5 Percentage of patients testing positive for viral and bacterial pathogens by age group amongst 
children <5 years hospitalised with severe acute respiratory illness (SARI) at four sentinel surveillance 
sites, South Africa, 2009-2012 
 
Age group 0-3 months 
n/N (%) 
4-11 months 
n/N (%) 
12-23 months 
n/N (%) 
24-59 months 
n/N (%) 
P** 
Influenza  109/2726 (4) 201/2637 (8) 153/1703 (9) 150/1328 (11) <0.001 
Adenovirus  298/2558 (12) 646/2448 
(26) 
600/1559 
(38) 
517/1234 (42) <0.001 
Enterovirus 207/2725 (8) 245/2637 (9) 249/1703 
(15) 
176/1328 (13) <0.001 
Human rhinovirus 816/2725 (30) 1027/2637 
(39) 
677/1703 
(40) 
595/1328 (45) <0.001 
Human 
metapneumovirus 
129/2725 (5) 211/2637 (8) 97/1703 (6) 67/1328 (5) <0.001 
Parainfluenzavirus 1 28/2725 (1) 54/2637 (2) 46/1703 (3) 33/1328 (2) <0.001 
Parainfluenzavirus 2 21/2725 (1) 42/2637 (2) 27/1703 (2) 26/1328 (2) 0.007 
Parainfluenzavirus 3 136/2725 (5) 229/2637 (9) 126/1702 (7) 44/1328 (3) <0.001 
Respiratory syncytial 
virus 
897/2725 (33) 717/2637 
(27) 
374/1703 
(22) 
228/1328 (17) <0.001 
Any respiratory virus 1883/2725 
(69) 
2146/2637 
(81) 
1410/1703 
(83) 
1078/1328 
(81) 
<0.001 
>1 respiratory virus 602/2725 (22) 932/2637 
(35) 
676/1703 
(40) 
550/1328 (41) <0.001 
Invasive bacterial 
infection on culture 
32/1440 (2) 19/876 (2) 14/499 (3) 13/381 (3) 0.503 
Pneumococcal infection* 67/1470 (5) 56/1086 (5) 44/852 (5) 71/1685 (4) 0.597 
 
*Detected on lytA PCR **For heterogeneity between age groups 
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Figure 5.2 Number of children aged <5 years enrolled with severe acute respiratory illness (SARI) and detection rates by epidemiologic week and 
year at four sentinel surveillance sites, South Africa, 2009-2012 
A Influenza, respiratory syncytial virus (RSV) and pneumococcal detection rates 
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B Enterovirus, human rhinovirus and human metapneumovirus detection rates 
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C Adenovirus and parainfluenza virus 1,2 and 3 detection rates 
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Table 5.6 Factors associated with death amongst children <5 years hospitalised with severe acute respiratory illness (SARI) at four sentinel 
surveillance sites, South Africa, 2009-2012  
 
Characteristics 
Case-fatality ratio 
(%)  
Univariate analysis Multivariable analysis† 
OR (95% CI) p OR (95% CI) p 
Demographic characteristics      
Age group (months) <12 
12-23 
24-59 
118/5560 (2) 
18/1742 (1) 
14/1360 (1) 
Reference 
0.5 (0.3-0.8) 
0.5 (0.3-0.8) 
<0.001   
Sex 
 
Male  
Female 
69/4977 (1) 
81/3685 (2) 
Reference 
1.6 (1.2-2.2) 
0.004   
Race 
 
Other race 
Black African 
5/158 (3) 
144/8490 (2) 
Reference 
0.5 (0.2-1.3) 
0.164   
Year 2009 
2010 
2011 
2012 
34/2175 (2) 
55/2003 (3) 
35/2331 (2) 
26/2153 (1) 
Reference 
1.8 (1.2-2.8) 
1.0 (0.6-1.5) 
0.8 (0.5-1.3) 
0.001 Reference 
3.0 (1.2-7.4) 
1.5 (0.6-3.8) 
0.9 (0.3-2.5) 
0.001 
Site CHBAH 
Matikwana and 
Mapulaneng 
Edendale 
52/5987 (1) 
86/1185 (7) 
 
4/1054 (<1) 
Reference 
8.9 (6.3-12.7) 
 
0.4 (0.2-1.2) 
<0.001 Reference 
13.4 (6.6-27.5) 
 
0.4 (0.1-1.2) 
<0.001 
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Klerksdorp 8/436 (2) 2.1 (1.0-4.5) 1.2 (0.4-4.0) 
Underlying medical conditions     
HIV status 
 
Negative 
Positive 
46/5240 (1) 
47/695 (7) 
Reference 
8.2 (5.4-12.4) 
<0.001 Reference 
3.8 (2.1-6.8) 
<0.001 
Underlying medical 
condition excluding HIV* 
No 
Yes 
143/8458 (2) 
5/194 (3) 
Reference 
1.5 (0.6-3.8) 
0.352   
2 or more doses of 
pneumococcal conjugate 
vaccine (eligible children 
<5 years) 
No 
Yes 
34/2005 (2) 
18/1733 (1) 
Reference 
0.6 (0.3-1.1) 
0.084   
Infectious agents identified      
Invasive bacterial infection 
on culture 
No 
Yes 
195/4260 (5) 
8/122 (7) 
Reference 
1.5 (0.7-3.0) 
   
Pneumococcal infection** No 
Yes 
78/4827 (2) 
9/236 (4) 
Reference 
2.4 (1.2-4.9) 
0.011 Reference 
3.1 (1.3-7.4) 
0.012 
Influenza (any type) No 
Yes 
128/7731 (2) 
6/609 (1) 
Reference 
0.6 (0.3-1.3) 
0.204   
Adenovirus  No 
Yes 
94/5698 (2) 
27/2050 (1) 
Reference 
0.8 (05-1.2) 
0.299   
Enterovirus No 
Yes 
120/7468 (2) 
14/871 (2) 
Reference 
1.0 (0.6-1.7) 
0.999   
SARI epidemiology children <5 years 
 
87 
 
Human rhinovirus No 
Yes 
98/5245 (2) 
36/3094 (1) 
Reference 
0.6 (0.4-0.9) 
0.014   
Human metapneumovirus No 
Yes 
129/7838 (2) 
5/501 (1) 
Reference 
0.6 (0.2-1.5) 
0.269   
Parainfluenzavirus 1 No 
Yes 
130/8179 (2) 
4/160 (3) 
Reference 
1.6 (0.6-4.3) 
0.369   
Parainfluenzavirus 2 No 
Yes 
131/8222 (2) 
3/116 (3) 
Reference 
1.6 (0.5-5.2) 
0.398   
Parainfluenzavirus 3 No 
Yes 
125/7808 (2) 
9/530 (2) 
Reference 
1.1 (0.5-2.1) 
0.863   
Respiratory syncytial virus No 
Yes 
120/6135 (2) 
14/2204 (1) 
Reference 
0.3 (0.2-0.6) 
<0.001 Reference 
0.5 (0.3-0.9) 
0.042 
Clinical presentation and course      
Duration of symptoms 
prior to admission 
< 2 days  
≥ 2 days 
60/3843 (2) 
88/4716 (2) 
Reference 
1.2 (0.9-1.7) 
0.276   
ICU admission 
 
No 
Yes 
145/8497 (2) 
4/109 (4) 
Reference 
2.2 (0.8-6.0) 
0.179   
Mechanical ventilation 
 
No  
Yes 
128/8512 (2) 
21/95 (22) 
Reference 
18.6 (11.1-31.1) 
<0.001 Reference 
9.1 (3.1-27.0) 
<0.001 
Supplementary Oxygen 
therapy 
No  
Yes 
30/5579 (1) 
119/3029 (4) 
Reference 
7.6 (5.1-11.3) 
<0.001 Reference 
32.8 (14.7-73.1) 
<0.001 
Antibiotics prescribed on 
admission 
No 
Yes 
7/576 (1) 
142/7847 (2) 
Reference 
1.5 (0.7-3.2) 
0.322   
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Duration of hospitalisation 
(days) 
<2 
2-7 
>7 
22/3238 (1) 
85/4001 (2) 
42/1362 (3) 
Reference 
3.2 (2.0-5.1) 
4.7 (2.8-7.9) 
<0.001   
OR – Odds ratio, CI – confidence interval, HIV – human immunodeficiency virus, ICU – Intensive care unit 
*Asthma, other chronic lung disease, chronic heart disease (valvular heart disease, coronary artery disease, or heart failure excluding 
hypertension), liver disease (cirrhosis or liver failure), renal disease (nephrotic syndrome, chronic renal failure), diabetes mellitis, 
immunocompromising conditions excluding HIV infection (organ transplant, immunosuppressive therapy, immunoglobulin deficiency, 
malignancy) or neurological disease (cerebrovascular accident, spinal cord injury, seizures, neuromuscular conditions). Comorbidities were 
considered absent in cases for which the medical records stated that the patient had no underlying medical condition or when there was no 
direct reference to that condition. 
** Detected on lytA PCR  
***Pathogen isolated within 72 hours of hospitalisation from blood or pleural fluid; organisms viewed as likely contaminants were excluded 
****Co-infection with at least one of parainfluenza virus 1, 2 and 3; respiratory syncytial virus; enterovirus; human metapneumovirus; 
adenovirus; human rhinovirus in addition to influenza 
†Odds ratios and p values shown for all variables included in the multivariable model. Hosmer-Lemeshow goodness of fit test for the final 
multivariable model p=0.54.
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5.4 Discussion 
 
In South Africa, HIV-infected children have an elevated incidence of SARI hospitalisation, duration of 
hospitalisation and in-hospital case-fatality ratio compared to HIV-uninfected children. This indicates 
that underlying HIV-infection remains a major risk factor for pneumonia morbidity and mortality in 
settings such as ours, even following HAART availability. Of the respiratory viruses with a likely 
pathogenic role, RSV was identified in more than 25% of children, particularly in infants, and influenza 
was identified in 7% of children. While pneumococcus was not as commonly identified (4% of cases), 
likely related to lower sensitivity of available diagnostic assays for pneumococcal pneumonia, infection 
with pneumococcus was an independent risk factor for death. 
 
The overall incidence of hospitalisation for SARI per 100,000 population in South Africa amongst children 
<5 years of age (∼2500-3000) was similar to that described from Africa in a recent systematic review of 
global pneumonia burden (∼2260, 95% CI 1530-3340).3  We observed the highest incidence in those 
aged <12 months (∼8000-11000/100,000 population), where incidences were slightly higher than other 
estimates for Africa (∼5080/100,000 population, 95% CI 3360-7690/100,000) but similar to those from 
some studies from middle-income countries.3;117 118 
 
Pneumonia is the most common reason for hospitalisation among African HIV-infected children.6 In our 
study, HIV-infected children experienced an elevated incidence of hospitalisation compared to HIV-
uninfected children but this excess risk decreased over the study period from 3.7 (95% CI 3.4-4.0) in 
2009 to 1.8 (1.6-2.1) in 2012, possibly related to more widespread availability of early HAART over this 
period.119;120 Studies have shown that more widespread HAART availability is associated with a reduction 
in pneumonia incidence in HIV-infected children, albeit HIV-infected children on HAART still have a 
higher incidence of pneumonia.110;113;114 We found that HIV-infected children experienced a four times 
increased risk of death compared to HIV-uninfected children once hospitalised. This is similar to several 
other studies which reported case-fatality ratios 3-6 times greater in HIV-infected children.6;89;121;122 The 
overall case-fatality ratios among HIV-infected children in our study are however lower than has 
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previously been described in HIV-infected children from South Africa, possibly related to more 
widespread HAART availability. 
 
Human rhinovirus (37%), RSV (26%) and adenovirus (26%) were the most commonly identified 
respiratory viruses, while influenza was identified in 7% of patients, similar to what has been found in 
other studies from Africa using PCR for viral diagnosis.118;123-125 Challenges remain for the attribution of a 
causal role for some viruses (including human rhinovirus, adenovirus and enterovirus), which are also 
identified at high frequency from healthy individuals.118;123;125 RSV and human metapneumovirus (both 
thought to have a likely pathogenic role) were identified less frequently in HIV-infected than -uninfected 
children suggesting that the increased risk of hospitalisation due to HIV-associated immunosuppression 
is relatively lower for these pathogens than for other aetiologies. Previous studies from South Africa 
have shown that while the detection rate for viruses may be lower in HIV-infected children, the 
incidence of hospitalisation is substantially higher in HIV-infected compared to HIV-uninfected 
children.89;126 Children with RSV were less likely to die, as has been previously described.118 This is likely 
because the relative contribution of viral aetiologies compared with bacterial aetiologies is greater for 
hospitalised pneumonia than amongst deaths.127 A high proportion of children were co-infected with 
multiple respiratory viruses (33%), as has been described previously, although co-infection was not 
associated with adverse outcome.7;43;125 HIV-infected children have been described to have an increased 
risk of polymicrobial infections due to multiple bacterial, viral and fungal pathogens.110 We were not 
able to assess this as we did not systematically test for important pathogens in HIV-infected children, 
particularly tuberculosis, P. jirovecii and cytomegalovirus. 
 
Blood cultures were performed in less than half of children, limiting our ability to comment on the 
proportion with bacteraemic pneumonia, but similar to other studies from South Africa, the 
pneumococcus and S. aureus were the most common bacteria identified. S. pneumoniae is an important 
cause of pneumonia in HIV-infected and uninfected children.121;122 In our study we identified 
pneumococcus from 5% of children overall using PCR. These rates are similar to other studies from 
South Africa prior to PCV introduction which used systematic blood culture collection.121;122 Failure to 
observe lower detection rates following PCV introduction may be attributed to our diagnostic technique, 
real-time PCR, identifying more pneumococcal cases than blood culture in our setting.128 
Notwithstanding this, additional cases of pneumococcal co-infection may still have been missed.129;130 
Pneumococcal DNA in the blood may reflect occult bacteraemia in some individuals.131-133 Patients 
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testing positive for pneumococcus had a high prevalence of detection of respiratory viruses although 
many of these may have been co-incidental viral shedding.7 Influenza was the only virus to be more 
commonly detected in patients testing positive for pneumococcus. The association between influenza 
and pneumococcal infection has been described previously. 82;134 
 
Our study had potential limitations. HIV status data was only available for ∼60% of children. If the 
characteristics of untested children differed from those of tested children this may have biased findings, 
however, we did not find any significant differences in epidemiologic characteristics of tested and 
untested patients. In addition, for the estimation of incidence stratified by HIV status we conducted a 
sensitivity analysis to explore the scenario if all untested children were HIV-uninfected. Data on access 
to HAART and CD4+ T cell count were only available for a limited number of HIV-infected children 
limiting our ability to comment on the effect of HAART and degree of immunosupression on disease 
incidence and severity. Incidence data were only available for one urban site with available denominator 
data and thus may not be generalisable to other settings within South Africa. We may have 
underestimated incidence as not all cases may have sought care at CHBAH hospital. In addition, we did 
not account for individuals who did not seek care at all. Children who died may have been less likely to 
consent to inclusion into studies such as ours or may die before or shortly after hospital admission prior 
to being consented and this may lead to underestimation of case-fatality ratios and potential exclusion 
of most severely ill children.123 Therefore our incidence and mortality estimates likely represent a 
minimum estimate. The denominators for the numbers of HIV-infected and -uninfected children each 
year were obtained from the 2008 version of the ASSA model. Subsequent to the development of this 
model, rates of access to interventions for prevention of mother-to-child transmission of HIV (PMTCT) 
and early HAART amongst children have been more rapid than expected leading to possible 
overestimation of the numbers of children with AIDS in South Africa, which could have led to an 
underestimation of the relative risk of hospitalisation in HIV-infected children.23;119 There were a large 
number of statistical analyses conducted on these data and corrections were not made for multiple 
testing. 
 
In conclusion, we have demonstrated a high incidence of hospitalisation for SARI amongst children aged 
<5 years in South Africa, particularly in children aged <1 year and HIV-infected children. HIV-infected 
children also experience increased hospitalisation duration and mortality. RSV was an important cause 
of pneumonia. Vaccines for RSV are currently under development and could be expect to have a 
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substantial impact on pneumonia burden if they become available. 135 Ongoing reductions in burden of 
pneumococcal pneumonia may be expected following PCV introduction. Influenza was identified in 7% 
of children and influenza vaccination is recommended for children <5 years in South Africa but very few 
children in our study reported being vaccinated.45 Influenza vaccines are less effective in children <5 
years and efficacy has not been demonstrated in HIV-infected children.136 More widespread access to 
influenza vaccines could, however, potentially impact on disease burden, particularly if newer 
formulations such as adjuvanted vaccines are shown to be safe and effective in our setting. HIV remains 
a major risk factor for SARI and adverse outcome, and more widespread adherence to PMTCT protocols 
and availability of HAART can be expected to have ongoing impact in reducing disease burden.6;110
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Chapter 6 Epidemiology of SARI among adults and children ≥5 years age 
in a high HIV-prevalence setting, 2009-2012 
 
6.1 Introduction 
There are few published studies estimating the incidence and aetiology of pneumonia amongst older 
children and adults from high HIV-prevalence settings in sub-Saharan Africa.137 Data on the burden, 
severity and aetiology of SARI amongst HIV-infected and -uninfected older children and adults are 
necessary to guide the relative prioritisation of prevention and control efforts. In South Africa the HIV 
prevalence amongst individuals aged 15-49 years, the age group with the highest prevalence of HIV, was 
estimated to be 17% in 2012.23 South Africa embarked on a national programme of provision of HAART 
in 2004.138 HAART coverage amongst eligible HIV-infected adults (CD4+ T cell count<350/mm3) in South 
Africa was estimated to be 29% in 2009 and 52% in 2011.120  
 
We aimed to describe the incidence, viral aetiology and factors associated with death amongst HIV-
infected and -uninfected individuals aged ≥5 years hospitalised with SARI in South Africa from 2009 
through 2012. 
  
6.2 Materials and Methods 
 
Case definitions, study procedures, laboratory methods, definitions, evaluation of HIV serostatus and 
calculation of incidence are described in Chapter 2 Methods section 2.2.  
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6.3 Results 
6.3.1 Demographic, clinical characteristics and aetiology 
From February 2009 through December 2012, 7977 individuals  ≥5 years  of age who fulfilled the SARI 
case definition were screened for study enrolment, of whom 7193 (90%) were enrolled (Figure 6.1). The 
most common reasons for non-enrolment were being confused or too ill to consent (55%) and study 
refusal (11%). Of the 7193 enrollees, 8% (579) were 5-14 years of age, 8% (599) 15-24 years, 53% (3784) 
25-44 years, 25% (1778) 45-64 years and 6% (453) ≥65 years (Table 6.1). The majority of subjects were 
enrolled at CHBAH (76%, 5443/7193), and 61% (4413/7193) were female. Among patients with available 
information, the overall case-fatality ratio was 7% (514/7154). 
 
HIV-infection status was available for 6334 (88%) of enrolled individuals (Figure 6.1). When comparing 
patients tested for HIV to those not tested for HIV, controlling for year of test, surveillance site and age 
group there were no differences in patient epidemiologic characteristics or case-fatality ratios (data not 
shown). The overall HIV prevalence among persons ≥5 years with available data was 74% (4663/6334) 
and was highest in the 25-44 year age group 88% (3016/3421) (Table 6.1). Twelve percent of individuals 
(879/7191) had an underlying medical condition, excluding HIV. Only 14 individuals reported having 
been vaccinated against influenza in the current year and no subject had received pneumococcal 
vaccines. 
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Figure 6.1 Flow chart of patients aged ≥5 years included in the study 
SARI - severe acute respiratory illness, HIV - human immunodeficiency virus
SARI patients aged  ≥5 years meeting 
case definition
N=7977
SARI patients enrolled 
n=7193 (90%)
Tested for HIV n=6334 
(88%)
HIV infected 
n=4663 (74%)
Died 
n=352 (8%)
Survived
n=4290 (92%)
Unknown outcome
n=21 (<1%)
HIV uninfected
n=1671 (26%) 
Died 
n=87 (5%)
Survived
n=1573 (94%)
Unknown outcome 
n=11 (1)
Not tested for HIV    
n=859 (12%)
Died
n=75 (9%)
Survived 
n=777 (90%)
Unknown outcome
n=7 (1%)
SARI patients not enrolled
n=784 (10%)
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Table 6.1 Comparison of the clinical and epidemiologic characteristics of HIV-infected and -uninfected individuals aged ≥5 years hospitalised with 
severe acute respiratory illness (SARI) at four sentinel surveillance sites, South Africa, 2009-2012 
 
Characteristics 
All patients  
n/N (%) 
HIV-infected 
n/N (%) 
HIV-uninfected 
n/N (%) 
Univariate analysis (HIV-
infected vs. uninfected) 
Multivariable 
analysis**** 
OR(95% CI) p OR (95% CI) p 
Demographic characteristics       
Age group 
(years) 
5-14 
15-24 
25-44 
45-64 
≥65 
579/7193 (8) 
599/7193 (8) 
3784/7193 (53) 
1778/7193 (25) 
453/7193 (6) 
191/4663 (4) 
336/4663 (7) 
3016/4663 (65) 
1047/4663 (22) 
73/4663 (2) 
185/1671 (11) 
192/1671 (11) 
405/1671 (24) 
564/1671 (34) 
325/1671 (19) 
Reference 
1.7 (1.3-2.2) 
7.2 (5.7-9.1) 
1.8 (0.4-2.3) 
0.2 (0.2-0.3) 
<0.001 Reference 
1.1  (0.8-1.6) 
5.4 (4.1-7.2) 
1.6 (1.2-2.1) 
0.2 (0.1-0.3) 
<0.001 
Female  4413/7193 (61) 3037/4663 (65) 891/1671 (53) 1.6 (0.5-1.87) <0.001 1.7 (1.5-2.0) <0.001 
Black African race 6998/7185 (97) 4597/4659 (99) 1573/1670 (94) 4.5 (3.3-6.3) <0.001 3.8 (2.6-5.7) <0.001 
Year 2009 
2010 
2011 
2012 
1464/7193 (20) 
2022/7193 (28) 
1935/7193 (27) 
1772/7193 (25) 
857/4663 (18) 
1407/4663 (30) 
1291/4663 (28) 
1108/4663 (24) 
302/1671 (18) 
423/1671 (25) 
544/1671 (33) 
402/1671 (24) 
Reference 
1.2 (1.0-1.4) 
0.8 (0.7-1.0) 
1.0 (0.8-1.2) 
<0.001  
 
 
 
Site CHBAH 
Matikwana and 
Mapulaneng 
5443/7193 (76) 
950/7193 (13) 
 
3648/4663 (78) 
543/4663 (12) 
 
1230/1671 (74) 
231/1671 (14) 
 
Reference 
0.8 (0.7-0.9) 
 
<0.001   
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Edendale 
Klerksdorp 
565/7193 (8) 
235/7193 (3) 
348/4663 (7) 
124/4663 (3) 
123/1671 (7) 
87/1671 (5) 
1.0 (0.8-1.2) 
0.5 (0.4-0.6) 
Underlying medical conditions        
Underlying medical condition 
excluding tuberculosis and HIV* 
879/7191 (12) 345/4663 (7) 433/1671 (26) 0.2 (0.2-0.3) <0.001 0.3 (0.2-0.4) <0.001 
Underlying tuberculosis (receiving 
tuberculosis treatment on 
admission) 
276/7167 (4) 217/4646 (5) 28/1668 (2) 2.9 (1.9-4.3) <0.001 2.1 (1.3-3.2) 0.002 
Alcohol use  1175/7174 (16) 729/4650 (16) 344/1667 (21) 0.7 (0.6-0.8) <0.001 0.6 (0.5-0.7) <0.001 
Smoking  1029/7175 (14) 625/4651 (13) 310/1667 (19) 0.7 (0.6-0.8) <0.001   
Infectious agents identified        
Pneumococcus** 600/6519 (9) 499/4506 (11) 70/1601(5) 2.7 (2.1-3.5) <0.001 2.2 (1.6-2.9) <0.001 
>1 virus identified 470/7056 (7) 289/4608 (6) 98/1640 (6) 1.1 (0.8-1.3) 0.669   
Influenza (any type) 621/7067 (9) 350/4609 (8) 185/1650 (11) 0.7 (0.5-0.8) <0.001 0.6 (0.5-0.8) <0.001 
Influenza A 366/7067 (5) 190/4609 (4) 113/1650 (7) 0.6 (0.5-0.7) <0.001   
Influenza B 246/7067 (3) 153/4609 (3) 70/1650 (4) 0.8 (0.6-1.0) 0.083   
Adenovirus  613/6453 (10) 394/4206 (9) 132/1509 (9) 1.1 (0.9-1.3) 0.475   
Enterovirus 119/6933 (2) 65/4610 (1) 30/1636 (2) 0.8 (0.5-1.2) 0.230   
Human rhinovirus 1267/7049 (18) 835/4608 (18) 265/1636 (16) 1.1 (1.0-1.3) 0.080   
Human metapneumovirus 124/7052 (2) 88/4610 (2) 23/1636 (1) 1.4 (0.9-2.2) 0.188   
Parainfluenzavirus 1 28/7052 (<1) 20/4610 (<1) 6/1636 (<1) 1.2 (0.5-3.0) 0.718   
Parainfluenzavirus 2 43/7052 (1) 31/4610 (1) 3/1636 (<1) 3.7 (1.1-12.1) 0.031   
Parainfluenzavirus 3 127/7050 (2) 94/4610 (2) 22/1634 (1) 1.5 (1.0-2.4) 0.077   
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Parainfluenza virus 1,2 or 3 194/7052 (3) 141/4610 (3) 31/1636 (2) 1.6 (1.1-2.4) 0.014   
Respiratory syncytial virus 321/7052 (5) 209/4610 (5) 60/1636 (4) 1.2 (0.9-1.7) 0.139   
Any virus identified 2279/7056 (32) 1507/4608 (33) 473/1640 (29) 1.2 (1.1-1.4) 0.004   
Any aetiology identified 2951/7193 (41) 2032/4663 (44) 570/1671 (34) 1.5 (1.3-1.7) <0.001   
Clinical presentation and course        
Symptoms ≥2 days prior to 
admission 
5934/7059 (84) 3998/4576 (87) 1296/1636 (79) 1.8 (1.6-2.1) <0.001 1.6 (1.3-1.9) <0.001 
Admission to intensive care 11/7165 (<1) 7/4650 (<1) 2/1665 (<1) 1.3 (0.3-6.0) 0.778   
Mechanical ventilation  11/7167 (<1) 5/4651 (<1) 3/1666 (<1) 0.6 (0.1-2.5) 0.480   
Oxygen required  2682/7164 (37) 1788/4649 (38) 641/1666 (38) 1.0 (0.9-1.1) 0.991   
Antibiotics prescribed on 
admission  
6787/7002 (97) 4468/4569 (98) 1549/1630 (95) 2.3 (1.7-3.1) <0.001 2.5 (1.7-3.6) <0.001 
Duration of 
hospitalisation (days) 
<2 
2-7 
>7 
525/7092 (7) 
4014/7092 (57) 
2553/7092 (36) 
208/4605 (5) 
2580/4605 (56) 
1817/4605 (39) 
158/1647 (10) 
1016/1647 (62) 
473/1647 (29) 
Reference 
1.9 (1.5-2.4) 
2.9 (2.3-3.7) 
<0.001 Reference 
1.6 (1.2-2.1) 
2.4 (1.8-3.2) 
<0.001 
Duration of hospitalisation (days) 
(median, interquartile range) 
6 (1-20) 7 (2-20) 5 (1-19)  <0.001   
Case-fatality ratio 514/7154 (7) 352/4642 (8) 87/1660 (5) 1.5 (1.2-1.9) 0.001 1.6 (1.2-2.2) 0.002 
OR – Odds ratio, CI – confidence interval, HIV – human immunodeficiency virus, CHBAH – Chris Hani Baragwanath Academic Hospital 
* Asthma, other chronic lung disease, chronic heart disease (valvular heart disease, coronary artery disease, or heart failure excluding 
hypertension), liver disease (cirrhosis or liver failure), renal disease (nephrotic syndrome, chronic renal failure), diabetes mellitis, 
immunocompromising conditions excluding HIV infection (organ transplant, immunosuppressive therapy, immunoglobulin deficiency, 
malignancy), neurological disease (cerebrovascular accident, spinal cord injury, seizures, neuromuscular conditions) or pregnancy. Comorbidities 
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were considered absent in cases for which the medical records stated that the patient had no underlying medical condition or when there was 
no direct reference to that condition.  
**Positive on lytA PCR  
***Infection with at least one of influenza, parainfluenza virus 1, 2 and 3; respiratory syncytial virus; enterovirus; human metapneumovirus ; 
adenovirus; human rhinovirus in addition to influenza 
**** HIV-infected vs. -uninfected. Odds ratios and p values shown for all variables included in the multivariable model 
† Not evaluated in multivariable model due to large amount of missing data 
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Enrolment occurred throughout the year and peaked in the winter months (May-August) (Figure 6.2). 
Overall, among those tested for respiratory viruses, 18% (1267/7049) were positive for human 
rhinovirus, 10% (613/6453) for adenovirus and 9% (621/7067) for influenza (Table 6.1). Other 
respiratory viruses tested positive in less than 5% of individuals. Adenovirus, human rhinovirus and 
enterovirus were more commonly identified in individuals 5-14 years old than other age groups (Table 
6.2). Also, 9% (600/6519) of subjects tested positive for pneumococcus (Table 6.1). The detection of 
influenza virus-associated SARI peaked during the winter months (Figure 6.2). Although pneumococcus 
on lytA PCR was detected perennially, there was also a peak in detection during winter months of at 
least two years (2009 and 2010). 
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Table 6.2 Percentage of patients testing positive for viral and bacterial pathogens by age group amongst individuals aged ≥5 years hospitalised 
with severe acute respiratory illness (SARI) at four sentinel surveillance sites, South Africa, 2009-2012 
 
Age group (years) 5-14 
n/N (%) 
15-24 
n/N (%) 
25-44 
n/N (%) 
45-64 
n/N (%) 
≥65 
n/N (%) 
p* 
Influenza  64/560 (11) 64/590 (11) 306/3715 (8) 139/1756 (8) 48/446 (11) 0.010 
Adenovirus  115/489 (24) 49/520 (9) 286/3403 (8) 138/1628 (8) 25/413 (6) <0.001 
Enterovirus 43/550 (8) 12/585 (2) 40/3715 (1) 17/1756 (1) 7/446 (2) <0.001 
Human rhinovirus 189/550 (34) 128/585 (22) 652/3715 (18) 249/1756 (14) 49/446 (11) <0.001 
Human 
metapneumovirus 
13/550 (2) 9/585 (2) 68/3715 (2) 26/1756 (1) 8/446 (2) 0.694 
Parainfluenzavirus 1 3/550 (1) 2/585 (<1) 11/3715 (<1) 9/1756 (1) 3/446 (1) 0.599 
Parainfluenzavirus 2 8/550 (1) 4/585 (1) 25/3715 (1) 6/1756 (<1) 0/446 (0) 0.021 
Parainfluenzavirus 3 7/550 (1) 17/585 (3) 67/3715 (2) 27/1756 (2) 9/446 (2) 0.220 
Respiratory syncytial 
virus 
36/550 (7) 21/585 (4) 171/3715 (5) 77/1756 (4) 16/446 (4) 0.118 
Any respiratory viral 
infection 
315/550 (57) 209/585 (36) 1159/3715 (31) 491/1756 (28) 105/446 (24) <0.001 
Infection with >1 
respiratory virus 
108/550 (19) 47/585 (8) 211/3715 (6) 85/1756 (5) 19/446 (4) <0.001 
Pneumococcus** 24/381 (6) 48/553 (9) 348/3507 (10) 166/1655 (10) 14/423 (3) <0.001 
 
*chi squared test **On lytA PCR or blood culture 
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Figure 6.2 Number of patients enrolled with severe acute respiratory illness (SARI) and influenza, pneumococcal and respiratory syncytial virus 
(RSV) detection rates by epidemiologic week and year at four sentinel surveillance sites, South Africa, 2009-2011
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6.3.2 Incidence of hospitalisation in HIV-infected and -uninfected 
patients 
The annual incidence of hospitalisation per 100,000 population for SARI at CHBAH ranged between 325 
(95% CI 315-335) in 2012 and 617 (95% CI 603-632) in 2010 and was highest in the 45-64 year age-
group; annual range 501 to 1284 (Table 6.3). HIV-infected individuals experienced an age-adjusted 
increased relative risk of 13 to 19 times for SARI hospitalisation compared to HIV-uninfected individuals. 
On sensitivity analysis, assuming that all patients not tested for HIV were HIV-uninfected, the trend 
towards a higher incidence of SARI hospitalisations in HIV-infected individuals remained in all age groups 
and years. 
 
6.3.3 Characteristics of HIV-infected patients and factors associated 
with HIV infection 
Compared to HIV-uninfected cases, using multivariable analysis, in addition to other factors, HIV-
infected subjects were more likely to be receiving tuberculosis treatment at admission (OR 2.1, 95% CI   
1.3-3.2), have pneumococcal infection (OR 2.2, 95% CI   1.6-2.9) and had a higher case-fatality ratio 
(OR1.6, 95% CI   1.2-2.2; Table 6.1). In contrast, HIV-infected subjects were less likely to have an 
underlying medical condition (OR 0.3, 95% CI   0.2-0.4), or be infected with influenza (OR 0.6, 95% CI   
0.5-0.8). 
 
Only 1455 (31%) of 4663 HIV-infected patients had available CD4+ T cell count data, of whom 68% (987) 
had CD4+ T-lymphocyte cell counts <200/mm3. The case-fatality ratio was significantly higher in HIV-
infected subjects with severe immunosuppression (12%, 117/983) than those with CD4+ T-lymphocyte 
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count of >200/mm3 (5%, 22/462, p<0.001). Of those with available data, 41% (1083/2629) reported 
currently receiving HAART and 34% (1566/4569) reported receiving prophylaxis with trimethoprim-
sulfamethoxazole. The case-fatality ratio was similar in individuals receiving (7%, 80/1075) and not 
receiving HAART (vs. 8%, 121/1536, p=0.681). 
 
6.3.4 Factors associated with mortality 
The overall case-fatality ratio was 7% (514/7154), with a median age of 42 years (interquartile range 23-
74) among those who died. The case-fatality ratio was 1.5 times greater amongst HIV-infected (8%) as 
compared to HIV-uninfected (5%) individuals with SARI (Table 6.4). On multivariable analysis, 
independent risk indicators associated with death included increasing age group, HIV infection (OR 1.8, 
95% CI   1.3-2.4), receipt of mechanical ventilation (OR 6.5, 95% CI   1.3-32.0) and receiving 
supplementary-oxygen therapy (OR 2.6, 95% CI   2.1-3.2) (Table 6.4).
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Table 6.3 Incidence of severe acute respiratory illness (SARI) hospitalisations per 100,000 population by year and HIV status at Chris Hani-
Baragwanath Hospital, South Africa 
 
Year 
Age 
group 
(years) 
% with  HIV 
result (n/N) 
HIV 
prev
alenc
e % 
IR 
(95% CI) 
All patients 
IR 
(95% CI) 
HIV infected 
IR 
(95% CI) 
HIV uninfected 
RR 
(95% CI) 
HIV infected vs. 
HIV uninfected 
RR 
(95% CI) 
HIV infected vs. 
HIV uninfected 
sensitivity 
analysis∫ 
2009 
5-14 41 (53/129)  36 126 (112-141) 1833 (1496-2227) 82 (71-96) 22.1 (17.2-28.4) 6.9 (4.8-9.6) 
15-24 85 (88/103) 65 283 (261-308) 2005 (1806-2223) 110 (95-126) 18.2 (15.3-21.8) 12.3 (10.4-14.5) 
25-44 89 (553/625) 91 846 (818-875) 2947 (2845-3053) 101 (90-114) 29.0 (25.8-32.8) 11.8 (10.8-12.8) 
45-64 88 (232/263) 62 925 (882-970) 4682 (4403-4973) 400 (370-432) 11.7 (10.6-12.9) 8.7 (7.9-9.5) 
≥65 79 (37/47) 14 624 (562-690) 8777 (6488-1152) 544 (487-608) 16.1 (11.7-21.7) 12.1 (8.5-16.9) 
All (≥5 
years) 
83 (963/1167) 76 591 (577-606) 3072 (2985-3162) 179 (171-188) 18.1 (17.0-19.3)* 10 (9.8-11.0)* 
         
2010 
5-14 53 (41/77) 37 65 (56-76) 876 (670-1126) 42 (35-52) 20.5 (14.7-28.4) 8.4 (5.5-12.5) 
15-24 89 (121/136) 70 206 (187-226) 1665 (149-1858) 67 (56-79) 24.9 (20.3-30.6) 17.5 (14.5-21.3) 
25-44 92 (906/981) 90 753 (727-779) 2576 (248-267) 105 (95-117) 24.3 (21.8-27.3) 13.5 (12.4-14.8) 
45-64 93 (435/468) 69 
1284 (1237-
1334) 
7025 (671-735) 456 (426-488) 15.4 (14.2-16.7) 12.4 (11.4-13.4) 
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≥65 92 (85/92) 21 
1101 (1022-
1185) 
19793 (16749-
23169) 
878 (808-954) 22.5 (18.7-26.9) 20.5 (16.9-24.6) 
All (≥5 
years) 
91 
(1588/1754) 
78 617 (603-632) 3175 (3091-3262) 194 (186-203) 19.3 (18.2-20.4)* 13.6 (12.9-14.3)* 
         
2011 
5-14 73 (29/40) 31 36 (29-44) 376 (252-541) 25 (20-33) 14.4 (9.0-22.7) 9.4 (5.5-15.5) 
15-24 97 (97/100) 55 150 (134-167) 998 (859-115) 74 (63-87) 13.4 (10.8-16.7) 12.6 (10.1-15.6) 
25-44 98 (755/770) 85 588 (566-611) 1914 (1837-1996) 117 (106-130) 16.3 (14.7-18.3) 14.4 (13.0-16.0) 
45-64 97 (368/379) 62 641 (608-677) 3056 (2854-3269) 282 (259-308) 10.8 (9.7-12.1) 10 (9.0-11.2) 
≥65 96 (71/74) 9 419 (372-470) 2490 (1564-3633) 389 (344-440) 6.3 (3.9-9.5) 6 (3.7-9.2) 
All (≥5 
years) 
97 
(1320/1363) 
71 389 (378-401) 1934 (1869-2001) 134 (127-141) 13.1 (12.2-14.0)* 11.9 (11.1-12.7)* 
2012 
        
5-14 60 (22/37) 27 33 (26-41) 285 (186-431) 25 (19-32) 11.6 (6.9-18.8) 5.9 (3.1-10.6) 
15-24 82 (75/91) 67 134 (119-149) 1154 (1002-1323) 48 (40-59) 23.8 (18.7-30.5) 14.6 (11.6-18.4) 
25-44 88 (586/665) 86 505 (485-527) 1665 (1592-1741) 94 (84-106) 17.6 (15.6-19.9) 8.9 (8.1-9.8) 
45-64 89 (270/302) 65 501 (472-532) 2448 (2271-2635) 203 (184-225) 12 (10.6-13.6) 9 (8.0-10.2) 
≥65 84 (53/63) 26 337 (296-381) 5260 (4052-6692) 252 (217-291) 20.8 (15.4-27.8) 16.6 (12.1-22.5) 
All (≥5 
years) 
87 
(1006/1158) 
75 325 (315-335) 1703 (1642-1766) 99 (93-105) 15.8 (14.7-17.1)* 9.6 (8.9-10.3)* 
 
IR – incidence rate, RR – relative risk, CI – confidence interval, HIV – human immunodeficiency virus 
Significant relative risk value at p<0.05 are in bold ∫Assuming that all patients not tested for HIV are HIV negative *Age-adjusted 
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Table 6.4 Factors associated with death amongst patients aged ≥5 years hospitalised with severe acute respiratory illness (SARI) at four sentinel 
surveillance sites, South Africa, 2009-2012 
 
Characteristics 
Case-fatality ratio 
(%)  
Univariate analysis Multivariable analysis† 
OR (95% CI) p OR (95% CI) p 
Demographic characteristics      
Age group (years) 
 
5-14 
15-24 
25-44 
45-64 
≥65 
12/577 (2) 
28/594 (5) 
255/3760 (7) 
171/1774 (10) 
48/449 (11) 
Reference  
2.3 (1.2-4.6) 
3.4 (1.9-6.2) 
5.0 (2.8-9.1) 
5.6 (3.0-10.7) 
 
<0.001 
Reference  
3.0 (1.2-7.5) 
3.4 (1.5-7.9) 
5.9 (2.5-13.7) 
9.1 (3.7-22.2) 
<0.001 
Sex 
 
Male  
Female 
204/2773 (7) 
310/4381 (7) 
Reference  
1.0 (0.8-1.2) 
0.654   
Race 
 
Other race 
Black African 
6/187 (3) 
508/6959 (7) 
Reference  
2.4 (1.0-5.4) 
0.038 Reference  
3.5 (1.1-11.2) 
0.033 
Year 2009 
2010 
2011 
2012 
106/1456 (7) 
164/2018 (8) 
132/1927 (7) 
112/1753 (6) 
Reference 
1.1 (0.9-1.5) 
0.9 (0.7-1.2) 
0.9 (0.7-1.1) 
0.196   
Site CHBAH 
Matikwana and 
Mapulaneng 
371/5424 (7) 
77/948 (8) 
 
Reference 
1.2 (0.9-1.6) 
 
0.016 Reference  
1.8 (1.3-2.6) 
 
0.001 
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Edendale 
Klerksdorp 
55/554 (10) 
11/228 (5) 
1.5 (1.1-2.0) 
0.7 (0.4-1.3) 
1.6 (1.1-2.4) 
0.9 (0.5-1.8) 
Underlying medical conditions     
HIV status 
 
Negative 
Positive 
87/1660 (5) 
352/4642 (8) 
Reference  
1.5 (1.2-1.9) 
0.001 Reference  
1.8 (1.3-2.4) 
<0.001 
Underlying medical 
condition excluding 
tuberculosis and HIV* 
No 
Yes 
456/6281 (7) 
58/871 (6) 
Reference  
0.9 (0.7-1.2) 
0.520   
Underlying tuberculosis 
(receiving tuberculosis 
treatment on admission) 
No 
Yes 
475/6854 (7) 
36/274 (13) 
Reference  
2.0 (1.4-2.9) 
<0.001 Reference 
2.0 (1.3-3.0) 
0.001 
Alcohol  No 
Yes 
447/5963 (8) 
65/1172 (6) 
Reference  
0.7 (0.6-0.9) 
0.018   
Smoking  No 
Yes 
461/6108 (8) 
51/1028 (5) 
Reference  
0.6 (0.5-0.9) 
0.003   
Infectious agents identified      
Invasive bacterial infection 
on culture† 
No 
Yes 
108/994 (11) 
5/41 (12) 
1.1 (0.4-3.0) 0.789   
Pneumococcal infection** No 
Yes 
413/5885(7) 
50/597 (8) 
Reference  
1.2 (0.9-1.6) 
0.187   
Laboratory-confirmed 
tuberculosis† 
No 
Yes 
132/2951 (4) 
30/373 (8) 
Reference  
1.9 (1.2-2.8) 
0.003   
Influenza (any type) No 473/6413 (7) Reference  0.014   
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Yes 29/616 (5) 0.6 (0.4-0.9) 
Influenza A No 
Yes 
485/6666 (7) 
17/363 (5) 
Reference  
0.6 (0.4-1.0) 
0.062   
Influenza B No 
Yes 
490/6785 (7) 
12/244 (5) 
Reference  
0.7 (0.4-1.2) 
0.170   
Adenovirus  No 
Yes 
456/6401 (7) 
46/613 (8) 
Reference  
1.1 (0.8-1.4) 
0.727   
Enterovirus No 
Yes 
495/6895 (7) 
7/119 (6) 
Reference  
0.8 (0.4-1.7) 
0.586   
Human rhinovirus No 
Yes 
413/5747 (7) 
89/1264 (7) 
Reference  
1.0 (0.8-1.2) 
0.856   
Human metapneumovirus No 
Yes 
493 /6890 (7) 
9/124 (7) 
Reference  
1.0 (0.5-2.0) 
0.965   
Parainfluenzavirus 1 No 
Yes 
499/6986 (7) 
3/28 (11) 
Reference  
1.6 (0.5-5.1) 
0.464   
Parainfluenzavirus 2 No 
Yes 
499/6971 (7) 
3/43 (7) 
Reference  
1.0 (0.3-3.2) 
0.963   
Parainfluenzavirus 3 No 
Yes 
496 (6886 (7) 
6/126 (5) 
Reference  
0.6 (0.3-1.5) 
0.292   
Respiratory syncytial virus No 
Yes 
472/6695 (7) 
30/319 (6) 
Reference  
1.4 (0.9-2.0) 
0.111   
Clinical presentation and course      
Duration of symptoms < 2 days  56/1122 (5) Reference  0.003 Reference 0.039 
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prior to admission ≥ 2 days 441/5899 (7) 1.5 (1.2-2.0) 1.4 (1.0-2.0) 
ICU admission 
 
No 
Yes 
511/7133 (7) 
3/11 (27) 
Reference  
4.9 (1.3-18.4) 
0.010   
Mechanical ventilation 
 
No  
Yes 
510/7135 (7) 
4/11 (36) 
Reference  
7.4 (2.2-25.4) 
<0.001 Reference 
6.5 (1.3-32.0) 
0.022 
Oxygen therapy 
 
No  
Yes 
215/4466 (5) 
299/2677 (11) 
Reference  
2.5 (2.1-3.0) 
<0.001 Reference  
2.6 (2.1-3.2) 
<0.001 
Antibiotics prescribed on 
admission 
No 
Yes 
19/215 (9) 
484/6760 (7) 
Reference  
0.8 (0.5-1.3) 
0.349   
Duration of hospitalisation 
(days) 
<2 
2-7 
>7 
39/523 (7) 
252/4011 (6) 
219/2552 (9) 
Reference  
0.8 (0.6-1.2) 
1.2 (0.8-1.7) 
0.002 Reference  
0.5 (0.3-0.7) 
0.6 (0.4-1.0) 
<0.001 
OR – Odds ratio, CI – confidence interval, HIV – human immunodeficiency virus, CHBAH- Chris Hani Baragwanath Academic Hospital, ICU – 
Intensive care unit 
*Asthma, other chronic lung disease, chronic heart disease (valvular heart disease, coronary artery disease, or heart failure excluding 
hypertension), liver disease (cirrhosis or liver failure), renal disease (nephrotic syndrome, chronic renal failure), diabetes mellitis, 
immunocompromising conditions excluding HIV infection (organ transplant, immunosuppressive therapy, immunoglobulin deficiency, 
malignancy), neurological disease (cerebrovascular accident, spinal cord injury, seizures, neuromuscular conditions) or pregnancy. Comorbidities 
were considered absent in cases for which the medical records stated that the patient had no underlying medical condition or when there was 
no direct reference to that condition. 
**On lytA PCR  
† Not evaluated in multivariable model due to large amount of missing data   
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6.4 Discussion 
More than two thirds (>70%) of individuals aged ≥5 years hospitalised with SARI in South Africa are co-
infected with HIV, making this by far the most important underlying risk condition for this syndrome 
even in the era of  widespread availability of HAART. HIV-infected individuals had a 13-19 times greater 
incidence of SARI hospitalisation than HIV-uninfected individuals and also experienced prolonged 
hospitalisation and increased risk of death. The spectrum of infectious agents identified from HIV-
infected and -uninfected individuals was generally similar, however HIV-infected individuals were more 
likely to test positive for pneumococcus.  
 
The overall incidence of SARI hospitalisation ranged from 325-617/100,000, somewhat greater than was 
described for the same age group in another high HIV-prevalence setting in Kenya (229/100,000).139 The 
incidence of SARI hospitalisation in HIV-uninfected individuals aged ≥5 years ranged from 99-
194/100,000 population each year, similar to what has been described from low HIV-prevalence middle 
income countries such as Bangladesh (110-130/100,000) and Thailand (incidence in all ages 177-
580/100,000) and slightly lower than the incidence in US adults (267/100,000).117;140;141 Differences in 
incidence observed in different settings may be related to differences in health-seeking behavior, 
differing thresholds for hospital admission and case definitions or may reflect real differences. The 13-19 
times elevated incidence (1703-3175/100,000) of hospitalised SARI which we observed in HIV-infected 
individuals was somewhat greater than the 4 times elevated incidence described in HIV-infected adults 
from Kenya with outpatient and hospitalised acute respiratory illness.137 Amongst HIV-uninfected 
individuals, incidence increased with increasing age, similar to that seen in low HIV-prevalence 
countries.141 
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We identified at least one respiratory virus in approximately one-third of all patients, similar to other 
studies from adults.7;142 The prevalence of detection of most respiratory viruses was highest in the 5-14 
year age-group and decreased with increasing age. Human rhinovirus and adenovirus were most 
commonly detected, followed by influenza. While the detection of influenza virus in persons aged ≥5 
years with SARI likely reflects an aetiologic role, the clinical relevance of many of the other respiratory 
viruses is unclear without a comparison to controls.7;137 Unfortunately we did not have data available on 
the prevalence of these viruses amongst healthy controls. 
 
Pneumococcus was identified in 9% of individuals overall with the highest detection rate in persons aged 
25-64 years, the age group most affected by HIV. While real-time PCR is more sensitive than blood 
culture for diagnosing pneumococcal SARI, additional cases of pneumococcal co-infection may still have 
been missed.130 Sterile specimen cultures for bacteria were performed uncommonly (<15% of patients) 
and thus we were not able to compare bacterial culture with PCR results. On multivariable analysis 
pneumococcus was significantly more likely to be detected in HIV-infected than HIV-uninfected 
individuals, likely reflecting the very high relative risk of hospitalisation for pneumococcal SARI in HIV 
infected adults.143 Pneumococcal polysaccharide vaccine is used uncommonly in South Africa, but PCV 
was introduced into the routine childhood immunisation programme in 2009. This may have impacted 
on the proportion of patients testing positive for pneumococcus over time as a result of indirect 
protection conferred to unvaccinated adults.105;144 
 
In contrast to pneumococcus, influenza virus was significantly less commonly identified from HIV-
infected individuals. We have previously demonstrated, in the same population, that HIV-infected 
individuals aged 25-44 years have an ∼10-20 times increased incidence of hospitalisation for influenza.134 
The relatively lower detection rates in our study likely reflect the fact that HIV-infected individuals have 
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a substantially elevated risk of other important pathogens such as pneumococcus, P. jirovecii and 
tuberculosis which contribute to a greater proportion of SARI cases in the HIV-infected, rather than an 
absolute lower risk in HIV-infected individuals. This has been described for respiratory viral infections in 
HIV-infected children from South Africa.89  
 
The overall case-fatality ratio was 7%, similar to other studies from Africa and the US.137;139;141;145;146 
Increasing age was a risk factor for death, similar to that observed in developed country settings.147 
However, the median age at death was 42 years, lower than the median age at death in more developed 
settings where death is more common in elderly individuals. HIV-infected individuals were 1.5 times 
more likely to die than HIV-uninfected individuals in contrast to other studies which have found a similar 
case-fatality ratio in HIV-infected and -uninfected individuals.145;148;149 Earlier studies included smaller 
numbers of cases and may have been underpowered to detect the relatively modest increased relative 
risk of death. In addition, in other studies, HIV-uninfected individuals may have had a higher proportion 
of elderly or persons with underlying illness than in our study. Receiving tuberculosis treatment on 
admission was also a risk factor for death. A study among South African gold miners found that 
underlying lung damage from tuberculosis was a risk factor for SARI mortality.150 Patients who died had 
a shorter duration of hospitalisation, suggesting that death occurred early during admission. A longer 
duration of symptoms prior to hospitalisation was also associated with increased mortality, thus delayed 
clinical presentation and subsequent delayed treatment initiation may have contributed to mortality in 
some cases. 
 
Approximately 40% of patients with available data reported receiving HAART on admission, suggesting 
that even in the presence of HAART, pneumonia remains a common clinical presentation in HIV-infected 
individuals. More than two thirds of patients with available data had severe immunosuppression on 
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CD4+ T cell count and a low CD4+ T cell count was associated with increased mortality. Data on receipt 
of HAART and CD4+T cell counts was unfortunately available for less than half of all HIV-infected 
patients potentially biasing results.  
 
Additional limitations of our study include that subjects were only tested systematically for ten viruses 
and pneumococcus. Blood cultures were not performed systematically and we did not test for P. jirovecii 
or tuberculosis, important causes of pneumonia in HIV-infected individuals.149 Our study may have 
underestimated mortality because severely ill cases may have been less likely to consent to inclusion or 
may have died before or shortly after hospital admission prior to being consented.123 Our estimates of 
incidence were only obtained from one surveillance hospital and assumed that all individuals in the 
community accessed care at CHBH hospital. In addition, we did not account for individuals who did not 
seek care at all. Therefore our incidence and mortality estimates likely represent a minimum estimate. 
Nevertheless, the estimates of relative risk by HIV status should be robust, unless patients had 
differential access to care by HIV-infection status. 
 
Efforts to promote earlier diagnosis of HIV infection and earlier HAART initiation as well as more 
widespread HAART availability may reduce the substantial burden of disease in HIV-infected individuals 
and improve outcomes in patients with SARI. Pneumococcus and influenza were commonly detected 
aetiologies. This suggests that more widespread access to vaccination against influenza and 
pneumococcus as well as indirect protection following the introduction of PCV in children in South Africa 
could also reduce the burden of SARI.
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Chapter 7 Severe influenza-associated lower respiratory tract infection 
in a high HIV-prevalence setting-South Africa, 2009-2011 
 
7.1 Introduction 
 
There is limited knowledge about influenza epidemiology in HIV-infected individuals, particularly in sub-
Saharan Africa where the burden of HIV is greatest.89;151 Studies from the US suggest that in the absence 
of HAART, HIV-infected adults have an increased risk of seasonal influenza hospitalisation,151 mortality152  
and prolonged illness compared to the general population. This risk decreased following the widespread 
introduction of HAART.90;152 In 2011 ∼52% of eligible HIV-infected adults in South Africa were receiving 
HAART.120 
 
In South Africa, HAART-naïve HIV-infected children had an 8-fold greater risk of hospitalisation for 
laboratory-confirmed influenza infection, and a trend toward higher case-fatality (8% vs. 2% in HIV-
uninfected children).89;92 South African adults with AIDS experienced similar influenza-associated 
mortality to US adults with AIDS in the pre-HAART era.152 In Kenya, HIV-infected adults were at increased 
risk of influenza-associated pneumonia hospitalisation compared with HIV-uninfected adults.137;153  
 
Data from low HIV prevalence countries where most individuals evaluated had access to HAART and 
influenza antivirals suggest that HIV-infected individuals were more likely to be hospitalised with 
influenza A(H1N1)pdm09 infection compared to the general population, but  did not differ in rates of 
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ICU admission or death.151;154 Conversely, a high HIV prevalence (53%) was described amongst patients 
who died with confirmed influenza A(H1N1)pdm09 infection in South Africa.12  
 
We aimed to estimate the incidence of hospitalisation for influenza-associated SARI and describe the 
clinical course of illness in HIV-infected and -uninfected individuals in South Africa.  
 
7.2 Materials and Methods 
Case definitions, study procedures, laboratory methods, definitions, evaluation of HIV serostatus and 
calculation of incidence are described in Chapter 2 Methods section 2.2.  
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7.3 Results 
7.3.1 Demographic, clinical characteristics, and seasonality of 
influenza-associated SARI 
From February 2009 through December 2011, 14,725 individuals fulfilling the SARI case definition were 
approached for study enrolment, of whom 2562 (17%) were not enrolled. The commonest reasons for 
non-enrolment were study refusal (n=779, 30%), unavailable legal guardian (n=758, 30%) and patients 
being confused or too ill to consent (n=242, 9%). Of 12,163 patients enrolled and meeting the SARI case 
definition, 11,925 (98%) were tested for influenza and 1056 (9%) tested positive (Figure 7.1). The 
influenza detection rate varied by age group from 7% (266/4046) in those <1 year, 11% (252/2292) in 1-
4 years, 12% (111/934) in 5-24 years, 9% (270/2930) in 25-44 years, 9% (119/1395) in 45-64 years and 
12% (38/328) in ≥65 years (p<0.001). The overall influenza detection rate was similar amongst HIV-
infected (358/4208, 9%) and HIV-uninfected (461/4473, 10%) individuals (p=0.163). The majority of 
patients (8961/12163, 74%) were enrolled at CHBAH.  
 
In 2009, influenza circulation was biphasic with a peak in influenza A(H3N2) (190/386, 49% of annual 
cases), followed by a second peak of influenza A(H1N1)pdm09 (158/386, 41% of annual cases). In 2010, 
influenza B was the predominant subtype (172/289, 60% of annual cases) and in 2011 there were again 
two influenza peaks; influenza A(H1N1)pdm09 predominated (152/381, 40% of annual cases) initially, 
followed by influenza B and A(H3N2) (129/381, 34% and 100/381, 26% of annual cases respectively) 
(Figure 7.2).
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Figure 7.1 Flow chart of patients included in the study 
SARI – Severe acute respiratory illness, HIV – human immunodeficiency virus
SARI patients meeting case 
definition
N=14,725
SARI patients 
enrolled 
n=12,163 (83%)
Tested for influenza 
n=11,925 (98%)
Influenza positive   
n=1056 (9%)
Tested for HIV 
n=819 (78%)
HIV positive  
n=358 (44%)
Died
n=19 (5%)
Survived 
n=337 (94%)
Unknown outcome 
n=2(1%)
HIV negative n=461 
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Figure 7.2 Number of patients testing influenza positive by subtype and influenza detection rate by epidemiologic week and year amongst 
patients with hospitalised pneumonia at four sentinel surveillance sites, South Africa, 2009-2011
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Of the 1056 patients testing influenza positive, 819 (78%) had an available HIV-infection status result 
(597 (73%) on anonymised HIV testing; 83 (10%) tested by ward clinicians; 139 (17%) both anonymous 
and clinician testing) (Figure 7.1). The proportion of influenza-positive patients with available HIV results 
increased over the study period from 62% (239/386) in 2009 to 89% (339/381) in 2011 (p<0.001); and 
increased with increasing age from 65% (335/518) among children <5 years to 90% (484/538) amongst 
persons ≥5 years (p<0.001). When comparing patients tested for HIV to those not tested for HIV, 
controlling for year of test and age group, there were no differences in patient epidemiologic 
characteristics or case-fatality ratios (data not shown). The proportion of patients tested for HIV and the 
HIV prevalence amongst tested patients did not differ between surveillance sites (data not shown). The 
overall HIV prevalence among influenza-positive case-patients was 44% (358/819) and varied by age 
group: 10% (16/164) in those <1year, 17% (29/171) in 1-4 years, 46% (38/82) in 5-24 years, 84% 
(212/251) in 25-44 years, 54% (61/113) in 45-64 years and 5% (2/38) in ≥65 years (p<0.001).  
 
Amongst patients testing influenza positive, 10% (106/1056) had tuberculosis co-infection, 7% (63/889) 
had pneumococcal co-infection on lytA PCR and 7% (78/1056) had another underlying medical 
condition. Amongst 106 patients classified as having tuberculosis, only 31 (29%) were laboratory 
confirmed. There were only three pregnant women identified in this surveillance testing influenza 
positive, all of whom were HIV infected. No influenza-positive patient reported receiving influenza 
vaccine or oseltamivir treatment. Forty-eight HIV-infected and 116 HIV-uninfected patients with 
influenza had sterile site specimens submitted for bacterial culture, amongst which three HIV-infected 
patients (two S. pneumoniae and one H. influenzae) and two HIV-uninfected patients (one Neisseria 
meningitidis and one S. pneumoniae) tested positive. 
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7.3.2 Incidence of influenza hospitalisation in HIV-infected and -
uninfected patients 
The incidence of hospitalisation for influenza-associated SARI amongst patients at CHBAH was highest in 
patients aged 0-4 years in all study years and for all influenza subtypes with highest incidence in those 
aged <1 year (Table 7.1, Figure 7.3). Smaller peaks in incidence were observed in the adult (25-54 years) 
and elderly (≥65 years) age groups each year (Figure 7.3). HIV-infected individuals experienced a four to 
eight times greater incidence of influenza-associated SARI (age-adjusted RR 4.2 (95% CI 3.6-4.8) in 2009, 
age-adjusted RR 7.5 (95% CI 6.4-8.8) in 2010 and age-adjusted RR 5.5 (4.7-6.3) in 2011) (Table 7.1). The 
incidence of hospitalisation amongst HIV-infected as compared to HIV-uninfected individuals was three 
to five times greater for influenza A(H3N2) (age-adjusted RR 3.3 (95% CI 2.7-4.0) in 2009 and age-
adjusted RR 4.9 (3.5-6.5) in 2011), four to six times greater for influenza A(H1N1)pdm09 (age-adjusted 
RR 4.4 (95% CI 3.6-5.4) in 2009 and 5.6 (95% CI 4.4-7.1) in 2011), and nine times greater for influenza B 
(age-adjusted RR 8.7 (13.2-38.5) in 2010 and 8.7 (4.4-7.2) in 2011) (Table 7.2). The relative risk of 
hospitalisation for influenza-associated SARI amongst HIV-infected individuals was elevated in all age 
groups (generally highest in age group 25-44 years) and for all influenza subtypes however this was not 
statistically significant in children aged 0-4 years in some analyses (Table 7.1 and Table 7.2). On 
sensitivity analysis, assuming that all patients not tested for HIV were HIV negative, the trend towards a 
higher incidence of influenza in HIV-infected individuals remained in all age groups and subtypes except 
amongst those aged 0-4 years, the group with the lowest proportion of patients tested for HIV.
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Table 7.1 Incidence of laboratory-confirmed influenza-associated severe acute respiratory illness (SARI) hospitalisations per 100,000 population 
by year and HIV status at Chris Hani-Baragwanath Academic Hospital, South Africa 
 
Year 
Age 
group 
(years) 
% with  HIV 
result (n/N) 
HIV 
prev
alenc
e % 
IR 
(95% CI) 
All patients 
IR 
(95% CI) 
HIV infected 
IR 
(95% CI) 
HIV uninfected 
RR 
(95% CI) 
HIV infected vs. 
HIV uninfected 
RR 
(95% CI) 
HIV infected vs. 
HIV uninfected 
sensitivity 
analysis∫ 
2009 
0-4 55 (103/188) 11 336 (304-370) 766 (553-1021) 314 (284-349) 2.4 (1.7-3.3) 1.3 (0.8-1.9) 
5-24 62 (18/29) 39 27 (23-33) 194 (142-261) 17 (14-22) 11.0 (7.4-16.1) 5.5 (3.5-8.5) 
25-44 93 (41/44) 88 59 (52-67) 198 (173-227) 9 (7-14) 20.3 (13.8-31.3) 12.7 (9-17.9) 
≥45 100 (27/27) 41 67 (57-78) 260 (201-331) 44 (36-54) 5.9 (4.2-8.2) 5.9 (4.2-8.2) 
Total 66 (189/288) 34 78 (73-83) 228 (206-254) 54 (50-60) 4.2 (3.6-4.8)* 3.3 (2.9-3.8)* 
         
2010 
0-4 64 (54/84) 9 153 (131-177) 317 (187-514) 145 (124-170) 2.2 (1.3-3.6) 1.4 (0.7-2.5) 
5-24 68 (15/22) 33 14 (11-18) 89 (57-135) 10 (7-13) 8.8 (5.2-15.2) 5.2 (2.8-9.5) 
25-44 94 (73/78) 89 60 (53-68) 203 (178-231) 9 (6-13) 22.9 (15.4-34.7) 14.1 (10.1-19.8) 
≥45 97 (38-39) 55 47 (40-56) 243 (191-307) 24 (18-31) 10.3 (7.2-14.8) 9.7 (6.8-13.9) 
Total 81 (180/223) 53 49 (45-53) 197 (176-219) 26 (23-29) 7.5 (6.4-8.8)* 6.2 (5.3-7.3)* 
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2011 
0-4 84 (81/96) 6 186 (162-212) 273 (151-463) 182 (159-209) 1.5 (0.8-2.6) 1.3 (0.6-2.3) 
5-24 100 (13/13) 46 8 (6-11) 71 (42-111) 5 (3-7) 15.4 (7.7-30.3) 15.4 (7.7-30.3) 
25-44 99 (88/89) 80 68 (61-76) 206 (180-234) 19 (15-24) 10.9 (8.2-14.7) 10.4 (7.9-14) 
≥45 98 (42/43) 38 56 (48-65) 192 (146-247) 39 (32-48) 4.9 (3.5-6.9) 4.8 (3.4-6.7) 
Total 93 (224/241) 43 54 (50-58) 186 (167-207) 34 (31-37) 5.5 (4.7-6.3)* 5.3 (4.6-6.2)* 
 
IR – incidence rate, RR – relative risk, CI – confidence interval, HIV – human immunodeficiency virus 
Significant relative risk value at p<0.05 are in bold ∫Assuming that all patients not tested for HIV are HIV negative *Age-adjusted 
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Figure 7.3 Incidence of laboratory-confirmed influenza-associated severe acute respiratory illness (SARI) hospitalisation, per 100,000 population, 
by year and age group, at Chris Hani-Baragwanath Academic Hospital, South Africa 
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Table 7.2 Incidence rate (IR) of laboratory-confirmed influenza associated severe acute respiratory illness (SARI) hospitalisation per 100,000 
population by year, HIV status and influenza type or subtype at Chris Hani-Baragwanath Hospital, South Africa 
Year Dominant 
influenza 
type/subtype 
Age 
group 
(years) 
% with 
HIV 
result 
HIV 
prevalence 
% 
IR 
(95% CI) 
All patients 
IR 
(95% CI) 
HIV infected 
IR 
(95% CI) 
HIV uninfected 
RR 
(95% CI) 
HIV infected vs. 
HIV uninfected 
RR 
(95% CI) 
HIV infected vs. 
HIV uninfected 
sensitivity 
analysis∫ 
2009 A(H3N2) 0-4 51 8 211 (186-238) 375 (238-576) 202 (178-230) 1.9 (1.2-2.9) 0.9 (0.4-1.6) 
A(H3N2) 5-24 53 50 14 (11-18) 129 (88-185) 7 (5-11) 17.3 (10.1-29.8) 6.3 (3.3-11.4) 
A(H3N2) 25-44 87 100 20 (16-25) 77 (62-96) 0 (0-1)** -  18.3 (9.6-38.1) 
A(H3N2) ≥45 100 38 20 (15-26) 71 (42-112) 13 (9-20) 5.2 (2.7-9.5) 5.2 (2.7-9.5) 
A(H3N2) Total 57 28 38 (34-41) 94 (80-111) 28 (26-32) 3.3 (2.7-4.0) * 2.2 (1.8-2.8)* 
A(H1N1)pdm09 0-4 61 11 109 (92-129) 251 (145-428) 101 (84-122) 2.5 (1.4-4.4) 1.4 (0.7-2.9) 
A(H1N1)pdm09 5-24 77 30 12 (9-16) 67 (40-112) 9 (6-12) 7.4 (4-14.3) 5.2 (2.5-10.1) 
A(H1N1)pdm09 25-44 96 86 30 (25-36) 97 (87-119) 5 (3-9) 16.9 (10.2-30.5) 12.7 (7.9-21) 
A(H1N1)pdm09 ≥45 100 31 40 (32-48) 118 (80-169) 30 (23-39) 3.9 (2.4-6.1) 3.9 (2.4-6.1) 
A(H1N1)pdm09 Total 75 36 34 (30-37) 101 (87-119) 23 (20-26) 4.4 (3.6-5.4)* 3.8 (3.1-4.7)* 
          
2010 B 0-4 62 6 94 (78-114) 133 (53-272) 93 (76-112) 1.4 (0.6-3) 0.9 (0.2-2.1) 
B 5-24 77 30 8 (6-11) 47 (24-82) 6 (4-9) 7.6 (3.5-15.3) 5.3 (2.1-11) 
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B 25-44 96 92 37 (32-44) 131 (111-154) 4 (2-7) 30.3 (17.5-56.9) 20.2 (12.7-34.4) 
B ≥45 96 73 28 (22-35) 189 (143-246) 9 (5-13) 22.1 (13.2-38.5) 19 (11.5-32.7) 
B Total 81 58 30 (27-33) 129 (113-147) 15 (13-17) 8.7 (13.2-38.5)* 7.5 (6.1-9.2)* 
          
2011 A(H3N2) 0-4 65 0 45 (34-58) 0 (0-72)** 47 (35-61) 0 (0-1.6) 0 (0-1.6) 
A(H3N2) 5-24 25 100 1 (0-2) 12 (2-34) - - - 
A(H3N2) 25-44 51 84 15 (11-18) 47 (35-61) 3 (1-6) 15 (7.7-33.5) 15 (7.7-33.5) 
A(H3N2) ≥45 94 33 19 (15-25) 59 (34-91) 15 (10-20) 4 (2.1-7) 4 (2.1-7) 
A(H3N2) Total 63 40 13 (11-15) 42 (34-53) 9 (7-11) 4.9 (3.5-6.5)* 4.9 (3.5-6.5)* 
A(H1N1)pdm09 0-4 52 8 85 (70-104) 160 (68-311) 82 (66-100) 2.0 (0.8-3.9) 1.7 (0.7-3.6) 
A(H1N1)pdm09 5-24 67 38 5 (3-7) 35 (16-67) 3 (2-5) 10.8 (4.2-26.3) 10.8 (4.2-26.2) 
A(H1N1)pdm09 25-44 26 84 25 (208-303) 81 (66-100) 5 (3-9) 15.2 (8.9-26.1) 12.7 (7.9-22.2) 
A(H1N1)pdm09 ≥45 19 46 16 (11-21) 64 (39-99) 10 (6-14) 6.7 (3.5-12.6) 5.7 (2.9-10.5) 
A(H1N1)pdm09 Total 33 43 21 (19-24) 74 (62-88) 13 (11-15) 5.6 (4.4-7.1)* 5.2 (4.1-6.6)* 
B 0-4 81 8 60 (47-75) 133 (43-258) 57 (45-74) 1.4 (0.7-4.7) 1.4 (0.5-4.1) 
B 5-24 100 50 2 (1-4) 23 (9-51) 1 (0-3) 7.6 (4.8-67.1) 7.6 (4.8-67.1) 
B 25-44 100 73 28 (24-34) 78 (64-97) 10 (7-15) 30.3 (5.1-11.6) 30.3 (5.1-11.6) 
B ≥45 100 38 21 (16-27) 189 (44-106) 9 (10-20) 22.1 (2.7-8.3) 22.1 (2.7-8.3) 
B Total 93 45 20 (18-23) 129 (58-84) 15 (10-15) 8.7 (4.4-7.2)* 8.7 (4.3-7.1)* 
IR – incidence rate, RR – relative risk, CI – confidence interval, HIV – human immunodeficiency virus 
Significant relative risk values at p<0.05 in bold ∫Assuming that all patients not tested for HIV are HIV negative **1 sided 
*Age-adjusted 
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7.3.3 Characteristics of HIV-infected patients and factors associated 
with HIV infection among influenza virus positive patients 
Among influenza virus-positive cases, the case-fatality ratio was four times greater amongst HIV-
infected (19/356, 5%) as compared to HIV-uninfected (6/461, 1%) individuals (p=0.002).  In each age 
group except for the elderly the case-fatality ratios were significantly higher in HIV-infected compared to 
HIV-uninfected individuals (0-4 years 7%, 36/509 vs. 1% 34/3630 RR 7.6, 95% CI 4.7-12.1; 5-24 years 6%, 
28/433 vs. 1%, 3/298 RR 6.4, 95% CI 2.0-21.1; 25-44 years 7%, 164/2381 vs. 3%, 8/308 RR 2.7, 95% CI 
1.3-5.4; 45-64 years 12%, 100/833 vs. 7%, 34/456 RR 1.6, 95% CI 1.1-2.4; ≥65 years 4%, 2/50 vs. 9%, 
23/246 RR 0.4, 95% CI 0.1-1.8). 
 
Compared to patients without HIV infection who were hospitalised with influenza, using multivariable 
analysis, HIV-infected patients hospitalised with influenza were more likely to be  age group 5-24 years 
(OR 4.4, 95% CI 2.4-8.2), 25-44 years (OR 24.2, 95% CI 14.1-41.7) or 45-64 years (OR 6.2, 95% CI 3.4-
11.3), female sex (OR 1.9, 95% CI 1.2-2.8), black African race (OR 4.0, 95% CI 1.1-14.6), co-infected with 
pneumococcus (OR 2.3,  95% CI 1.0-5.0), have influenza type B (vs. A) infection (OR 1.6 95% CI 1.0-2.4), 
hospitalised for 2-7 days (OR 2.8 95% CI 1.5-5.5) or >7 days (OR 4.5, 95% CI 2.1-9.5) and more likely to 
die (OR 3.9, 95% CI 1.1-14.1) (Table 7.3). In contrast they were less likely to have underlying medical 
conditions other than HIV (OR 0.4, 95% CI 0.2-0.8).  
 
One hundred and eighteen (33%) HIV-infected patients had available CD4+ T cell count data, seven of 
these were aged <5 years. The majority, (60%, 70/118) had severe immunosuppression (CD4+ T cell 
counts <200/mm3 or age-specific equivalent). The case-fatality ratio was not significantly different 
between patients with (13%, 9/70) and without (6%, 3/47, p=0.258) severe immunosuppression, 
although numbers were small. The duration of hospitalisation was longer amongst those with (median 7 
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days, interquartile range (IQR) 2-11 days) than those without (median 5 days, IQR 1-7 days, p=0.02) 
severe immunosuppression. Fifty-one percent (111/218) of those with available data reported currently 
receiving HAART and 25% (60/241) reported receiving prophylaxis with trimethoprim-sulfamethoxazole. 
The case-fatality ratio was similar in patients receiving (7/113, 6%) and not receiving (8/107, 7%) HAART 
(p=0.706). 
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Table 7.3 Comparison of the clinical and epidemiologic characteristics of HIV-infected and -uninfected patients hospitalised with influenza-
associated severe acute respiratory illness (SARI) at four sentinel surveillance sites, South Africa 2009-2011 
Characteristics 
HIV-infected 
n/N (%) 
HIV-uninfected 
n/N (%) 
Univariate analysis Multivariable analysis**** 
OR(95% CI) p OR (95% CI) p 
Demographic characteristics    
Age group (years) 
 
<5 
5-24 
25-44 
45-64 
≥65 
45/358 (13) 
38/358 (11) 
212/358 (59) 
61/358 (17) 
2/358 (1) 
290/461 (63) 
44/461 (10) 
39/461 (8) 
52/461 (11) 
36/461 (8) 
Referent 
5.6 (3.3-9.5) 
35.0 (22.0-55.7) 
7.6 (4.7-12.3) 
0.4 (0.1-1.5) 
<0.001 Referent 
4.4 (2.4-8.2) 
24.2 (14.1-41.7) 
6.2 (3.4-11.3) 
0.2 (0.04-0.9) 
<0.001 
Female  253/358 (71) 224/461 (49) 2.5 (1.9-3.4) <0.001 1.9 (1.2-2.8) 0.003 
Black African race 353/358 (99) 445/460 (97) 2.4 (0.9-6.6) 0.096 4.0 (1.1-14.6) 0.036 
Year 2009 
2010 
2011 
88/358 (25) 
127/358 (35) 
143/358 (40) 
151/461 (33) 
114/461 (25) 
196/461 (43) 
Referent 
1.9 (1.3-2.8) 
1.3 (0.9-1.8) 
0.002   
Co-infections and underlying medical conditions      
Underlying medical condition 
excluding tuberculosis and HIV* 
25/358 (7) 47/461 (10) 0.7 (0.4-1.1) 0.109 0.4 (0.2-0.8) 0.008 
Smoking (≥12 years) 32/299 (11) 24/151 (16) 0.6 (0.4-1.1) 0.117   
Alcohol (≥12 years) 28/299 (9) 26/151 (17) 0.5 (0.3-0.9) 0.017   
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Underlying tuberculosis  60/357 (17) 19/461 (4) 4.7 (2.7-8.0) <0.001   
Pneumococcal co-infection on PCR ** 37/345 (11) 17/389 (4) 2.7 (1.5-5.0) <0.001 2.3 (1.0-5.0) 0.043 
Viral respiratory co-infection*** 82/358 (23) 152/456 (33) 0.6 (0.4-0.8) 0.001   
Influenza type B (vs. A) 148/358 (41) 133/461 (29) 1.7 (1.3-2.3) <0.001 1.6 (1.0-2.4) 0.035 
2 or more doses of pneumococcal 
conjugate vaccine(<5 years) 
3/39 (8) 53/242 (22) 0.3 (0.1-1.0) 0.051   
Clinical presentation and course      
Symptoms ≥ 2 days prior to admission 296/358 (83) 295/461 (64) 2.7 (1.9-3.7) <0.001   
Admission to intensive care 0/357 (0) 6/461 (1) Undefined 0.031   
Mechanical ventilation  2/357 (1) 4/461 (1) 0.6 (0.1-3.5) 0.612   
Oxygen required  142/357 (40) 141/461 (31) 1.5 (1.1-2.0) 0.006   
Antibiotics prescribed on admission  351/358 (98) 438/460 (95) 2.5 (1.1-6.0) 0.036   
Duration of hospitalisation 
(days) 
<2 
2-7 
>7 
20/352 (6) 
217/352 (62) 
115/352 (33) 
149/460 (32) 
241/460 (52) 
70/460 (15) 
Referent 
6.7 (4.1-11.1) 
12.2 (7.0-21.3) 
<0.001 Referent 
2.8 (1.5-5.5) 
4.5 (2.1-9.5) 
<0.001 
 
Duration of hospitalisation (days) 
(median, interquartile range) 
6 (4-8) 3 (1-6) 1.1 (1.05-1.13) <0.001   
Case-fatality ratio 19/356 (5) 6/461 (1) 4.3 (1.7-10.8) 0.002 3.9 (1.1-14.1) 0.038 
OR – Odds ratio, CI – confidence interval, HIV – human immunodeficiency virus 
* Asthma, other chronic lung disease, chronic heart disease (valvular heart disease, coronary artery disease, or heart failure excluding 
hypertension), liver disease (cirrhosis or liver failure), renal disease (nephrotic syndrome, chronic renal failure), diabetes mellitis, 
immunocompromising conditions excluding HIV infection (organ transplant, immunosuppressive therapy, immunoglobulin deficiency, 
malignancy), neurological disease (cerebrovascular accident, spinal cord injury, seizures, neuromuscular conditions) or pregnancy. Comorbidities 
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were considered absent in cases for which the medical records stated that the patient had no underlying medical condition or when there was 
no direct reference to that condition.  
**Three additional cases of Streptococcus pneumoniae on blood culture not included  
***Co-infection with at least one of parainfluenza virus 1, 2 and 3; respiratory syncytial virus; enterovirus; human metapneumovirus ; 
adenovirus; human rhinovirus in addition to influenza 
**** Odds ratios and p values shown for all variables included in the multivariable model 
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7.4 Discussion 
 
We have shown that HIV-infected individuals experienced elevated incidence of hospitalisation, 
prolonged hospitalisation and increased in-hospital mortality due to influenza. In contrast to what is 
described in most other countries,154 in our setting, HIV is the commonest underlying risk condition 
associated with hospitalised influenza (overall >40% of patients with laboratory-confirmed influenza 
were HIV infected). This results in a W-shaped age-distribution of influenza hospitalisations, with peaks 
in young children, somewhat in the elderly and an additional peak in young adults associated with HIV 
infection. These findings highlight the need to target HIV-infected individuals for influenza prevention 
including vaccination and early influenza antiviral treatment during the influenza season. 
 
Bacterial co-infections may have contributed to some of the hospitalisations and mortality in the HIV-
infected group. HIV-infected individuals with influenza-associated SARI had an elevated risk of co-
infection with pneumococcus. HIV-infected individuals have an elevated risk of hospitalisation for 
invasive pneumococcal disease129 and there is a synergistic relationship between influenza and 
pneumococcus.82;102 HIV-infected individuals with influenza-associated SARI were also more likely to 
have underlying tuberculosis. However, not all cases of tuberculosis were laboratory-confirmed. 
Tuberculosis was also common in a South African case-series of influenza A(H1N1)pdm09 deaths.12 An 
association between tuberculosis and influenza-associated mortality has been suggested, but further 
studies are needed to evaluate these interactions.153;155 
 
The observed prevalence of underlying medical conditions was lower in HIV-infected (7%) than -
uninfected individuals (10%) and lower than has been observed in the US (68% of HIV-infected and 74% 
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of hospitalised HIV-uninfected adults with influenza A(H1N1)pdm09).154 This could be because these 
conditions are not well documented or may reflect a true difference in the relative contribution of 
underlying risk conditions in our setting.  
 
The increased risk of hospitalisation for influenza-associated SARI amongst HIV-infected individuals 
appeared to be greater for influenza B (~8 times increased risk) than influenza A (~3-4 times increased 
risk). Reasons for this are unclear. Influenza B severity is intermediate between that of influenza 
A(H3N2) and A(H1N1). Bacterial superinfection may contribute to mortality in patients (particularly 
adults) with influenza B, and severe and fatal disease due to influenza B has been described in previously 
healthy individuals.156  
 
Influenza vaccination is safe and efficacious in African HIV-infected adults,108;157 while the efficacy 
amongst HIV-infected children is unclear.136 No patients reported receiving influenza vaccination or 
antiviral treatment despite national recommendations for influenza vaccination of risk groups and for 
treatment of individuals with severe illness or underlying risk conditions.45 TIVs (between 170,000-
1,000,000 doses for a population of ∼40 million each year) and oseltamivir treatment are made available 
free of charge through the public health sector in South Africa, although challenges in procurement and 
distribution may limit practical availability. The low uptake of oseltamivir may be related to clinician 
perception that antiviral therapy is ineffective when patient presentation to hospital is delayed (>80% of 
HIV-infected patients reported symptoms for more than 48 hours prior to admission). More data on 
effectiveness of antivirals from settings similar to ours are needed. An additional contributing factor may 
be a low index of suspicion for influenza in HIV-infected persons who are at risk of other causes of 
respiratory disease such as pneumococcus, P. jirovecii and tuberculosis.154 Communication of 
surveillance data to inform clinicians about the influenza season should increase the clinical index of 
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suspicion for influenza infection. Maternal immunisation against influenza has been suggested as a 
strategy to reduce the high burden of influenza in children aged <6 months.158 Data are needed on the 
effectiveness of this intervention in HIV-infected women. 
 
Our study has several limitations. The low rate of HIV testing amongst children may have introduced bias 
if the characteristics of children not tested for HIV differed from those tested. Incidence data were 
derived from a temperate urban area and may not be representative of more subtropical rural areas, 
but incidences in HIV-uninfected individuals were similar to what has been described in other 
developing countries.25;159 This analysis included the years following the introduction of influenza 
A(H1N1)pdm09 and thus we cannot comment on age-specific influenza incidence prior to this period. 
Several studies have suggested that pregnancy is an important risk factor for severe influenza and 
mortality.20;160 Very few pregnant women were enrolled in our study, likely because these patients may 
have been missed as review of admissions to maternity wards was not always consistent. The case 
definition of physician-diagnosed SARI in children aged three months through <5 years relied on 
subjective clinician assessment and did not include fever as a criterion because fever reporting may be 
subjective in this age group. CD4+ T cell count data were only available for a third of HIV-infected 
patients and CD4+ T cell counts among tested patients may have differed from those in untested 
patients.  
 
In conclusion, we have demonstrated that in a high HIV-prevalence setting, HIV is an important risk 
factor for influenza hospitalisation and severe disease. Additional data on the efficacy of newer 
(adjuvanted, increased dose or intradermal) influenza vaccine strategies in HIV-infected children and 
adults and children with advanced HIV-associated immunosupression or tuberculosis co-infection are 
needed. Studies exploring the cost-effectiveness of influenza vaccination strategies in high HIV-
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prevalence settings are needed to guide the relative prioritisation of these interventions for HIV-
infected individuals in relation to other risk groups and other interventions.
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Chapter 8 Conclusions 
Using vital statistics data on underlying causes of death for individuals age ≥65 years from South Africa 
and the US, and Serfling-type linear regression modeling, we have demonstrated that influenza causes 
substantially greater rates of excess mortality amongst South African compared to the US elderly. These 
elevated rates of excess mortality were observed for several different underlying causes of death and 
increased with increasing age group. This challenges the perception held by clinicians and public health 
officials in many African countries that influenza does not cause substantial mortality in Africa and 
supports ongoing efforts to expand access to influenza control measures in the region.33;35;40 
 
Using a similar approach amongst adults with AIDS aged 25-54 years in South Africa and the US, we were 
able to demonstrate that in the US, adults with AIDS experienced dramatically (150-200 times) elevated 
influenza-related mortality rates compared to the general population in the pre-HAART era. These rates 
declined substantially following widespread HAART availability, but still remained elevated compared to 
age peers. South African adults with AIDS experienced similar mortality burden in the pre-HAART era to 
US adults with AIDS. This provides useful data to guide policy in South Africa regarding interventions to 
control influenza.161 Specifically, it is likely that more widespread access to HAART will have a substantial 
impact on influenza-associated mortality in this risk group, however even in the presence of HAART this 
group will remain important to target for influenza prevention for the foreseeable future.  
 
In order to prioritise influenza control measures in relation to other interventions aimed at reducing the 
hospitalisation and mortality burden due to SARI in South Africa, it is important to describe the 
epidemiology of influenza in relation to the syndrome overall and other aetiologic agents. In our analysis 
of SARI surveillance data amongst children aged <5 years from 2009 through 2012, when considering 
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viral pathogens with a likely aetiologic role, influenza was less common than RSV (26% of disease) but 
accounted for 7% of SARI hospitalisations. For comparison, 4% of patients tested positive for 
pneumococcus, although tests for the diagnosis of pneumococcal pneumonia lack sensitivity (5-20% 
sensitivity for blood culture) and PCV was introduced into the EPI in 2009.63;115;130;131;162 Influenza was the 
only respiratory virus for which detection rate varied by severity of pneumonia, with patients with very 
severe pneumonia being more likely to test influenza positive as compared to those with pneumonia or 
severe pneumonia.116 In addition, the only virus with a significantly different prevalence amongst 
pneumococcal-positive compared to -negative children was influenza, with the influenza detection rate 
being approximately two times higher in pneumococcus-positive children. This supports other data 
demonstrating the synergistic relationship between these two pathogens.82;102 Amongst children, two 
seasonal peaks in SARI hospitalisations were observed in most years, the first larger peak coinciding with 
RSV circulation and the second coinciding with the influenza season, although in some years, peaks 
coincided with circulation of other respiratory viruses.  
 
Analysis of SARI surveillance data amongst individuals aged ≥5 years, found that HIV-infected individuals 
were proportionately more likely to be infected with pneumococcus and less likely to be infected with 
influenza when compared to HIV-uninfected individuals with SARI. However, we have demonstrated 
that HIV-infected individuals experience a 4-8 times greater incidence of hospitalisation for influenza-
associated SARI than HIV-uninfected individuals. The lower influenza detection rate in HIV-infected 
individuals likely reflects the fact that a greater proportion of SARI in HIV-infected individuals is due to 
other pathogens such as P. jirovecii or tuberculosis, which we did not test for. Amongst adults with SARI, 
9% tested positive for influenza, making it the commonest virus detected with a likely aetiologic role. 
Also, 9% of patients tested positive for pneumococcus although tests for pneumococcal pneumonia may 
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lack sensitivity and underestimate the true contribution of this pathogen.63;130;131 Hospitalisations for 
SARI amongst adults peaked in the winter months coinciding with influenza virus circulation. 
 
Amongst both adult and paediatric patients we detected high prevalences of respiratory viruses such as 
human rhinovirus and adenovirus. The clinical significance of detection of these viruses amongst 
patients with SARI is unclear as these viruses may also be identified at high prevealences in control 
individuals.123 Since 2012, we have been collecting respiratory specimens from healthy control 
individuals at our sentinel surveillance sites. Preliminary analyses of these data indicate that on 
multivariable analysis influenza virus, RSV, human metapneumovirus and human rhinovirus were more 
commonly identified in patients with SARI and ILI than healthy controls.163 Simple comparison of the 
prevalence of respiratory virus detection amongst cases of SARI and ILI as compared to healthy controls 
does not in itself confirm an aetiologic role. The pneumonia aetiology research for child health (PERCH) 
project, an international multicentre case-control study (including the CHBAH surveillance site), aiming 
to determine the aetiology of pneumonia amongst children aged <5 years will hopefully provide 
additional insight related to this issue.164  
 
Using data from active sentinel syndromic surveillance for SARI, we were able to demonstrate that HIV is 
the most important underlying risk factor for hospitalisation for influenza-associated SARI in our setting 
(44% of all patients were HIV infected). HIV-infected individuals had 4-8 times elevated incidence of 
hospitalisation for influenza-associated SARI and experienced prolonged hospitalisations and increased 
case-fatality ratios. These data complement the above data on influenza-associated mortality in HIV-
infected individuals, highlighting the importance of this risk group in South Africa. Children aged <5 
years and particularly <1 year of age experienced the highest rates of hospitalisation for influenza-
associated SARI, confirming this group as an important risk group for influenza prevention 
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interventions.25 Interestingly, population-based surveillance data did not demonstrate a substantial 
burden of influenza-associated hospitalisations in the elderly, in contrast to the large mortality burden 
estimated using modelling approaches. This could possibly be related to age-specific differences in 
health-seeking behaviour, with elderly individuals with SARI being less likely to seek care in hospital 
compared to other age groups. Data on health seeking behavior in this age group are, however, not 
available to support this hypothesis. Our ability to evaluate the risk of influenza hospitalisation in 
pregnant women was limited by the lack of systematic enrolment from maternity wards. This represents 
a substantial data gap both within South Africa and on the African continent.33;35 Future studies 
targeting this specific risk group are needed. 
 
Numbers of adult and paediatric patients enrolled with SARI drop sharply each year around week 1. This 
is likely as a result of end of year effects (i.e. people are less likely to be hospitalised at this time) 
although changes in contact patterns and hence risk of infections related to school holidays and closing 
of many businesses at this time of year could be a contributing factor. 
 
We observed the highest rates of SARI hospitalisations amongst children aged <5 years. More recently 
we have conducted an analysis of vital statistics data demonstrating the substantial mortality burden 
(greater than that observed in the US and Europe) associated with influenza and RSV in this age group in 
South Africa.165 Additional planned analyses of South African vital statistics data include estimation of 
the mortality impact of influenza in pregnant women and evaluation of the interaction between 
influenza and other pathogens such as tuberculosis and pneumococcus.166;167 
 
The arrival of the influenza A(H1N1)pdm09 pandemic in 2009 heralded an increased interest in influenza 
both globally and in Africa.35 A major limitation of the analyses modelling vital statistics data presented 
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here, is the inherent delays in data availability (data are released an average of three years after the 
year of death). This limits the ability to use these methods to provide timeous information on the 
mortality burden of important public health events such as the 2009 influenza pandemic. Unfortunately 
due to limitations in data availability we were not able to include an evaluation of the pandemic 
mortality impact using modelling approaches in this thesis. The year 2009 was the first year of the SARI 
surveillance programme. In this year we were able to show that the overall incidence of influenza was 
approximately double that of a typical influenza season. This was mostly because South Africa 
experienced the equivalent of two influenza seasons in that year with a full H3N2 season preceding the 
circulation of influenza A(H1N1)pdm09  virus which  circulated for a  similar duration of time. When we 
estimated the incidence by subtype the overall incidence of influenza A(H1N1)pdm09 was similar to that 
of seasonal influenza. Influenza A(H1N1)pdm09 was associated with a substantial increase in rates of 
SARI hospitalisation in individuals aged <25 years but no obvious difference in rates in young adults. This 
is similar to findings from other studies from other regions of the world that the greatest increase in 
incidence was experienced amongst children and adolescents, although some studies have found an 
increased incidence in young adults.168 We did not specifically evaluate the epidemiologic characteristics 
of patients with pandemic as compared to seasonal influenza in our study. However, in a separate 
analysis comparing characteristics of patients with influenza A(H1N1)pdm09 to those with influenza B 
and influenza A(H3N2) we found that the only significant difference between subtypes was the age 
distribution of cases [B, median age 23.7 years (95% CI 0.2-63.2); A(H3N2), median age 2.8 years (95% CI 
0.2-64.6); A(H1N1), median age 5.1 years (95% CI 0.3-60.6); p<0.001 by Wilcoxon rank sum test).169  
 
More recently, we have conducted updated analyses of South African vital statistics data from 2009 and 
have estimated a total of 4662 pandemic influenza-associated deaths for all causes of which 93% 
occurred among individuals <65 years of age.170 This estimate is similar to the lower-bound estimates for 
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South Africa from a global influenza A(H1N1)pdm09 mortality study in which country-level data for 
Africa were interpolated based on data from other regions of the world.14 Estimates were also similar to 
but slightly greater than those from a second global study aiming to estimate influenza A(H1N1)pdm09 
mortality burden utilizing time-series mortality data.171 Interestingly, while overall estimates of global 
number of deaths associated with influenza A(H1N1)pdm09 are similar (100,000–400,000 deaths from 
respiratory causes during the first year of circulation) between the two studies, estimates of the relative 
distribution of these deaths vary widely.14;171 Dawood et al. estimate that the highest rate of mortality 
was experienced in Africa in contrast to Simonsen et al. who estimated a particularly high impact in the 
Americas and South East Asia. Because in both analyses there were very few direct estimates of 
mortality burden from these regions the differences mostly result from the different approaches to 
interpolation of burden taken in these two papers. Data are lacking on the most important factors 
determining the between-country variability in influenza associated mortality both for seasonal and for 
pandemic influenza. To date, estimates of pandemic mortality from South Africa represent the only 
country-specific estimates of pandemic mortality from the African continent. More studies aiming to 
estimate influenza-associated mortality both for seasonal and pandemic influenza from Africa are 
needed although the lack of reliable vital statistics data remains an ongoing challenge.35 Novel 
approaches to estimation of influenza-associated mortality using data from verbal autopsy have been 
described and may have applicability in some African countries.172 
 
One of the key objectives of the SARI surveillance programme has been to describe the relative burden 
and contribution of different pathogens to the burden of SARI in South Africa. A major limitation in 
achieving this objective has been the focus on viral aetiologies and pneumocococus and a lack of data 
for some other important pathogens. In order to address this, since mid 2012 at two sentinel sites, 
surveillance has been expanded to include the collection of additional clinical specimens (induced 
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sputum) and testing of specimens expanded to include active testing for M. tuberculosis, P. jirovecii, 
Legionella spp., Mycoplasma spp., Chlamydophila spp. and Bordetella pertussis. 173 In addition, at these 
sites patients with milder influenza-like illness and healthy controls are being enrolled, which may assist 
in addressing outstanding questions related to the aetiologic role of some pathogens detected amongst 
patients with SARI, as well as the spectrum of illness cause by these pathogens. These data, when 
available, will be an important supplement to the data presented here. Another limitation of the 
programme is that we have only been able to generate estimates of incidence from one sentinel site 
(CHBAH) and for this site we have not had data on health-seeking behaviour in the community. Towards 
the end of 2012, we conducted health utilisation surveys in Soweto and Klerksdorp. In addition, we 
conducted a health utilisation survey in the second half of 2013 in the area around Edendale hospital. 
These surveys, once analysed, should provide more robust incidence estimates for the CHBAH site. In 
addition, in combination with denominator estimates of the populations serving Klerksdorp-Tshepong 
and Edendale Hospitals, this should allow for estimation of incidence from additional sites. This should 
provide insight into the relative influenza burden between different geographic regions and allow for 
more broadly generalisable estimates of influenza hospitalisation burden for South Africa.  
 
Estimation of the incidence of hospitalisation stratified by HIV status depends on the availability of 
robust denominator data stratified by HIV status. We obtained these data from the ASSA2008 model 
which is a widely used validated model aiming to provide demographic data related to the HIV epidemic 
in South Africa.23 Data are generally thought to be robust and correlate well with data from other 
sources.97 One limitation of the ASSA2008 model is that this model likely overestimates the rate of 
mother-to-child transmission of HIV in recent years and consequently the size of the population of HIV-
infected children.174 This has likely led to an underestimation of the increased risk of illness experienced 
in HIV-infected children <5 years, however this model represents the best currently available source of 
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such data. This limitation is stated in the relevant papers included in this thesis. A new version of the 
ASSA model is currently under development. Once this is released we may need to generate revised 
estimates of these risks if revised estimates are found to differ substantially from those published.       
 
An important limitation of ecological approaches to estimate influenza-associated excess mortality, is 
that the approach used assumes that all winter deaths above the seasonal winter baseline during 
influenza circulation periods are attributable to influenza, and does not account for the possible 
contribution of other co-circulating winter pathogens or the contribution of secondary bacterial 
infection (particularly with pneumococcus). Data from SARI surveillance confirmed that among patients 
with SARI testing positive for influenza, HIV-infected individuals are significantly more likely to have 
pneumococcal co-infection than HIV-uninfected individuals. A separate study using data from the SARI 
surveillance programme has demonstrated that both influenza and HIV co-infection are independent 
risk factors for elevated pneumococcal blood bacterial load and that pneumococcal bacterial load is an 
independent risk factor for mortality.128 Another limitation is that the modelling approach which we 
have used was not able to directly evaluate the relative contribution of RSV and other viruses to 
influenza-associated mortality in the elderly. Subsequent to the study included in this thesis we have 
conducted an analysis utilising more recent data and a different modelling approach (Poisson 
regression) and have found similar estimates of influenza-associated excess deaths in the South African 
elderly but noted no RSV-associated deaths in this group, in contrast to publications from some other 
settings.30;170  
 
Data included in this thesis has contributed to policy recommendations related to influenza vaccination 
and treatment both internationally and locally. The WHO SAGE updated their recommendations on 
influenza vaccination in 2012.17 Data on influenza-associated mortality in the elderly in South Africa 
Conclusions 
144 
 
were cited in the background documentation justifying the updated recommendations. In addition, 
unpublished data from SARI surveillance on influenza incidence in children aged <5 years were 
requested by the SAGE group for consideration in their deliberations. Data on SARI burden in children 
aged <5 years were also included in an international collaborative paper aiming to estimate global SARI 
burden amongst children aged <5 years.3 In 2012, South Africa began a process of development of a 
draft policy on influenza vaccination for the country.161 Local mortality and surveillance data are 
extensively cited in this document and have been utilised to develop local recommendations for risk 
groups to be targeted through public health vaccination programmes in South Africa.45 Despite 
recommendations for influenza vaccination and oseltamivir treatment, as well as free availability 
through the public sector, data from our surveillance programme suggests that these interventions are 
not widely utilised in the populations under surveillance.  
 
Challenges for influenza policy and vaccination in South Africa remain substantial. The number of 
individuals falling into risk groups to be targeted for influenza vaccination identified based in review of 
international and local data was estimated at more than 20 million individuals in 2011.161 This includes 
over 5 million HIV-infected individuals, over 5 million children <5 years, over 6 million individuals with 
underlying illnesses and just over 800,000 pregnant women. In 2012, <1 million doses of TIV were 
distributed through the public sector, thus significant challenges remain in order to be able to scale-up 
influenza vaccination programmes to meet this demand. In addition, there are substantial challenges for 
influenza vaccine delivery to risk groups over a limited time period preceding the influenza season which 
lead to wastage of a proportion of the limited available stock.161 While influenza antivirals are 
recommended in South Africa for persons at high risk and are freely available through the public sector, 
uptake is extremely low and no SARI patients with influenza reported receiving oseltamivir treatment. 
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Data on the effectiveness of oseltamivir treatment from developing and middle-income country settings 
where patients frequently present late for care may be needed in order to change clinician practices.  
 
In conclusion, using a combination of ecological studies modelling influenza-associated excess mortality 
as well as individual data from active syndromic surveillance we were able to demonstrate that influenza 
causes substantial morbidity and mortality in South Africa each year. Important risk groups for influenza-
associated hospitalisations and mortality in South Africa include children <5 years, HIV-infected adults 
and the elderly. TIV vaccine effectiveness is reduced in young children and the elderly.17 While TIVs are 
effective in HIV-infected adults with minimal immunosupression,108 there are no data on efficacy in 
severely immunosupressed adults and efficacy in HIV-infected children has not been demonstrated.136 
More effective influenza vaccines including vaccines with a longer duration of protection and 
heterosubtypic protection as well as vaccines which are more effective in risk groups and at an 
affordable price are needed if routine influenza vaccination is to be included in national routine 
vaccination policies in African countries.35 Influenza was one of the commonest causes of SARI amongst 
both children and adults in South Africa from 2009-2012. Over the next few years in South Africa, 
interventions such as HAART, PMTCT and PCV can be expected to have a marked impact on the 
epidemiology of SARI and the relative contribution of influenza in South Africa. Ongoing surveillance will 
be important to document these changes and guide influenza vaccination and treatment policies. 
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Severe Acute Respiratory Illness (SARI) 
Surveillance 
Centre for Respiratory Diseases and Meningitis (CRDM) 
Case Investigation Form (CIF) 
TEL: 011 386 6410 or 011 386 6434  
FAX: 086 723 3569 
 
SO Initials:    
Date completed: / /
             (DD/MM/YYYY) 
 
SARI Study ID: 
 
 
TSAP Study ID:  
 
Patient Hospitalised at:  CHBH                                     Selby                        Mapulaneng                      Matikwana    
Edendale                     Klerksdorp                             Tshepong                         
Note: surveillance officer to review criteria for all case definitions before making a decision about  the case definition/s met 
SARI*                                           SRI** (severe respiratory illness not SARI)                                              Febrile illness*** 
(enrolled on TSAP)      
*SARI with duration of symptoms ≤ 7 days. 
** SARI with duration of symptoms > 7 days, SARI/TB or TB (for Edendale and Klerksdorp-Tshepong Hospital Complex only). 
***If patient co-enrolled in the TSAP study (for Edendale Hospital only). 
NB: For Edendale and Klerksdorp-Tshepong Hospital Complex only 
Enrolled in shedding study               Yes                      No                      
1. Date of birth 
(DOB): 
/ /  If DOB unknown, please enter age: _____Years    Months    
Days  
2. Gender:  Male                             Female      
3. Race: Asian/Indian                   Black                  Coloured                  White                  Other    
(Specify) ___________ 
4. What is your house made 
of:  
                      Bricks          Iron sheeting                     Mud                 Other    
(Specify) ___________ 
5. Number of rooms used for 
sleeping? 
5.1 Number of people living in the 
house? ______________ ___________________________ 
6. What is the interviewee’s relationship to the participant?   Self     Parent/Caregiver      Other     
(Specify) ________________________ 
7. Date of admission:                         / /  
8. Admission 
diagnosis: (Tick all 
that apply) 
Neonatal Sepsis            Bronchiolitis          Bronchopneumonia/Pneumonia/Lower Respiratory 
Tract Infection      
TB          Bronchitis         Diarrhoea          Febrile seizures          Meningitis            Sepsis 
(not neonatal)   
Other   (Specify)_____________________________________________ 
9. Date of onset of 
symptoms:  
/ /  
9.1 Duration of symptoms:               0-7days                  8-14days                  
>14days   
 
Note: Complete the signs and symptoms at the time of admission, some of the signs or symptoms may have resolved by the 
time you interview the patient. This information should be available in the patient records. 
10. Maximum recorded temperature within 24hours of admission ____.____C° (##.#C°) 
Note: Record the maximum temperature recorded in the clinical notes or a temperature taken by the surveillance officer 
Note: For Edendale 
Hospital only if patient 
co-enrolled in TSAP study. 
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within 24 hours of admission if no temperature in the file. 
11. Date of maximum temperature recorded:   / /
 
                               Temperature not recorded     
12. History of 
fever?  
Yes     No     Unk  
 
      If yes, date of fever onset: / /  
13. Respiratory Rate: __________ breaths per minute             Not recorded   
14. Oxygen saturation (room air): ___________%
         Recorded on file                   Measure by Surveillance Officer within 24h of admission   
                     Date of O2 Saturation:      / /  
         Not recorded on file and not measured by Surveillance Officer within 24h of admission   
15. Patient length (if not recorded, surveillance officer to measure): ______.______cm          Percentile (if patient < 5 
years) ________          Unk   
15.1 Patient weight (if not recorded, surveillance officer to measure): ______.______kg           Percentile (if patient < 5 
years) ________          Unk   
15.2 Mid upper arm circumference (MUAC) (for patients < 5 years of age only) _____________________ cm 
16. Blood pressure on day of admission: _______/_________               Not recorded   
17. Mental status of the patient (based on AVPU), within 24 hours of admission 
Alert             Disorientated                                         Stuporous                                 Comatose                     Sedated                      
Unknown   
                           (responds to verbal commands)              (responds to painful stimuli) 
Note: If patient is alert report 15/15. 
18. Glasgow Coma Score (GCS) ______/15                     GCS from medical records:  Yes        No   
         GCS Unk   (if patient not alert and GCS not recorded on medical records) 
Note: Complete for patients ≥ 12 years, if patient < 12 years skip to Q 20. 
19. Patient oriented to: 
Person:  Yes         No         Unk                             Place:  Yes         No         Unk                             Time:  Yes         
No         Unk   
Note: Complete the table below for children < 5 years, if patient ≥ 5 years skip to Q 21. 
20. Were any of the following signs and symptoms present? 
Cough Y N Difficulty breathing Y N Chest in drawing  (retraction) Y N 
Stridor in a calm child Y N 
Tachypnoea/respiratory 
distress (2mnth-1yr 
RR>50, 1-5 RR>40) 
Y N Diarrhoea  (>3 loose stools per day) Y N 
Unable to drink or breast 
feed Y N Vomits everything Y N Convulsions Y N 
Lethargy Y N Unconsciousness  Y N Any vomiting Y N 
Wheezing Y N  
Note: Complete the table below for patients ≥ 5 years, if patient < 5 years skip to Q 22. 
21. Were any of the following signs and symptoms present? 
Sore throat Y N Cough  Y N Chest pain Y N 
Shortness of 
breath/difficulty 
breathing 
Y N Diarrhoea  (>3 loose stools per day) Y N Wheezing Y N 
Note: Complete the table below for all patients. 
22. Were any of the following signs and symptoms present? 
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Chronic cough for 2 
weeks or more Y N 
Fever for more than 2 
weeks 
(14 days) 
Y N Cough up blood (Hemoptysis) Y N 
Loss of appetite Y N Night sweats Y N Loss of weight Y N 
Painless enlarged lymph 
glands Y N 
History of close contact 
with a person with 
recently active TB 
(diagnosis ≤ 12 months 
ago) 
Y N 
If yes, is the patient staying 
in the same house with the 
TB contact 
Y N 
Note: Complete the following questions for patients ≥ 18 years, if patient < 18 years skip to Q 26. 
23. Do you drink alcohol?                                  Yes          
No   
If yes, how many units per week? _______________ 
24. Do you currently smoke?                            Yes          
No   
If yes, how many cigarettes do you smoke per 
day? ______________ 
24.1   If no, have you smoked in the past?       Yes          
No   
If yes, date stopped smoking: / /  
25. Do you currently or have you ever worked in a mine before?  Yes        No        Unk   
Note: If no or unknown, skip to Q 26) 
25.1   If yes, date started working in the mine: / /                Date unknown   
25.2   If working in a mine or worked in a mine before, when did you stop working in the mine?   / /                 
Ongoing    
                                                                                                                                                                              Date Unknown   
25.3   If currently or worked in mine before, what type of mine/s? (tick all that apply) 
Gold            Coal            Platinum            Asbestos            Other     
(Specify) __________________________________ 
26. Do you have any underlying illness or condition at the moment?     Yes             No   
Note: Check patient’s notes for details if necessary.  If no skip to Q 27 
Asthma  Y N Other chronic lung disease Y N CVA/Stroke Y N 
Cirrhosis/Liver failure Y N Chronic renal failure Y N Heart failure Y N 
Valvular heart disease Y N Coronary artery disease (except H/T) Y N Pregnancy  Y N 
Organ transplant Y N 
Any immunosuppressive therapy, 
cortisone, chemotherapy, radiation 
therapy 
Y N Sickle cell Y N 
Splenectomy  Y N Diabetes  Y N Burns  Y N 
Immunoglobulin 
deficiency Y N Autoimmune disease, SLE Y N 
Kwashiorkor/ 
Marasmus Y N 
Nephrotic syndrome Y N Spinal cord injury  Y N Seizure disorder Y N 
Prematurity  Y N Obesity / BMI >=30 Y N COPD/Emphysema Y N 
Malignancy/Cancer Y N If yes, specify:  
Other  Y N If yes, specify:  
Does the patient live in 
an institution/care 
facility 
Y N If yes, name of institution:  
27. Has the patient been admitted to hospital in the last 12months? (prior to this admission)   Yes       No       Unk   
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Note: If no or unknown, skip to Q 28. 
27.1   If yes, what was the date that you were discharged from your last hospital admission?     / /           
Date Unk    
27.2   Was the patient admitted more than once in the past year?   Yes       No       
Unk   
If yes, how many 
times? ___________ 
Note: Complete for patients < 5 years, if patient ≥ 5 years skip to Q 29. 
28. HIV result during pregnancy (mother of patient):     Yes       No       Unk   
Note: If no or unk skip to Q 29 
28.1 If yes, what was the result?     Positive       Negative        
28.2 What was the source of the results?  RTHC        Laboratory report         Medical records        Verbal        Other  
  Specify _________ 
28.3  Was the child exposed to HIV (yes if the mother tested HIV positive during pregnancy)               Yes       No       Unk  
    N/A   
29. Has the patient been tested for HIV prior to this admission?      Yes       No       Unk   
Note: If no or unknown skip to Q 30 
29.1   If yes, what was the result?     Positive       Negative       Unk   
Note: If negative or unknown skip to Q 30 
29.2   Currently on ART?  Yes       No       Unknown   If yes, date of initiation of ART:   / /  
29.3   Bactrim (contrimoxazole/trimethoprim) prophylaxis taken currently?    Yes       No       Unk   
Note: If no or unknown skip to Q 29.5 
29.4   If yes, how long have you taken Bactrim? _____Years _____Months _____Weeks _____Days 
29.5   What is the patient’s clinical HIV stage according to WHO criteria (refer to WHO clinical staging information and HIV 
staging tick box document)      
   1         2         3           4    
30. Have you ever taken TB prophylaxis?           Yes     No     
Unk   
If yes, date TB prophylaxis initiated:  / /
 
Note: If no or unknown skip to Q 31 
30.1   Are you still taking TB prophylaxis?           Yes       No     
Unk   
If no, date TB prophylaxis stopped:   / /
 
Note: If yes skip to Q 32 
31.   TB treatment in the last 12 months?         Yes       No     
Unk   
If yes, date TB treatment initiated:    / /
 
Note: If no or unknown skip to Q 32 
31.1   Are you still taking TB treatment?              Yes       No     
Unk   
If no, date TB treatment stopped:      / /
 
Note: Ask patients and check medical records for PCP diagnosis and/or treatment 
32. Have you ever been diagnosed with PCP before this admission? (check from medical records)     Yes       No       Unk  
 
Note: If no or unknown skip to Q 33 
32.1   If yes, date last treatment started:     / /                Date Unk   
32.2   If yes, date last treatment stopped:   / /                Date Unk                   Ongoing   
32.3   If yes, treatment started with steroid therapy?        Yes                 No            Unk   
33. Has the patient been prescribed and taken antibiotics in the 24 hours before this admission?      Yes       No       Unk  
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Note: If no or unknown skip to Q 34 
33.1   If yes, what is the name of the antibiotic?     1. ____________________ 2. ____________________ 
3. ____________________ 
AMO Amoxicillin; AMP Ampicillin; AUG Augmentin; CEF Cefuroxime, CIP Ciprofloxacin; CLI Clindamycin; CTX Ceftriaxone; DOX 
Doxycycline; ERY Erythromycin, PEN Penicillin, TMX/SMX Contrimoxazole, VAN Vancomycin. If other, 
specify _________________________  
34. Vaccination history. Complete for patients < 5 years, if patient ≥ 5 years skip to Q 35 
34.1   Is the person being interviewed the primary caregiver of the child?          Yes           No        
Note: If no skip to Q 34.3 
34.2   If yes, has the child ever been vaccinated?       Yes       No       Unk   
Note: Excluding the vaccines given at birth 
34.3   Was the Road to Health Card seen?   Yes            
No    
34.4   Was a copy of the Road to Health Card made?  Yes           
No     
Note: If no skip to Q 35 
34.5  If copy was not made, state reason:     Mother refused             Other   
(specify) ______________________________________ 
If Road to Health Card seen, please copy the following information from the card: 
34.6   What is patients’ gestational age:     Term           Pre-term            Not recorded on Road to Health Card   
If pre-term, record gestational age: __________weeks 
34.7   If Road to Health Card seen, please complete the details on the following vaccines for all children < 5 years old 
Note: Tick no for vaccines that are not yet due according to the schedule.  At 18 months if only the DTP was given tick DTP 
only and N/A for the combined DTP/HIB, if a combined DTP/HIB was given tick yes under combined and N/A under DTP only 
Vaccine Dose due Given Date given 
BCG Birth  Y N / /
 
DTP 
+ 
HIB vaccine 
Dose 1 (6 weeks) Y N / /
 
Dose 2 (10 weeks) Y N / /
 
Dose 3 (14 weeks) Y N / /
 
Dose 4 (18 months) Y N N/
A 
/ /
 
DTP only (tick N/A if 
DTP+HIB) 
Dose 4 (18 months) Y N N/
A 
/ /
 
S.pneumoniae 
conjugate vaccine 
(PCV7/13/Prevenar) 
Dose 1 (6 weeks) Y 
Batch N°_______________     
Unk    
N 
/ /
 
Dose 2 (14 weeks) Y 
Batch N°_______________     
Unk    
N 
/ /
 
Dose 3 (9 months) Y 
Batch N°_______________     
Unk    
N 
/ /
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Catch up Y 
Batch N°_______________     
Unk    
N 
/ /
 
Measles 
Dose 1 (9 months) Y N / /
 
Dose 2 (18 months) Y N / /
 
Hepatitis B 
Dose 1 (6 weeks) Y N / /
 
Dose 2 (10 weeks) Y N / /
 
Dose 3 (14 weeks) Y N / /
 
Rotavirus  
Dose 1 (6 weeks) Y N / /
 
Dose 2 (14 weeks) Y N / /
 
Note: Complete for patients ≥ 5 years, if patient < 5 years skip to Q 36 
35. Did the patient receive pneumococcal polysaccharide vaccine? 
Vaccine Dose given Date given 
Date unknown  
 Pneumococcal Vaccine (Pneumovax) Y N UNK / /
 
36. Did the patient receive an influenza vaccine in the past 12 months (For all patients) 
Vaccine Dose given Date given  
Influenza vaccine 
Dose 1 
Y N UNK / / 
Date unknown  
 
Dose 2 
Y N UNK / / 
Date unknown  
 
QC Performed by:     Initials:                                      Date:  / /  
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Severe Acute Respiratory Illness (SARI) 
Surveillance 
Centre for Respiratory Diseases and Meningitis (CRDM) 
Hospital Results Form (HRF) 
TEL: 011 386 6410 or 011 386 6434  
FAX: 086 723 3569 
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SO Initials:    
Date completed: / /              
(DD/MM/YYYY) 
 
SARI Study ID: 
 
 
TSAP Study ID:  
 
Please record these results from the laboratory if they are available.  
Note: Only results from this admission except for Q 4, 5 and 8 where the most recent available result should be entered and Q 7 where results before 
admission must be recorded. 
Test Date of test Result 
1. CRP on admission                                    Done   Not done   / /  ____________mg/l 
2. ESR on admission           Done        Not done   / /  ____________mm/Hr 
3. Urea on admission Done        Not done   / /  ____________mmol/l 
4. Documented HIV 
Antibody Result (ELISA or 
rapid) 
Yes                       No   
/ /  
Note: Enter date of most recent 
result available 
Reactive                   Non reactive    
Note: Enter most recent result available 
5. Documented HIV PCR 
Result 
Yes                       No   
/ /   
Note: Enter date of most recent 
result available 
Positive                           Negative   
Note: Enter most recent result available 
6. Based on all the information available to you, what is the current HIV status of the patient       Positive        Negative        Pending                      
Unknown   
6.1 If current HIV status unknown, why was the patient not tested? Refused consent    Patient died    No guardian   
Other   specify______________________________________ 
6.2 What was the source of the results?  RTHC        Laboratory report       Medical records       Verbal       Other   
Specify _______________________ 
6.3 if patient < 5 years, was the child exposed to HIV : N/A    Yes          No     Unk  
7. CD4 count on 
admission                                          
Done        Not done   / /  
_________ Absolute CD4   ____._____%                  
              
8. CD4 count collected 
before this admission                                           
Done        Not done   / /  
_________ Absolute CD4   ____.______%                  
               
9. HIV viral load Done        Not done   
/ /  
Note: Enter date of most recent 
result available 
_________ HIV RNA copies/ml   
____._____  Viral load log  
Note: Enter most recent result available             
 Note: For Edendale 
Hospital only if patient 
co-enrolled in TSAP 
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10. Was a CXR done on the patient?  Yes        No     
Note :If not done go to Q 11 
 
10.1. If X-ray done record X- ray number here:  
_____________________________ 
Note: For Klerksdorp Tshepong Hospital Complex only 
10.2 Copy of X-ray downloaded?     Yes          No     
 
10.3 if yes, date X-ray copy downloaded  / /  
11. Bacterial Culture, done within 48 hours of admission?          Yes          No     
Note: If yes, complete the table below, if no skip to Q11 
       Date of culture 
Site 
Organism Isolated If other (99), specify  
Blood CSF Pleural fluid 
/ /       
/ /       
/ /       
/ /       
 
Organism codes: 
01 = No growth 02 = Streptococcus pneumoniae 03 = Haemophilus influenzae 04 = Klebsiella pneumoniae     
05 = Staphylococcus aureus / 
MRSA 
06 = Neiserria meningitides 
07 = Coagulase negative 
staphylococcus / 
Staphylococcus epidermidis 
08 = Bacillus Species     
09 = Corynebacterium  species 11 = Cryptococcus neoformans 12 = Escherichia coli       13 = Salmonella species 
14 = Streptococcus agalactiae / 
        Group B Streptococcus 
15 = Acinetobacter baumanii 16 = Pseudomonas aeruginosa 17 = Enterococcus faecalis 
18 = Streptococcus viridans 19 = Micrococcus species 
20 = Salmonella enterica_ 
Non-Typhodial (NTS) 
21 = Salmonella enterica- Typhi 
22 = Salmonella parathyphi 99 = Other   
11.1 Blood Specimen and Culture taken by SO                   Clinician 
11.2. Blood Culture Specimen requested by clinician Yes                  No 
12. TB testing done during this admission?            Yes          No     
Date of Test / /  / /  / /  / /  
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Specimen*     
AFB’s present  
(Yes/No/Not 
Applicable) 
Y  
 
N  
 
N/A 
 
 
 
Y  
 
N  
 
N/A 
 
 
 
Y  
 
N  
 
N/A 
 
 
 
Y  
 
N  
 
N/A 
 
 
 
Culture Done  
(Yes/No ) Y N  
 
 
Y  
 
N  
 
 
Y  
 
N  
 
 
Y  
 
N  
 
 
Culture Results  
(Positive/Negative/ 
Contaminated)     
POS 
 
NEG 
 
 
CONT 
 
 
 
Date of final results report 
/ /  
POS 
 
NEG 
 
 
CONT 
 
 
 
Date of final results report 
/ /  
POS 
 
NEG 
 
 
CONT 
 
 
 
Date of final results report 
/ /  
POS 
 
NEG 
 
 
CONT 
 
 
 
Date of final results report 
/ /  
GeneXpert Done 
 Y 
 
 
 
N 
 
 
 
 
Y 
 
 
 
N 
 
 
 
 
Y 
 
 
 
N 
 
 
 
 
Y 
 
 
 
N 
 
 
 
 
GeneXpert Results  
(Positive/ Negative/ 
Inconclusive) 
POS NEG INC 
 
 
 
 
POS NEG INC 
 
 
 
 
POS NEG INC 
 
 
 
 
POS NEG INC 
 
 
 
 
*Specimen codes: 
1 = Sputum           2 = Gastric Washing          3 = Bone Marrow          4 = Pleural Aspirate          5 = Lymph Node          6 = Other (if other, write 
in full)  
Note: Culture results will be reviewed at a later date. 
Do not delay submission of CIF and Result Form while waiting for TB culture results. 
Note: complete the table below for TSAP (For Edendale Hospital KZN Only): 
13. Was a blood count done during this admission?                                               Yes          No     
Note: If not done end; if yes, complete table below 
 
WBC          .  (1000/µl) 
 
RBC                  .  (106/ µl) 
 
Platelets      .   (1000/µl)  Not recorded 
 
 
 
Hb                     .  (g/dl) 
Neutrophils        .  (%WBC)     Not recorded 
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Hct                    .  (%) 
 
MCV             .   (fl) 
 
MCH             .   (pg) 
 
MCHC                 .  (g/dl) 
 
Monocytes         .  (%WBC)      Not recorded 
 
Lympocytes        .  (%WBC)     Not recorded 
 
Eosinophils         .  (%WBC)      Not recorded 
 
Basophils            .  (%WBC)      Not recorded 
QC perfomed by: Initials                                                 Date: / /  
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Severe Acute Respiratory Illness (SARI) 
Surveillance 
Centre for Respiratory Diseases and Meningitis (CRDM) 
Final Outcome Form (FOF) 
TEL: 011 386 6410 or 011 386 6434  
FAX: 086 723 3569 
 
 
SO Initials:     
 
 
        SARI Study ID: 
 
 
Date of admission: / /        
(DD/MM/YYYY) 
Did any of the following occur during admission? 
1. Was TB therapy started?  Yes             No    
2. Did the patient receive oxygen? Yes             No    
3. Did the patient receive mechanical ventilation? Yes             No    
4. Did the patient have a cardiac arrest? Yes             No    
5. Was the patient admitted to ICU?  Yes             No    
6. Did the patient go into shock  
(Systolic BP < 90mmHg) or require inotropes?  
Yes             No    
37. Antibiotics prescribed during this admission:         Yes            No            Unk   
Note: If yes, complete the table below. If no/unknown, skip to Q 8 
 PO IVI IMI Date started 
(enter date prescribed) 
Total number of 
days 
Amoxicillin     / /   
Augmentin     / /   
Ceftriaxone (Rocephin)    / /   
Ciprofloxacin (Ciprobay)    / /   
Contrimoxazole (Bactrim)    / /   
Erythromycin     / /   
Penicillin G    / /   
Ampiclox     / /   
Ampicillin     / /   
Cefotaxime     / /   
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Final outcomes of patient (for this admission) 
10.1 What was the final outcome (for this admission)? 
Discharge                                        Death                 Refused hospital treatment/absconded      
Referred to step down                   Name of facility: ____________________________________________ 
Transferred                                     Name of facility: ____________________________________________ 
10.2 Date of final 
outcome:  
/ /   
11.Discharge/fin
al diagnosis or 
diagnosis on 
transfer/referral 
Neonatal Sepsis            Bronchiolitis          Bronchopneumonia/Pneumonia/Lower Respiratory Tract Infection      
Suspected TB            Confirmed TB             Bronchitis         Diarrhoea          Febrile seizures           
Meningitis            Sepsis (not neonatal)            Not recorded             Other   (Specify) ____________________ 
Outcome follow up (for all SARI and SRI cases enrolled at Edendale, Klerksdorp and Tshepong Hospitals only) 
Cefuroxime (Zinnat)    / /   
Clindamycin     / /   
Doxycycline     / /   
Gentamycin     / /   
Vancomycin     / /   
Metronidazole     / /   
Other ( Specify):    / /   
38. Was Oseltamivir (Tamiflu®) prescribed during this admission?          Yes         No           Unk   
38.1 If yes, date prescribed:     / /  
39. Was Pneumocystis jirovecii pneumonia (PCP) treatment prescribed during this admission?    Yes         No           Unk   
Note: If yes, complete table below, if no or unknown skip to Final Outcome of Patient 
 
Dose (Specify 
quantity and 
unit) 
Oral IMI IVI Frequency Date started (enter date prescribed) 
Total number of 
days 
Cotrimoxazole       / /   
Dapsone       / /   
Prednisone       / /   
Hydrocortisone       / /   
Other (specify) 
_____________________ 
     
/ /  
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12. Date of follow up:                / /                          Not done   
12.1 What was the follow up outcome?           Death                   If died, date of death   / /                Date Unk   
                                                                         Alive                     Unknown (not possible to determine)  
QC performed by: Initials:                                  Date:  / /  
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The mortality analysis involves analysis of routine data in the public domain and forms part of influenza 
surveillance at the National Institute for Communicable Diseases. The protocol for these surveillance 
activities was approved by the University of the Witwatersrand (Wits) Ethics committee on 06 May 
2005. Reference R14/49 Schoub.  
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